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Abstract 
 
 
The A2A adenosine receptor (A2AAR) functions as a key non-redundant suppressor of 
inflammatory responses in vivo. However, whether it regulates activation of the JAK-
STAT pathway utilised by many pro-inflammatory cytokines is unknown. Using a 
vascular endothelial cell model system, I have demonstrated that adenovirus-mediated 
expression of the human A2AAR conferred an ability of IFNα, leptin and a soluble IL-
6  receptor-α/IL-6  (sIL-6Rα/IL-6)  trans-signalling  complex  to  promote  a  time-
dependent  reduction  in  the  levels  of  STAT  proteins  that  was  entirely  due  to 
proteasomal  degradation.  In  terms  of  functional  consequences,  degradation  was 
sufficient  to  attenuate  sIL-6Rα/IL-6-stimulated  STAT3-dependent  up-regulation  of 
vascular  endothelial  growth  factor  receptor-2  (VEGFR-2)  and  enhance  eNOS 
expression.  Degradation  required  JAK  activity  since  A)  it  was  blocked  by 
preincubation with JAK inhibitor. B) STAT1 but not STAT3 was resistant to both 
tyrosine  phosphorylation  and  down-regulation  in  response  to  leptin  and  C)  a 
Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered degradation, 
suggesting that JAK-mediated phosphorylation of this residue is required to produce 
the  effect.  Consistent  with  this  hypothesis,  sIL-6Rα/IL-6  treatment  of  A2AAR-
expressing cells resulted in the accumulation of polyubiquitylated endogenous and 
epitope-tagged  recombinant  wild-type  but  not  Tyr705→  Phe-mutated  STAT3.  In 
addition  the  results  show  that  inhibition  of  proteasome  function  was  sufficient  to 
block the inhibitory effect of the A2AAR on STAT3 phosphorylation, demonstrating 
that priming of STATs for degradation is the only mechanism responsible for the 
reduced cytokine-stimulated STAT phosphorylation observed in A2AAR-expressing 
cells. To date there is only one E3 ligase known for mediating STAT degradation 
which is SLIM protein. However, our results suggest the involvement of another E3 
ubiquitin ligase in HUVECs, since we have been unable to detect SLIM message or 
protein in HUVECs under conditions in which STAT degradation occurs. In addition, 
while  Tyr-  phosphorylation  is  clearly  the  critical  step  in  targeting  STATs  for 
degradation in A2AAR-expressing cells, it is unclear as to whether it functions simply 
as a classical phosphodegron, or whether the nuclear translocation that occurs as a 
result of phosphorylation is also important for localising the phosphorylated STAT 
dimer with the relevant E3 ubiquitin ligase.   xv 
 
Together, these observations suggest a model whereby expression of the A2AAR in 
endothelial  cells  primes  JAK-phosphorylated  STATs  for  polyubiquitylation  and 
subsequent  degradation  by  the  proteasome  following  cytokine  treatment,  and 
represents  a  previously  unappreciated  mechanism  by  which  G-protein-coupled 
receptors can negatively regulate responsiveness to specific JAK-STAT-mobilising 
adipocytokines acting on the vascular endothelium. 
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1.1    JAKs in cytokine signalling  
 
JAKs are intracellular tyrosine kinases with molecular masses of 120-140 KDa. It 
was demonstrated that signalling of IL-6 crucially depends on the presence of JAK1.  
The interaction between gp130 and JAK1 is very tight and long lasting.  JAKs bind to 
the membrane-proximal region of IL-6 receptors containing box1 and box2 motifs. 
The general structure of JAKs is shown in (Figure1.1) (Murakami et al.; 1993; Haan 
et al.; 2006).  
 
Comparison of JAKs sequences reveals seven regions of high homology from JH1 to 
JH7. The C-terminal JH1 tyrosine kinase domain is preceded by a JH2 pseudokinase 
domain, which is devoided of catalytic activity, but regulates the activity of the kinase 
domain (Yamaoka et al.; 2004). Moreover, JAKs contain an SH2 domain.  The N-
terminal region of JAKs comprises a FERM domain, which is important for receptor 
association (Haan et al.; 2006; Haan et al.; 2008) (Figure 1.1). 
  
JAKs  are  constitutively  associated  with  the  proline-rich  membrane  proximal 
box1/box2  region.  Upon  ligand  stimulation,  receptors  undergo  conformational 
changes that bring JAKs into close proximity to each other, enabling activation by 
trans-phosphorylation (Haan et al.; 2006).  There are four members of the JAK family 
in  mammals;  JAK1  plays  a  critical  role  in  mediation  of  biological  responses  to 
several  major  cytokine  receptor  families,  while  JAK2  plays  a  critical  role  in 
transducting signals for Epo, IL-3, GM-SF, IL-5, Tpo and IFN-γ. JAK3 plays a vital 
role in lymphoid development (Giliani et al.; 2005) while Tyk2 appears to be most 
important in mediating the biological response to IL-12 and LPS.  JAK1, JAK2 and 
Tyk2 are expressed ubiquitously, whereas the expression of JAK3 is restricted to 
cells of the myeloid and lymphoid lineages (Cetkovic-Cvrlje and Uckun; 2004). 
 
The importance of JAKs in mediating signals from a variety of cytokines factors 
underscores  their  importance  in  signal  transduction  in  general.  However,  the 
complexity associated with processing signals from such diverse sources suggests a   3 
complicated mechanism of action for the JAK kinases. JAK activation is determined 
by an in vitro kinase assay that measures an increase in tyrosine phosphorylation of 
substrates. JAKs, when expressed in the baculovirus system are enzymatically active 
and  are  phosphorylated  on  tyrosine  residues  (Dezaire  and  Stark;  2007).  Their 
overexpression  in  mammalian  cells  also  leads  to  constitutive  activation,  most 
probably due to dimerisation (Staerk et al.; 2007). On the other hand, a JAK kinase in 
complex with a native un-liganded receptor is in a catalytically inactive latent state. 
Receptor  dimerisation/oligomerisation  due  to  ligand  binding  results  in  the 
juxtapositioning  of  the  JAKs,  which  are  in  the  vicinity  either  through  homo-  or 
hetero-dimeric interactions. This recruitment of the JAK kinases appears to result in 
either via autophosphorylation and/or cross phosphorylation by other JAK kinases or 
other tyrosine kinase family members. This activation is presumed to result in an 
increased JAK kinase activity. The phosphotyrosine sites on the receptors can then 
serve  as  docking  sites  that  allow  the  binding  of  other  SH2-domain  containing 
signalling  molecules  such  as  STATs,  Src-kinases,  protein  phosphatases  and  other 
adaptor signalling proteins such as Grb2  (Heinrich et al.; 2003).  
 
   4 
 
 
Figure  1.1  Structure  organisations  of  JAKs,  STAT  factors,  Tyrosine 
Phosphatase (SHP2) and SOCS proteins. 
The JAK kinases are divided into seven JAK homology (JH) domains starting from 
the tyrosine kinase domain located at the C-terminus of JAKs and designated as JH1. 
The tandem kinase domain structure is composed of the tyrosine kinase domain, JH1, 
and a pseudokinase or kinase-like domain, JH2, on the N-terminal side of JH1. Only 
the JH1 domain is catalytically active (Heinrich et al.; 2003). 
 
1.2    The  Signal  transducer  and  activator  of  transcription  (STAT)  family  of   
transcription factors 
 
The  mammalian  STAT  factors  are  designated  as  STAT1,  2,  3,  4,  5a,  5b  and  6.  
STATs  are  proteins  with  a  conserved  structural  organisation  (Figure1.1).    They 
consist of 750-850 amino acids and comprise various domains as follows: a tetra-  5 
merisation domain and a leucine-zipper-like domain at the N-terminus, DNA-binding 
domain  in  the  middle,  a  Src  homology  3  (SH3)-like  domain,  a  SH2/tyrosine 
activation domain, linker domain, and a transactivation domain at the C-terminus. 
The C-terminal transcriptional activation domain is quite divergent between STAT 
members and contributes to signalling specificity (Lim and Cao; 2006).  
 
The  N-terminal  domain  comprising  approximately  130  amino  acids  is  conserved 
among the STATs.  Several studies suggest that the N-terminal dimerisation promotes 
cooperativity of binding to tandem GAS elements.  Other studies have suggested that 
the terminal STAT domain promotes interaction with the transcriptional coactivator 
CBP  and  p300,   PIAS  family  members, receptor domains,  as  well as    regulating 
nuclear translocation (Horvath; 2000; Lim and Cao; 2006). 
 
The coiled-coil domain consists of four α-helices.  The crystal structures of STAT1 
and STAT3 reveal that this domain forms a large predominantly hydrophilic surface 
that  is  available  for  specific  interaction  with  other  helical  proteins.  Proteins 
interacting with the coiled-coil domain include IFN regulatory factor-9 (IRF-9), the 
transcription  factor  c-jun,  N-myc  interactor  (Nmi)  and  STAT3  interacting  protein 
(StIP1).  In addition the coiled-coil domain is also implicated in receptor binding, 
tyrosine phosphorylation and nuclear export (Kisseleva et al.; 2002; Lim and Cao; 
2006). 
 
Most  investigators  have  found  an  increase  in  transcription  of  target  genes  after 
cytokine-induced  serine  phosphorylation  of  STAT1,  STAT3  and  STAT5.    Earlier 
studies had already shown serine
727 phosphorylation of STAT3 to occur slower than 
the phosphorylation of Tyr
705 (Beuvink et al.; 2000). SH2 domains play an important 
role in signalling through their ability to bind to specific phosphotyrosine motifs.  
Activation  of  STATs  requires  phosphorylation  of  the  conserved  tyrosine  residue 
located directly on the C-terminal side of the SH2 domain (Tyr
705 in STAT3).  During 
this process, the STATs are recruited to tyrosine phosphorylated cytokine receptors   6 
through their SH2 domains, and following phosphorylation of the conserved tyrosine, 
the  STATs  undergo  dimerisation  through  a  reciprocal  SH2-phosphotyrosine 
interaction (Greenlund et al.; 1994; Mayya and Loew; 2005).  Only the STAT dimer 
is  transcriptionally  active,  and  STAT  monomers  are  unable  to  bind  DNA,  and 
importantly, only the dimer translocates to nucleus from the cytoplasm, where the 
STATs are activated.  Furthermore, during activation of STATs, the SH2 domain has 
been found to be required for interaction with and subsequent phosphorylation by 
JAKs (Gupta et al.; 1996).  Mutation of either the conserved phosphotyrosine-binding 
Arg  of  the  SH2  domain  or  the  conserved  tyrosine  following  the  SH2  domain 
abrogates STAT activity (Kim et al.; 1998).   Differences in the SH2 domains of 
STATs  determine,  at  least  partially,  the  specificity  of  STAT  binding  to  various 
cytokine receptors (Heim et al.; 1995; Zhukovskaya et al.; 2004). 
 
Although the sequence of the STAT SH2 domain is quite divergent from other SH2 
domains, its tertiary-structure is well conserved (Gao et al.; 2004).  It consists of an 
anti parallel β-sheet flanked by two α-helices, which form a pocket.  An absolutely 
conserved arginine, which mediates the interaction with phosphate, lies at the base of 
this pocket (Arg-602 for STAT1 and Arg-609 for STAT3). The ability of the SH2 
domain to recognise specific phosphotyrosine motifs play an essential role in three 
STAT signalling events; recruitment to the cytokine receptor through recognition of 
specific  phosphotyrosine  motifs,  association  with  the  activating  JAK  STAT 
homodimerisation  or  heterodimerisation,  STAT  dimerisation  depends  on  the 
interaction  between  the  SH2  domain  of  one  STAT  monomer  and  the  tyrosine 
phosphorylated tail segment of the other monomer (T. Kawata; 1997; Mayya and 
Loew; 2005). 
 
STAT dimerisation is a pre-requisite for DNA binding.  The DNA-binding domain of 
STAT  proteins  is  located  in  the  middle  of  the  molecule  (amino  acid  300-480).  
STATs  are  activated  in  the  cytoplasm;  however  they  function  within  the  nucleus 
(Matsukawa; 2007).  In general, serine phosphorylation of STAT1, STAT2, STAT3   7 
and STAT4 increase their signal potential (Chung et al.; 1997b; Schuringa et al.; 
2000). 
 
STAT  dimers  need  to  cross  the  nuclear  envelope  to  functionally  link  the  cell 
membrane with the promoters of cytokine-responsive genes.  Movement of STATs in 
either compartment is diffusion controlled and not directed along permeant structures.  
Passage  through  nuclear  gateways  (nuclear  pore  complexes  NPCs)  (Rabut  et  al.; 
2004).  NPCs  form  channels  in  the  nuclear  envelope  with  a  diameter  of  ~  40nm 
(Laskey; 1998; Vasu and Forbes; 2001). Vertebrate NPCs have a mass of ~125MDa 
and contain 30–50 different proteins, which are called nucleoporins. Small molecules 
of 40kDa can passively diffuse through the NPC (Caesar et al.; 2006). In contrast, 
the  translocation  of  larger  macromolecules  into  the  nucleus  occurs  via  an  active 
mechanism  involving  nuclear  transport  receptors.  The  majority  of  the  nuclear 
transport pathways are mediated by receptors of the importin family. Proteins or other 
cargo  molecules  that  carry  a  classical  nuclear  localisation  sequence  (NLS)  are 
recognised by importin-α, which subsequently forms a complex through its importin-
β-binding  domain  with  importin-β  (Gorlich  et  al.;  1996;  Caesar  et  al.;  2006). 
Analysis  of  their  nucleo-cytoplasmic  translocation  has  to  consider  that  the  STAT 
proteins exist in two different states in terms of signalling:  Before the stimulation of 
cells with cytokines the STAT molecule exists in a nontyrosine phosphorylated state, 
the  oligomerisation  status  of  which  is  still  debated  (Hurt;  1997;  Meyer  and 
Vinkemeier; 2004).  
 
 Reporter  gene  studies  have  determined  that  serine  phosphorylation  enhances 
transcriptional  activity  of  STAT1  and  STAT3  (Kovarik  et  al.;  2001).  More 
physiological  studies  in  STAT1-deficient  cells  reconstituted  with  STAT1  and 
STAT1
S727A demonstrated that serine phosphorylation only enhances the ability of 
STAT1 to drive expression of some, but not all target genes (Kovarik et al.; 2001; Shi 
and Kehrl; 2004). Many studies also indicate that serine phosphorylation enhance 
STAT4 transcriptional activity. Although both STAT5 and STAT6 can become serine   8 
phosphorylated,  enhanced  transcriptional  activity  has  not  been  convincingly 
demonstrated (Kovarik et al.; 2001). 
 
1.3  Regulation  of  cytokine  signalling  by  suppressor  of  cytokine  signalling 
(SOCS) family molecules 
 
Cytokine  signalling  is  negatively  regulated  in  part  by  suppressor  of  cytokine 
signalling (SOCS), which bind to tyrosine phosphorylated residues of target proteins 
via their SH2 domains (Krebs and Hilton; 2001; Johnston; 2004).  They inhibit JAK 
activity through their N-terminal domains and are thought to induce degradation of 
bound molecules through a conserved SOCS box motif that interacts form part of an 
E3 ubiquitin (Ub) ligase complex (Zhang et al.; 2001).   
 
SOCS proteins are characterised by a relatively divergent N-terminal region followed 
by a SH2 domain and a C-terminal SOCS box region. SOCS proteins inhibit IL-6 
signalling either by suppressing the kinase activity of JAKs or by direct interaction 
with the receptors or by both mechanisms (Yasukawa et al.; 1999; Kurdi and Booz; 
2007). 
 
It is becaming increasingly appreciated that SOCS proteins also act by promoting the 
degradation of specific signalling proteins.  Recent work suggests that SOCS box-
containing proteins act as adapter molecules that recruit activated signalling proteins 
to the proteasome. SOCS proteins interact with elongins B and C through their SOCS 
box.  In  turn,  elongin  BC  complexes  associate  with  cullin  2  and  a  ring  finger-
containing protein Rbx1 (Roc1) to form part of a putative E3 Ub ligase (Figure1.2). 
The SH2 domains of SOCS bind to tyrosine phosphorylated signalling proteins. They 
can  therefore  act  as  adapters  to  facilitate  the  polyubiquitination  and  subsequent 
degradation of associated signalling proteins (Zhang et al.; 1999a; Johnston; 2004).  
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Figure  1.2  SOCS  family  members  might  target  signalling  proteins  for 
degradation by the proteasome. 
All SOCS proteins bind the elongin BC complex through their SOCS box. In turn, the 
elongin BC complexes associate with cullin 2 and a ring finger-containing protein 
Rbx1 (Roc1) to form part of a putative E3 Ub ligase. Signalling proteins associated 
with the N-terminal or SH2 domains of SOCS proteins could be ubiquitinated by 
cullin-2 targeting them for degradation by the proteasome. 
  
 
1.3.1  SOCS1 
 
SOCS1 was initially reported as a molecule induced by STATs.  However, SOCS1 
expression is now known to be induced by insulin (Le et al.; 2002; Ueki et al.; 2004), 
LPS (Crespo et al.; 2000; Mostecki et al.; 2005), CpG DNA and other molecules that 
do not use STATs in signal transduction. The SH2 domain of SOCS1 recognises the 
phosphorylated  tyrosine  residue  located  in  the  activation  loop  of  the  JAK  kinase 
domain (Brysha et al.; 2001; Greenhalgh and Hilton; 2001).  However, inhibition of 
JAK activation requires not only the SH2 domain but also a 30 amino acid kinase 
inhibitory region located upstream of the SH2 domain (Waiboci et al.; 2007).  
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Many studies suggest that SOCS1 inhibits cytokine signalling by associating with 
JAK1, JAK2, JAK3 and TYK2 to inhibit their catalytic activity.  Structure-function 
studies using truncated or chimeric version of SOCS1 have revealed the mechanism 
by which SOCS proteins bind to and inhibit JAKs. Interestingly, although the SOCS1 
SH2  domain  is  sufficient  to  mediate  the  association  between  SOCS1  and  JAKs 
(Yasukawa  et  al.;  2000),  both  the  SH2  domain  and  24  residues  immediately  N-
terminal to the SH2 domain is necessary for inhibition of JAK2 activity.  Thus, the 
region immediately N-terminal to the SOCS1 SH2 domain appears to have a kinase 
inhibitory function (Waiboci et al.; 2007).  Within this N-terminal region SOCS1 
contains a sequence of 12 residues that resembles the JAK activation loop (Yasukawa 
et  al.;  1999).  In  vivo  study  of  SOCS  function  has  been  facilitated  by  SOCS1 
knockout mice (Alexander et al.; 1999). Phenotypically, SOCS1
-/ - mice are stunted 
and die at three weeks of age. These mice have the pathology characterised by severe 
lymphopenia, fatty degeneration of the liver and macrophage infiltration of major 
organs (Starr et al.; 1998).  The complex disease in SOCS1
-/- mice was prevented by 
administration  of  anti-IFN-γ  antibodies  and  did  not  occur  in  SOCS1
-/-  mice  also 
lacking the IFN-γ gene (Fenner et al.; 2006). Subsequent studies have established that 
mice lacking SOCS1 show both increased production of and heightened sensitivity to 
IFN-γ which contribute to the perinatal lethality of SOCS1 deletion (Brysha et al.; 
2001). 
 
1.3.2  SOCS3 
 
The  structure  of  SOCS3  is  similar  to  SOCS1,  including  the  position  of  a  kinase 
inhibitory  region  (KIR).  However,  these  two  molecules  differ  greatly  in  their 
mechanism of action; SOCS1 can inhibit activation of JAK by directly binding to 
JAK, while SOCS3 inhibit the action of JAK only in the presence of receptors, such 
as  gp130.  SOCS3  is  induced  by  IL-6  and  SHP2  are  simultaneously  activated 
(Terstegen et al.; 2000; Kisseleva et al.; 2002; Lehmann et al.; 2003) .  
 
   11 
 It  has  also  been  observed  that  an  inhibition  of  SHP2  activation  can  lead  to  an 
enhanced  induction  of  SOCS3  mRNA.    On  the  other  hand  the  expression  of  the 
SOCS3  protein  decreased  the  level  of  tyrosine-phosphorylated  SHP2  after  IL-6 
stimulation.  Furthermore,  SOCS3  inhibits  IL-6  signalling  by  inhibiting  the 
phosphorylation of gp130. SOCS3 has been found to bind to the phosphotyrosine 
motif 759 of gp130 which is also the binding site for SHP2 (Kisseleva et al.; 2002). 
The affinity of SOCS3 to a phosphotyrosine peptide corresponding to the Tyr
759 motif 
of gp130 is much higher than to a phospho-peptide comprising the JAK activation 
loop.  Moreover, the affinity of SOCS3 to bind gp130 is slightly higher than that of 
SHP2.  Thus the involvement of SHP2 and SOCS3 in Tyr
759 mediated attenuation has 
been  re-examined  to  determine  the  individual  contribution  of  both  proteins 
(Yasukawa et al.; 1999). Although both SOCS3 and SHP2 are recruited to the same 
site within gp130, there are two largely distinct modes of negative regulation of gp 
130 activity: through the feedback inhibition by SOCS3 or the dephosphorylation of 
phosphorylated JAKs, receptors and STATs by SHP-2 (Lehmann et al.; 2003). The 
proposed mechanisms of action of SOCS 1 and SOCS3 have indicated that the N-
terminal domains of each protein (but not the N-terminal domain of any other SOCS 
protein)  are  interchangeable.    This  suggests  that  SOCS1  and  SOCS3  may  inhibit 
JAKs  through  interaction  with  their  N-terminal  domains  (Yasukawa  et  al.;  2000; 
Krebs and Hilton; 2001). It has been shown by several investigators that SOCS1 and 
SOCS3 bind to the kinase domain of activated JAK1 and JAK2 (Marine et al.; 1999; 
Sasaki  et  al.;  1999;  Park  et  al.;  2003).    A  model  for  JAK  inhibition  by  SOCS1 
suggests that the kinase activation loop of JAK2 interacts with the SH2 domain of 
SOCS1.  This allows SOCS to present its KIR, which is quite homologous to the 
kinase activation loop, to the pocket in the activation site, which in turn might prevent 
the access of substrates or ATP (Alexander and Hilton; 2004). 
 
The  physiological  function  of  SOCS3  has  been  investigated.  In  vivo  expression 
pattern of SOCS3 revealed that although SOCS3 is expressed at low levels in adult 
tissues, it is highly expressed in fetal liver erythroid progenitors (Marine et al.; 1999).   12 
Furthermore,  SOCS3  expression  is  specifically  induced  during  a  stage  of 
erythropoiesis characterised by an explosive Epo-dependent expansion of cells of the 
erythroid  lineage,  leading  to  the    hypothesised  that  SOCS3  plays  a  role  in 
erythropoiesis (Sasaki et al.; 2000). It is interesting to note that neither the SOCS3
-/- 
mice nor the transgenic mice that overexpress SOCS3, survived to birth. Strikingly, 
transgenic embryos that constitutively overexpressed SOCS3 exhibited no detectable 
fetal liver erythropoiesis, whereas a proportion of SOCS3
-/- embryos died, exhibiting 
pathology characterised by massive erythrocytosis throughout the embryo (Marine et 
al.; 1999) and defects in the placenta (Roberts et al.; 2001). lethality in SOCS3
-/-  
mice results from placental insufficiency (Matsumoto et al.; 2003). Taken together, 
these experiments suggest that SOCS3 may play an important role in the regulation of 
fetal liver erythropoiesis  (Roberts et al.; 2001; Wormald and Hilton; 2007). Given 
that Epo signalling is required for erythropoiesis, it is possible that SOCS3 modulates 
this process by attenuating Epo signalling (Sasaki et al.; 2000). 
 
1.4  Cytokines 
 
Cytokines are soluble glycoproteins, which mediate intercellular communication by 
binding to their specific receptors on the surface of target cells and transducing a 
signal to the nucleus to induce transcription of a specific set of genes.  One way to 
classify  cytokines  is  based  on  their  structural  and  functional  properties  and  the 
receptor molecules they bind to.  Growth factors, such as epidermal growth factor 
(EGF)  and  platelet-derived  growth  factor  (PDGF),  utilise  receptors  with  intrinsic 
tyrosine  kinase  activity,  termed  receptor  tyrosine  kinases  (RTKs)  (Hubert;  2007). 
Conversely,  members  of  the  transforming  growth  factor-β  (TGF-β)  superfamily 
utilise receptors with serine/threonine kinase activity (Shimanuki et al.; 2007).  Other 
subsets of cytokines include the TNF family.  Sometimes the term “cytokine” is used 
only for factors whose main targets are the hematopoietic cells, and are thus called 
the hematopoietic cytokines.  The hematopoietic cytokines, together with structurally 
related cytokines acting for example in the neural system, are collectively called class 
I cytokines. This class includes interleukins (IL) -2, -3, -4, -5, -6, -7, -9, -11,-12, -13,   13 
15, -21, -23, erythropoietin (EPO), thrombopoietin (TPO), prolactin (PRL), growth 
hormone  (GH),  thymic  stromal  lymphopoietin  (TSLP),  ciliary  neurotrophic  factor 
(CNTF), oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-
1),  neurotrophin-1  (NNT-1)/B-cell-stimulating  factor-3  (BSF-3),  and  colony-
stimulating  factors  for  granulocytes  (G-CSF)  and  granulocyte-macrophages  (GM-
CSF) (John et al.; 2006).  Interferons (IFN) and IL-10 constitute an additional family 
termed  the  class  II  cytokine  family.  IL-19,  -20,  -22,  and  -24  have  been  recently 
identified as IL-10-related classII cytokines (Sabat et al.; 2007). The class I and class 
II cytokines share an α-helical three-dimensional structure. Class I cytokines typically 
consist  of  four  α-helices,  designated  from  A  to  D  and  connected  by  short  loops 
(Huyton et al.; 2007).  The class II cytokines, IFN-γ and IL-10, contain 6 α-helices 
instead of 4. The helical cytokines function usually as monomers, IFN-γ and IL-10 
are  dimers  (Oliveira  Neto  et  al.;  2008).  The  receptors  utilised  by  type  I  and  II 
cytokines are structurally related and form the hematopoietic receptor superfamily. 
Importantly,  receptors  of  the  hematopoietic  receptor  superfamily  share  common 
mechanisms for signal transduction (Nishimoto and Kishimoto; 2008).   
 
1.4.1  IL-6  
 
IL-6 plays an active role in immunity, bone metabolism, reproduction, arthritis, and 
in  the  development  of  neoplasia.  Dysregulation  of  IL-6-type  cytokine  signalling 
contributes  to  the  onset  and  maintenance  of  several  diseases  such  as  multiple 
myeloma,  inflammatory  bowel  disease  and  rheumatoid  arthritis  (Nishimoto  and 
Kishimoto;  2006).    Moreover,  IL-6  plays  a  significant  role  in  the  acute  phase 
inflammatory response.  IL-6 stimulates the acute phase reaction that enhances the 
innate immune system and protects against tissue damage. It results in the release of 
certain  proteins,  called  "acute  phase  proteins",  into  the  plasma  by  liver  cells  and 
induces  a  decrease  in  the  rate  of  synthesis  of  other  proteins.    Specifically,  IL-6 
increases  the  synthesis  of  the  two  major  acute  phase  proteins,  C-reactive  protein 
(CRP), which increase the rate of phagocytosis of bacteria, and serum amyloid (SAA) 
by regulating the rate of gene transcription (Dziedzic; 2008).   14 
IL-6 also increases the synthesis of fibrinogen, an important clotting agent albumin 
and transferrin levels are also decreased in the presence of IL-6 (Ohta et al.; 2004; 
Marquardt et al.; 2005). Not surprisingly,   knockout of the  IL-6  gene has severe 
effects on the immune system, including a major decrease in the acute phase immune 
reaction and production of IgA antibodies (Benihoud et al.; 2000).  On the other 
hand,  overexpression  of  the  IL-6  gene  can  lead  to  the  substantial  polyclonal 
proliferation  of  plasma  cells.    Lack  of  gene  regulation  can  lead  to  autoimmune 
disease  and  many  lymphoid  malignancies,  including  multiple  myeloma.  An 
uncontrolled or defective production of this protein most often leads to disease and is 
involved in the pathogenesis of many disease and autoimmune disorder such as liver 
autoimmune disease.  Furthermore, IL-6 is important for the development of specific 
immunological  responses  and  also  plays  an  important  role  in  bone  metabolism 
through the initiation of osteoclastogenesis and increasing osteoclast activity (Liu et 
al.; 2006). 
 
1.4.1.1  IL-6 structure 
 
The  average  molecular  weight  of  human  IL-6  ranges  between  21  to  28  KDa, 
depending on the post-translational processing, such as glycosylation. The full length 
IL-6 peptide comprises 212 amino acids (aa) from which a 28 aa hydrophobic signal 
peptide is cleaved off from the N-terminus resulting in a mature protein of 184 aa.  
IL-6  contains  four  conserved  cysteine  residues  within  a  highly  conserved  central 
region.  Additionally, the C-terminus appears to be critical for IL-6 activity, since 
deletion of four aa from the C-terminus abolishes IL-6 activity. In contrast, deletion 
of 28 aa from the N-terminus does not affect IL-6 activity (Maggio et al.; 2006). 
 
1.4.1.2   IL-6 Receptors 
 
IL-6 receptors can be subdivided into non-signalling α-chain and signal transducing 
subunits  such  as  gp130.    IL-6  first  binds  specifically  to  its  respective  α-receptor 
subunits.  The ectodomain of the receptors involved in IL-6 signalling comprise an 
array of FNII-like and Ig-like domains (Heinrich et al.; 2003) ( Figure 1.3).    15 
 
Mutagenesis  studies  have  identified  distinct  areas  on  the  surface  of  the  cytokine, 
which specifically interact with the respective receptors.  Common to all IL-6-family 
members is the site  II  that interacts  with the cytokine binding module (CBM) of 
gp130 (Nishimoto and Kishimoto; 2008).  
 
 
Figure 1.3 Receptor complexes of IL-6-type cytokines. For gp130 the box1 and box2 
regions, as well as the dileucine motif (LL, Leu786-Leu787), are highlighted 
(Heinrich et al.; 2003). 
 
Cytokine receptors are single trans-membrane glycoproteins that have a conserved 
extracellular domain and three short conserved motifs in the intracellular regions.  
The intracellular region of cytokine receptors do not have intrinsic catalytic activity, 
but are linked via ligand binding to activation of signal transduction by associating 
with a number of signalling proteins (Heinrich et al.; 2003).  The cytokine receptors 
have box1 and box2 motifs (Haan et al.; 2006).  Box1 is located within the first 20 
amino acids of the cytoplasmic domain. Box2 motif is characterised by a stretch of 
hydrophobic amino acids, which are followed by several charged amino acids (Haan 
et al.; 2002; Heinrich et al.; 2003).  
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The membrane-distal region of cytokine receptors also mediate essential signalling 
functions of receptors and contain tyrosine residues that become phosphorylated upon 
cytokine stimulation. These serve as docking sites for Src homology2 (SH2) domain-
containing signalling proteins.  IL-6 receptors are membrane proteins that belong to 
the cytokine receptor class I family.  This receptor family is defined by the presence 
of at least one cytokine binding module (CBM) consisting of two fibronectin-type-
III-like domains of which the N-terminal domain contains a set of four conserved 
cysteine residues (Aasland et al.; 2003) and the C-terminal domain a WSXWS motif 
(Heinrich et al.; 2003) (Figure 1.3).   
 
Moreover,  IL-6R  has  an  IgG-like  domain  located  at  the  N-terminus  and  three 
additional membranes proximal fibronectin typeIII like domain. In addition to the 
membrane-bound receptor, a soluble form of the IL-6R (sIL-6R) has been purified 
from  human  serum  and  urine.    This  soluble  receptor  binds  IL-6  with  an  affinity 
similar  to  that  of  the  cognate  receptor  and  prolongs  its  plasma  half-life 
(Michalopoulou et al.; 2004). More importantly the sIL-6R/IL-6 complex is capable 
of activating cells via interaction with membrane-bound gp130.  This is in contrast to 
the function of most soluble cytokine receptors that bind their ligand to antagonise 
cellular signalling by preventing the interaction of the cytokine with their respective 
plasma membrane-bound receptor (Jones et al.; 2005). Soluble IL-6 receptors present 
on  hematopoietic  progenitor  cells,  Kaposi’s  sarcoma  cell  lines  and  synovial 
fibroblasts can form a ligand receptor complex with IL-6 which stimulates a variety 
of  cellular  responses  including  proliferation,  differentiation  and  activation  of 
inflammatory processes (Peake et al.; 2006; John et al.; 2007).  Moreover, gp130 is 
used not only by the IL-6 receptor but also by the receptors for other members of IL-6 
family LIF and OSM (Nishimoto and Kishimoto; 2008). 
 
 
SIL-6R  performs  an  important  role  in  the  regulation  of  IL-6  responses  and 
consequently disease progression.  Although changes in sIL-6R concentration have   17 
been determined in numerous clinical disorders, high IL-6 concentrations hve been 
documented  in  the  serum  and  synovial  fluid  of  rheumatoid  arthritis  and  juvenile 
rheumhatoid arthritis patients (Pignatti et al.; 2003; Peake et al.; 2006). Through a 
series  of  in  vitro  approaches,  sIL-6R  has  been  implicated  in a  variety of  cellular 
conditions  typically  associated  with  arthritis,  such  as  the  severe  destruction  of 
cartilage and bone (Pignatti et al.; 2003). 
  
Examination of both IL-6 and sIL-6R concentrations in synovial fluid from arthritic 
patients  showed  that  the  extent  of  joint  destruction  correlated  with  the  increased 
concentration  of  these  mediators.    Furthermore,  synovial  fluids  from  rheumatoid 
arthritic patients containing high levels of IL-6 and sIL-6R promoted osteoclast like 
cell formation when added to cocultures of osteoblastic cells and bone marrow cells 
(Peake et al.; 2006). 
 
1.4.1.3  Signalling of IL-6-type cytokines 
 
 
IL-6 utilises tyrosine kinases of the JAK family and transcription factors of the STAT 
family as mediators of signal transduction.  gp130 is constitutively associated with 
Tyr kinases JAK1, JAK2 and TYK2.  Several phosphotyrosine residues of gp130 are 
docking sites for STATs with matching SH2 domains, particularly, STAT1 which 
bind to phospho Tyr
701 in gp130 and STAT3 binds to phospho Tyr
705 (Klein et al.; 
2005). STATs then become Tyr-phosphorylated, form dimers and translocate to the 
nucleus,  where  they  regulate  transcription  of  target  genes  (Lim  and  Cao;  2006) 
(Figure 1.4). 
 
Moreover, the tyrosine phosphatase SHP2 also binds to phosphotyrosine 759 motif of 
activated  gp130  and  counteracts  receptor  and  STAT  activation  (Lehmann  et  al.; 
2003).  Also, Suppressor of cytokine signalling (SOCS) 3 is a potent IL-6-induced 
feedback inhibitor terminating IL-6 signal transduction is bind to the same site in 
gp130 and inhibits JAK activity  (Fischer et al.; 2004).   18 
 
 
Figure  1.4  Schematic  presentation  of  gp130  mediated  activation  of  JAK/STAT 
pathway and MAPK / ERK cascade by IL-6 signalling (Heinrich et al.; 2003). 
 
1.4.2  IFN alpha  
 
The interferons (IFNs) represent proteins with anti-viral activity that is secreted from 
cells in response to avariety of stimuli. There are at least five classes of IFN alpha, 
beta, gamma, tau and omega. The interferons are divided into two groups designated 
type I and type II interferons. IFNγ is the only type II interferon, whereas the type I 
interferons consist of four major classes: IFN-α, IFN-β, IFN-W, IFN-I, and IFN-K 
(Caraglia et al.; 2005). 
 
Type I  IFNs have pleiotropic effects in both the innate and the adaptive immune 
responses.  Recently,  it  has  become  clear  that  one  of  the  key  cells  in  the  IFN-α 
physiological response is the natural IFN-producing cell (NIPC), also known as the   19 
immature plasmacytoid dendritic cell PDC or precursors of type 2 DC (pDC2). PDCs 
differentiate into mature antigen-presenting DCs, which have a crucial role in T and 
B  cell  activation.  NIPCs/PDCs  were  shown  to  be  the  major  IFN-α  producer  in 
response  to  a  wide  range  of  agents,  including  bacteria  and  immune  stimuli 
(Fitzgerald-Bocarsly and Feng; 2007). The pivotal role of IFN-α and NIPC/pDC in 
autoimmune disorders has also been demonstrated (Gottenberg and Chiocchia; 2007). 
Although IFN-γ production was thought to be restricted to T and NK cells, recent 
findings  demonstrate  that  other  cell  populations  of  the  DC  lineage  involved  in 
antitumour defense produce IFN-γ, which mediates cancer cell apoptosis via tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induction (Taieb et 
al.; 2006) Type I and type II IFNs play a central role in host defenses not only against 
viruses  but  also  against  intracellular  bacteria  and  parasites  (Casanova  and  Abel; 
2004). It has been clearly demonstrated that the lack of IFN receptors or defects in 
signalling  pathways  are  responsible  for  inherited  immunodeficiencies  against 
mycobacteria  (Jouanguy  et  al.;  1996;  Newport  et  al.;  1996).  Human  primary 
immunodeficiencies of type I IFNs have been recently discovered (Casrouge et al.; 
2006). They appear to be due to defects in either type I IFN production or in type I 
IFN responses.  
 
Type I and II IFNs are secreted cytokines that regulate numerous biological activities 
associated  with  host  defence  and  homeostasis.  The  JAK-STAT  pathway  is  the 
primary signalling pathway for the transcriptional regulation of many IFN-stimulated 
genes  (ISGs).    Following  high-affinity  binding  to  their  specific  cognate  receptor 
complexes, type I and type II IFNs transduce signals through activation of receptor-
associated JAKs.  Binding of the type I IFNs (IFN-α, IFN-β, IFN-W, IFN-I, and IFN-
K) to their cognate receptor complex induces association of the two receptor chains, 
IFNAR-1 and IFNAR2-c (Domanski et al.; 1997; Brierley and Fish; 2002), which 
leads to the phosphorylation of tyrosine residues located in the intracellular domain of 
each receptor chain. These tyrosine phosphorylation events are thought to be carried   20 
out by  TYK2 and JAK1, which are themselves activated by tyrosine phosphorylation 
(Uze et al.; 2007) .  
 
Similarly, the type II receptor complex comprises two receptor chains, IFNGR-1 and 
IFNGR-2.  Binding of the type II IFN for example, IFN-γ to its receptor complex 
leads to the phosphorylation and activation of JAK1 and JAK2.  Upon activation, the 
JAKs phosphorylate specific tyrosine residues within the intracellular domains of the 
receptor  subunits  (Caraglia  et  al.;  2005).  These  phosphorylated  residues  serve  as 
docking sites for STATs (Uze et al.; 2007). Once recruited to the receptor complex, 
the activated JAKs phosphorylate a single tyrosine residue within the C-terminus of 
the STAT proteins as described previously. The phosphorylated and activated STATs 
form both homodimeric and heterodimeric complexes that translocate to the nucleus 
and bind specific DNA sequences within the promoter regions of ISGs to initiate 
transcription (Wesoly et al.; 2007).  
 
1.4.2.1    IFN-inducible STAT complexes 
 
Type I IFN binding to its receptor induces the dimerisation of IFNAR-1 and IFNAR-
2c  receptor  chains  and  the  subsequent  activation  of  the  receptor-associated  JAKs 
(Figure 1.5).  The IFNAR-1 chain associates with Tyk2, and the IFNAR-2c chain 
associates  with  JAK1.  Once  activated,  Tyk2  phosphorylates  tyr
466  on  IFNAR-1, 
generating a docking site for STAT2 by means of its SH2 domain (Yan et al.; 1996; 
Campbell; 2005).  Tyk2 then phosphorylates STAT2 on Tyr
690, which serves as a 
docking  site  for  STAT1  (Wesoly  et  al.;  2007).  Subsequently,  STAT1  itself  is 
phosphorylated on Tyr
701.  This activated STAT1 and STAT2 heterodimer dissociates 
from the receptor complex and localises to the nucleus.  Only the intracellular domain 
of the IFNAR-2c chain is necessary for mediating the docking and phosphorylation of 
STAT protein as well as the formation of STAT complexes (Colamonici et al.; 1995; 
Kotenko et al.; 1999).   
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Figure 1. 5 Primary JAK/STAT pathways involved in cellular signalling by type 
I and type II IFNs. 
Binding of either class of IFN to its receptor leads to activation of receptor-associated 
JAK proteins that phosphorylate tyrosine residues on the intracellular domains of the 
receptor. This is followed by the docking of STAT molecules to the receptor that are 
in  turn  phosphorylated  at  tyrosine  residues  by  the  JAKs.  The  activated  STATs 
dissociate from the receptor chain and form dimers that translocate to the nucleus and 
bind to specific DNA recognition elements to modulate gene transcriptional activity. 
For the type I IFNs, both STAT1 and STAT2 are activated to form a heterodimer that 
associates in the nucleus with a third molecule, IRF-9. This trimolecular complex 
(also  called  ISGF3)  binds  to  the  interferon-stimulated  response  element  (ISRE) 
(Campbell; 2005). 
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Within the IFNAR-2c intracellular domain, only a single tyrosine residue at either 
position  337  or  512  is  required  for  a  full  IFN  response  (Velichko  et  al.;  2002).  
STAT2  associates  with  the  IFNAR-2c  subunit,  whereas  STAT1  binds  only  the 
IFNAR-2c-STAT2 complex, suggesting that STAT2 provides a recruitment site for 
the SH2 domain of STAT1, linking it to the receptor complex (Nadeau et al.; 1999; 
Campbell;  2005).    This  IFNAR-2c-STAT2  association  does  not  depend  on  the 
tyrosine phosphorylation of the receptor or the STAT protein. Type I IFN induces the 
activation of all members of the STAT family, namely, STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6 (Wesoly et al.; 2007). Although numerous 
different types of STAT-containing complexes are formed, STAT2 is an essential 
component of type I IFN signalling (Paulson et al.; 1999). Notably, IFNs-α/β induce 
the  formation  of  the  ISGF3  complex,  comprising  STAT1,  STAT2,  and  a  DNA-
binding  adapter protein  of  the  IFN  regulatory  factor  (IRF)  family,  IRF-9  (p48  or 
ISGF3γ) (Genin et al.; 2003).   
 
Upon  nuclear  import,  STAT1  and  IRF-9  of  this  ISGF3  complex  bind  the  IFN-
stimulated response element (ISRE), AGTTTN3TTTC, to initiate gene transcription.  
Within this complex, STAT2 does not contribute to DNA binding but provides a 
potent transactivation domain (TAD)  (Paulson et al.; 1999). Type I IFNs also induce 
the formation of other STAT-containing complexes: STAT1, STAT3, and STAT5 
homodimers as well as STAT1 and STAT3 hetrodimers (Wesoly et al.; 2007). These 
homodimers  and  heterodimers  bind  palindromic  so-called  ‘‘GAS’’  sequences, 
TTCN3GAA, designated GAS, located in the promoters of a different subset of ISGs.  
Type II IFN signalling primarily activates the STAT1 transcription factor (Figure1.5).  
The two chains of the type II IFN receptor, IFNGR-1 and IFNGR-2, associate prior to 
ligand binding. The biologically active form of IFN-γ is a noncovalent homodimer 
that binds its receptor complex in a 2:2 ratio (Walter et al.; 1995; Campbell; 2005).   
 
In  the  case  of  IFN-γ  binding,  the  intracellular  domains  of  the  receptor  complex 
undergo  a  conformational  change  upon  IFN-γ  binds  that  induces  the   23 
autophosphorylation  and  activation  of  JAK2  and  subsequent  JAK1 
transphosphorylation  by  JAK2  (Chang  et  al.;  2004).  Activation  of  JAK1 
phosphorylates  tyrosine  residue  440  within  the  intracellular  domain  of  the  two 
IFNGR-1 chains.  STAT1 proteins associate with the IFNGR-1 chains by means of 
SH2-phosphotyrosyl  interactions  and  are  subsequently  phosphorylated  on  Tyr
701 
(Hashemite et al.; 2004).  The activated STAT1 proteins dissociate from the receptor 
complex and form STAT1 homodimers. Once in the nucleus, these STAT1 dimers 
bind  GAS  elements  and  induce  gene  transcription.  These  IFN-inducible  STAT 
proteins  thus  permit  direct  transmission  of  signals  from  the  cell  surface  to  the 
nucleus, resulting in the generation of IFN-mediated biological responses (Campbell; 
2005; Wesoly et al.; 2007). 
 
1.4.3  Leptin Biology 
 
Leptin is a multifunctional cytokine that plays a key role in the regulation of food 
intake and energy expenditure. The discovery of leptin at the end of 1994 (Zhang et 
al.; 1994) opened up a whole new perspective to study the role of adipocyte-derived 
factors in energy balance and homoeostasis (Fruhbeck et al.; 2001).  The 16 kDa non-
glycosylated polypeptide product of the ob gene is mainly produced and secreted by 
fat cells in proportion to fat mass to signal the repletion of body energy stores to the 
hypothalamus  (Banks;  2004).  Leptin  exhibits  striking  structural  similarities  to 
members of the class I cytokine family, including LIF, CNTF, OSM and CT-1, as 
well as IL-6, IL-11 and IL-12 (Fruhbeck et al.; 1998; John et al.; 2006).  Both the 
crystal structure and NMR studies of leptin have revealed that the protein adopts a 
cytokine fold similar to that exhibited by the short-helix subfamily of cytokine folds 
(Zhang et al.; 1997).  The three-dimensional structure of the 167-amino-acid leptin 
molecule is based on four antiparallel α-helices, connected by two long crossover 
links and one short loop arranged in a left-handed helical bundle, which forms a two-
layer packing. A disulphide bond between two cysteine residues (Cys96 and Cys146) 
of the C-terminus of leptin and the beginning of one of the loops has been shown to   24 
be important for folding and receptor binding, as mutation of either of the cysteine 
residues renders the protein biologically inactive (Prolo et al.; 1998).   
 
Circulating  leptin  concentrations  have  been  reported  to  correlate  closely  with 
indvidual BMI (body mass index) and the total amount of body fat (Fruhbeck et al.; 
1998; Strocchio et al.; 2007).  Although leptin is mainly produced and secreted into 
the bloodstream by white adipocytes, this is not the only source of the hormone.  
Placenta  (Valuniene  et  al.;  2007),  gastric  mucosa  (Francois  et  al.;  2008),  bone 
marrow  (Isaia  et  al.;  2005),  mammary  epithelium  (Motta  et  al.;  2007),  skeletal 
muscle, pituitary (Tipsmark et al.; 2008), hypothalamus and bone have also been 
shown  to  be  able  to  produce  small  amounts  of  leptin  in  certain  circumstances 
(Masuzaki et al.; 1997; Bado et al.; 1998; Morash et al.; 1999).  Based on an almost 
ubiquitous  distribution  of  receptors,  leptin  has  been  reported  to  play  a  role  in  a 
diverse range of physiological functions both in the central nervous system and at the 
periphery (Fruhbeck; 2001; Fruhbeck; 2002; Bjorbaek and Kahn; 2004). Its functions 
encompass  metabolism,  reproduction,  immunity,  cardiovascular  pathophysiology, 
respiratory  function,  wound  healing,  as  well  as  in  growth  and  development 
(Gainsford et al.; 1996; Holness et al.; 1999).   
 
1.4.3.1   Leptin receptor 
 
The  hormone  leptin  is  encoded by  Ob  gene.  Leptin  acts  through  its  receptor (db 
gene), which has six isoforms (from ObRa to ObRf ) (Malendowicz et al.; 2006).  
Only one of them the leptin receptor b (ObRb), has full signalling capabilities and is 
able to activate the JAK/STAT pathway.  Like all other class I cytokines receptors, 
ObRb lacks any intrinsic kinase activity, and uses cytoplasmic-associated JAKs to 
signal downstream. Leptin binding results in formation of a dimmer receptor complex 
leading  to  trans-phosphorylation  and  activation  of  the JAKs  (Kloek  et al.;  2002). 
These then phosphorylate tyrosine residues (Tyr
974, Tyr
985, Tyr
1138 and Tyr
1077) in the 
cytosolic domain of the receptor, which provide binding sites for signalling molecules   25 
including SHP-2 and members of the STAT family, which are also subject to JAK-
mediated  phosphorylation  activation  (Baumann  et  al.;  1996;  Bjorbaek  and  Kahn; 
2004).  
 
 The full-length ObRb receptor contains several cytoplasmic sequence elements that 
are  required  for  subsequent  signalling  events.  ObRb  binds  JAK2  constitutively 
(Ghilardi  and  Skoda;  1997;  Bjorbaek  and  Kahn;  2004)  and,  like  other  cytokine 
receptors,  it  contains  a  highly  conserved,  proline-rich  box1  between  intracellular 
a.a.’s 6-17  and two putative less conserved box2 motifs between intracellular a.a.’s 
49-60 and 202-213 (Ghilardi and Skoda; 1997). While  Box1 and box2 motifs are 
thought to recruit and bind JAKs (Haan et al.; 2006), it has been demonstrated that 
only  box1  and  the  immediate  surrounding  amino  acids  are  essential  for  JAK 
activation.  Although an intact box2 motif is not required to activate JAK activity 
(Bahrenberg et al.; 2002), the pivotal STAT signalling pathway cannot be induced 
without box2. Forming homodimers and showing signalling capabilities with mutated 
box2 motfs, ObR can be classiflied as a member of the growth hormone receptor 
(GHR)  subfamily  (Fruhbeck;  2006).  For  downstream  signalling  events,  tyrosine 
residues at positions 985 and 1138 are needed to provide docking sites for subsequent 
signalling molecules with SH2 domains such as STATs and SHP2  (Banks et al.; 
2000; Heshka and Jones; 2001).  
 
1.5  Adenosine receptors  
 
Adenosine receptors belong to the G protein-coupled 7 transmembrane
 superfamily of 
cell surface receptors and include A1, A2A, A2B,
 and A3 subtypes. The interest in The 
realisation  that  the  psychostimulatory  effects  of  caffeine  are  largely  due  to 
antagonism of  brain-tissue adenosine receptor  signalling  (Fredholm;  1995)  further 
stimulated  interest  in  adenosine  receptors  system.  A  better  understanding  of  the 
purinergic  receptors  and  their  intracellular  signalling  pathways  lead  to  the 
classification  of  adenosine  receptors  according  to  the  rank  order  of  potencies  of 
agonists with respect to the intracellular production of cAMP.  ARs transduce their   26 
signal  by  heterotrimeric  G-proteins  that  can  either  stimulate  (Gs)  or  inhibit  (Gi) 
adenylyl cyclase, the enzyme that catalyses the formation of cAMP (Sitkovsky et al.; 
2004).  The cloning of four AR subtypes (A1, A2A, A2B, A3) (Olah and Stiles; 1995; 
Palmer  and  Stiles;  1997)  helped  to  prove  that  high-affinity  A2A  and  low-affinity 
A2BAR activate adenylyl cyclase, whereas high-affinity A1 and high-affinity A3ARs 
inhibit  it.  Accordingly,  when  immune  cells  acquire  the  expression  of  multiple 
adenosine receptors, they  will be recruited in a stepwise manner with  Gi-coupled 
A1AR activation initially at very low adenosine levels, followed by the stimulation of 
Gs-coupled A2A and A2BARs, and finally by Gi-coupled A3AR (Fredholm et al.; 2001; 
Sitkovsky et al.; 2004). 
 
1.5.1  A2AAR  
 
The A2AAR is highly expressed within most cells of the immune system, platelets, 
heart, lung and endothelium (Fredholm et al.; 2001). Classically, the A2AAR signals 
via the Gs family of G proteins leading to an activation of adenylyl cyclase and the 
generation of cAMP. However, it has been shown that there may be cell type-specific 
patterns  of  A2AAR-activated  signalling.  A2AARs  have  been  cloned  from  several 
species, including dog (Libert et al.; 1990), rat (Fink et al.; 1992) and man (Furlong 
et al.; 1992) and show 84% sequence identity between rat and human forms. 
 
Adenosine-induced  vasodilatation  is  thought  to  involve  both  A2AAR  and  A2BARs 
(Ralevic and Burnstock; 1998; Sitkovsky et al.; 2004; Fredholm; 2007). The A2AAR 
is expressed in ECs and its activation may lead to activation of nitric oxide synthase 
(Lin et al.; 2007). A direct effect of adenosine on arterial smooth muscle cells has 
also  been  proposed  to  contribute  to  vasodilatation  (Kleppisch  and  Nelson;  1995; 
Tamajusuku et al.; 2006). In addition to increasing local blood flow, the extracellular 
accumulation of adenosine triggers signalling cascades that enable oxygen-deprived 
tissues to cope with both the short-term (Fredholm; 1997; Picano and Abbracchio; 
1998) and the long-term effects of oxygen deprivation (Sexl et al.; 1995; Sexl et al.; 
1997). ECs proliferation is a consequence of the activation of ERK via A2AAR. This   27 
is  also  evoked  by  activation  of  b2-adrenergic  receptors.  It  is  surprising  that 
stimulatory receptors linked to cAMP formation activate ERK since cAMP inhibits 
proliferation  in  many  cells.  Indeed,  signalling  to  ERK  in  endothelial  cells  is 
independent of cAMP, but through an unidentified pathway that involves the small 
G-protein Ras (Barthomeuf et al.; 2004). In immortalised cell lines, A2AAR activation 
leads to ERK phosphorylation (Seidel et al.; 1999; Schulte and Fredholm; 2000). 
However, the signal cascade that links the A2AAR to ERK differs between cell types. 
In CHO cells, cAMP formed by stimulating A2AAR activates Rap1 through a cAMP-
dependent  exchange  factor  (EPAC).  Rap1  then  associates  with  B-raf,  but  this  is 
insufficient for ERK activation in CHO cells. Alternative intermediary candidates are 
protein kinase A (PKA) and members of the Src nonreceptor tyrosine kinase family 
because A2AAR-dependent ERK activation can be blocked by appropriate inhibitors 
(Seidel et al.; 1999).  
 
The coupling of the A2AAR to its cognate G protein Gs displays two unusual features.  
Firstly, adenylyl cyclase activation rates are incompatible with the collision coupling 
model  that  adequately  describes  the  kinetics  of  normal  receptor/Gs  interaction; 
nevertheless, in reconstitution experiments, the receptor can actually be shown to use 
Gs as a substrate (Nanoff et al.; 1994; Fredholm; 2007).  Secondly, in membranes, 
addition  of  guanine  nucleotides  fails  to  induce  dissociation  of  the  ternary  HR 
complex of agonist (H), receptor (R) and G protein (G), such that the agonist remains 
trapped in the high-affinity state. Brief incubation of the membranes with trypsin 
results  in  proteolytic  cleavage  of  the  receptor  and  restores  guanine  nucleotide 
regulation of agonist binding (Nanoff et al.; 1991). Proteolysis reduces the apparent 
molecular mass of the receptor by some 8 kDa; this is most likely accounted for by 
cleavage of the extended C-terminus because of the small size of the N-terminus. 
Taken together, these data suggest a role for the C-terminus in regulating the coupling 
properties of the A2AAR. Since the majority of the C-terminal tail itself is dispensable 
for a productive interaction with the G protein, this domain may represent the anchor 
for a modulatory component (Grieco et al.; 2003) .     28 
 
The  A2AAR  displays  a  considerable  degree  of  constitutive  activity  and  this  is 
independent of the cell line and the receptor expression level (Ledent et al.; 1992; 
Nanoff and Stiles; 1993; Yang et al.; 2005). Although both properties seem to reflect 
a preference of the receptor to remain in the active, G protein-coupled conformation, 
constitutive activity  and guanine nucleotide refractoriness can be dissociated. The 
extended C-terminal domain of the receptor is primarily responsible for constitutive 
activity. This is shown in truncated receptors which lose constitutive activity and in 
chimeric receptor constructs where cytoplasmic loop 3 and the C-tail of the A2AARs 
have then introduced into the A1AR and which become spontaneously active (Tucker 
et al.; 2000). However, the inability of guanine nucleotides to convert the receptor to 
the low-affinity conformation is preserved in the C-terminally truncated receptor. It 
seems  that the guanine nucleotide refractoriness of the membrane-bound receptor is 
solely due to coupling to Gs, the Gs selectivity being specified by cytoplasmic loop 3 
(Olah; 1997; Tucker et al.; 2000).  
 
Given the apparent link of constitutive activity with an intact C-terminus, this domain 
deserves closer examination. The C-terminus is rich in serine/threonine residues (12 
of  122  residues)  and,  in  cell  experiments,  is  rapidly  phosphorylated  following 
activation of PKC. However, mutations that remove the consensus sites for PKC-
dependent  phosphorylation  do  not  affect  the  ability  of  the  receptor  to  serve  as  a 
substrate for phosphorylation. It is therefore likely that PKC isoforms do not directly 
phosphorylate the receptor but that they activate an intermediary kinases (Palmer and 
Stiles; 1999). In addition, it is worth noting that the C-terminus of the A2AAR is 
enriched with proline residues: 22 prolines are present in the human A2AAR, 11 of 
which are interspersed in the first 311 amino acids.  The remaining 11 prolines are 
found in the last 100 amino acids with a cluster of four occurring in an acidic stretch 
at positions −10 to −18 removed from the C-terminus and a second cluster of five 
prolines between positions 341 and 357. A sequence comparison of the A2AAR shows 
a high degree of conservation in man, dog and guinea pig.  However, the C-terminus   29 
of  the  rat  receptor  diverges  substantially.  Regardless  of  this  discrepancy  between 
phylogenetic  relation  and  species  orthologues  of  the  receptor,  the  proline-rich 
stretches are obviously indicative of a potential interaction with SH3 domains.  In 
other instances, SH3 domain-containing proteins have indeed been found to bind to G 
protein-coupled receptors (Oldenhof et al.; 1998).  A recent study has provided a 
functional  link  between  the  A2AAR  and  the  actin  cytoskeleton.  Direct  interaction 
between  α-actinin  and  A2AAR  was  observed  suggesting  that  agoinst-mediated 
clustering and internalisation of the A2AAR regulated by its C-terminus is dependent 
on an intact α-actinin/actin network (Burgueno et al.; 2003). 
 
1.5.1.1  The A2AAR as anti-inflammatory GPCR 
 
Multiple in vivo and in vitro studies suggest a potent anti-inflammatory role of the 
A2AAR.  Early  reports  indicated  that  A2AAR  activation  could  inhibit  superoxide 
release from guinea pig and human eosinophils stimulated with opsonised zymosan 
(Yukawa  et  al.;  1989).  Furthermore,    the  A2AAR  agonist  NECA  inhibits  Fc-γ  R-
mediated phagocytosis and superoxide generation in polymorphonuclear leukocytes 
(PMN) which inhibited by the AR antagonist 8-ρ-sulphenyltheophylline (Salmon and 
Cronstein;  1990).  It  has  been  reported  that  adenosine  or  NECA  concentrations 
sufficient  to  inhibit  the  generation  of  ROS  decreases  adhesion  of  fMLP-induced 
PMNs to endothelial cells (Cronstein et al.; 1992). This reduction was found to be 
due to the inhibition of αMβ2 integrin expression (Wollner et al.; 1993). 
 
The potent anti-inflammatory effect of the folate drug methotrexate (MTX) is also 
adenosine-dependent  (Chan  and  Cronstein;  2002).  Low  concentrations  of  MTX 
reduce  leukocyte  accumulation  in  carrageenan-inflamed  air  pouches  (Cronstein; 
1994).  This  effect  was  completely  reversed  by  an  A2AAR  antagonist  DMPX, 
suggesting that adenosine acting at an A2AAR subtype mediated the protective effect.  
The  same  study  also  demonstrated  that  inhibition  of  adenosine  kinase  reduced 
leukocyte accumulation, an effect that was completely reversed by co-injection of 
adenosine deaminase (Cronstein et al.; 1994).   30 
 
A2AAR gene-deficient mice have proved to be an important tool in studying the anti-
inflammatory  effects  of  the  A2AAR  and  in  establishing  the  critical  role  of  these 
receptors in several models of immune-mediated tissue damage (Ledent et al.; 1997; 
Ohta  and  Sitkovsky;  2001).  The  absence  of  A2AAR  on  immune  cells  causes  the 
cessation  of  cAMP  production  in  activated  immune  cells,  allowing  uninterrupted 
tissue damage  (Sitkovsky et al.; 2004).  It has been reported that the A2AAR has a 
role in wound healing as mice lacking the A2AAR form less dense granular tissue and 
fewer  blood  vessels  during  wound  repair  and  accumulate  fewer  leukocytes  in 
response to inflammatory stimuli (Montesinos et al.; 2002).  
 
The  anti-inflammatory  role  of  A2AAR  has  driven  the  development  of  selective 
agonists  to  exploit  its  therapeutic  potential  (Lappas  et  al.;  2005).  Most  A2AAR-
selective agonists are 2-substitution of the non-selective AR agonist NECA, such as 
CGS21680, HENECA (Cristalli et al.; 1992; Rebola et al.; 2003), ATL-146e
 (Chang 
et al.; 2007) and MRE-0470 (Glover et al.; 2001).  Selective activation of the A2AAR 
has  been  shown  to  have  significant  protiective  effects  in  several  models  of 
inflammation, including a decrease in neutrophil transmigration into the cerebrospinal 
fluid  in  patients  with  endotoxin-stimulated  meningitis,  attenuation  of  the 
inflammation-induced increase in the blood-brain barrier permeability  (Sullivan et 
al.; 1999), inhibition of oxygen radical production (Thiel et al.; 2003)  and inhibition 
of  the production of cytokines such as TNFα (Majumdar and Aggarwal; 2003). In 
addition, ATL-146e reduced joint destruction caused by septic arthrosis and CGS-
21680  can  regulate  HIV-1  transactivation  regulating  protein  (Tat)-induced 
inflammatory responses (Cohen et al.; 2004; Fotheringham et al.; 2004).  
 
In  mouse  models  of  ischaemia/resperfusion  injury,  co-reperfusion  of  the  A2AAR-
selective agonist ATL-146e decreased liver injury by 90%. Co-administration of the 
A2AAR-selective antagonist ZM241385 attenuated this effect indicating the receptor 
specificity of the response (Day et al.; 2004).  In addition, the A2AAR was shown to   31 
protect from concanavilin A-induced liver injury in vivo (Ohta and Sitkovsky; 2001). 
In vitro studies suggests the anti-inflammatory response is due to a reduction in the 
expression of cytokine and chemokines from cells expressing the A2AAR (Bshesh et 
al.; 2002). THP-1  cells  treated  with  LPS increased the  expression of A2AAR and 
adenosine. Further treatment of the cells with an A2AAR-selective agonist CGS21680, 
decreased LPS-stimulated TNFα production in a time and dose-dependent manner.  
This  inhibitory  pathway  involves  A2AAR-mediated  activation  of  PKA  and 
phosphorylation of cAMP response element binding protein (Bshesh et al.; 2002) . 
 
One of the most well-defined protective effects of AR activation is inhibition of pro-
inflammatory  responses.  While  numerous  studies  have  shown  that  activation  of 
A2AARs  on  neutrophils  represents  a  critical  mechanism  by  which  adhesion  is 
blocked, selective activation of A2AAR in ECs from multiple origins also inhibits 
leukocyte-EC interaction. For example, Bouma et al. (1996) demonstrated that pre-
treatment with either adenosine or the non-selective AR agonist 2-chloroadenosine 
inhibited the release of IL-6 and IL-8 from IL-1β and LPS-activated HUVECs. AR 
activation also reduced the potency with which TNF-α could induce the cell surface 
expression of E-selectin and VCAM-1 with no effect on ICAM-1 induction (Bouma 
et al.; 1996). Analysis of these anti-inflammatory effects suggests the involvement of 
one or both of the A2AAR subtypes. Recent work employing more selective drugs has 
revealed that A2AAR activation is sufficient to inhibit E-selectin induction both in 
vivo (McPherson et al.; 2001) and in vitro (Sands et al.; 2004). Interestingly, while 
A2AAR stimulation is capable of inhibiting induction of VCAM-1 in vitro, this effect 
cannot be mimicked simply by elevation of intracellular cAMP levels (Bouma et al.; 
1996), suggesting that the receptor must activate at least one additional signalling 
pathway in ECs to mediate this effect. A2AARs on ECs are potentially useful targets 
for  drugs  aimed  at  alleviating  endothelial  dysfunction.  Administration  of  agonists 
should enhance the protective effects of receptor activation and reverse the excessive 
inflammation associated with disease progression. Several observations support the 
potential utility of the A2AAR in this regard. First, administration of the selective   32 
agonist ATL-146e reverses the accumulation of VCAM-1, P-selectin and ICAM-1 
observed in a carotid ligation model of vascular injury (McPherson et al.; 2001), 
although the ability of A2AAR activation to inhibit leukocyte and platelet activation 
may also indirectly inhibit EC activation by attenuating leukocyte-EC and platelet-EC 
interaction. Second, it has been demonstrated that potentiation of A2AAR-activated 
signalling  pathways  in  vascular  ECs  by  adenovirus-mediated human  A2AAR  gene 
transfer is sufficient to block E-selectin induction and monocyte adhesion to TNFα-
stimulated HUVECs even in the absence of an A2AAR-selective agonist (Sands et al.; 
2004). This is an important observation as it suggests that increasing flux through 
A2AAR-activated  signalling  pathways  in  ECs  can  dramatically  suppress  the  pro-
inflammatory  events  associated  with  diseases,  such  as  atherosclerosis  and  sepsis 
(Montesinos et al.; 2002) and rheumatoid arthritis (Montesinos et al.; 2000). 
 
Blocking the effects of endogenous extracellular adenosine in wild type mice using 
selective A2AR antagonists addressed possible caveats for interpreting experiments 
using  genetically  engineered  mice.  These  experiments  confirmed  the  conclusions 
derived  from  the  studies  of  A2AAR  gene-deficient  mice.  Injection  of  A2AAR 
antagonists  exacerbates  tissue  damage  by  sub-threshold  doses  of  inflammatory 
stimuli.  In  addition,  control  experiments  confirmed  that  although  extracellular 
adenosine-triggered cAMP accumulation was severely inhibited in A2AAR-deficient 
mice, agonists at other Gs-protein-coupled receptors were still capable of inducing 
similar  degrees  of  elevation  of  cAMP  in  wild-type  and  A2AAR-deficient  mice 
(Lukashev  et  al.;  2003).  Other  studies  confirmed  that  A2A  adenosine  receptor-
deficient  mice  did  not  have  unanticipated  spontaneous  mutations  in  the  cAMP-
signalling,  inflammation-inhibiting  pathway  downstream  of  the  A2AAR  (Ohta  and 
Sitkovsky; 2001).  
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1.6  Ubiquitination 
 
Ubiquitination/ubiquitylation refers to the post-translational modification of a protein 
by  the  covalent  attachment (via  an ε-amino isopeptide  bond)  of one  or  more  Ub 
mnomers.  Ub  is  a  highly  conserved  small  (8  kDa)  regulatory  protein  that  is 
ubiquitous in  eukaryoyes  (Hershko  and  Ciechanover;  1998;  Hochrainer  and  Lipp; 
2007).  The  most  well  characterised  function  of  Ub  is  labeling  proteins  for 
proteasomal degradation (Hochrainer and Lipp; 2007). Ubiquitination also controls 
the stability, function and intracellular localisation of a wide variety of proteins. Ubs 
covalently attach via an isopeptide bond to the ε-amino group of Lys residues on 
target  proteins.  This  occurs  through  a  three-step  process  involving  Ub-activation 
(E1), Ub-conjugation (E2) and Ub-ligation (E3) enzymes (Hershko and Ciechanover; 
1998; Gao and Karin; 2005). The types of Ub modifications that can form are diverse. 
In  the  simplest  form,  a  single  Ub  molecule  is  attached,  which  is  defined  as 
monoubiquitylation (Hicke and Dunn; 2003).  Alternatively, several Lys residues can 
be tagged with single Ub molecules, giving rise to multiple monoubiquitylation, also 
referred to as multiubiquitylation (Haglund et al.; 2003).  Since Ub contains seven 
Lys residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), Ub molecules 
can form different types of chains in an iterative process known as polyubiquitylation 
(Pickart and Fushman; 2004).  All seven Lys residues are possibly involved in chain 
formation in vivo, and Ub chains linked via Lys48 or 63 are the best characterised so 
far (Hicke et al.; 2005).  It is clear that Lys48-linked poly-Ub chains represent a 
signal for proteasomal degradation of modified substrates.  This discovery merited 
the award of a Nobel Prize in Chemistry 2004 and has been extensively reviewed 
(Hershko  and  Ciechanover;  1998).  However,  other  types  of  Ub  conjugates  are 
involved in the regulation of different cellular processes independently of proteolytic 
degradation  (Haglund  et  al.;  2003;  Hicke  and  Dunn;  2003;  Krappmann  and 
Scheidereit; 2005). 
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1.6.1  Ub as an inducible and reversible signal 
 
It is well established that protein ubiquitylation is induced by a vast variety of stimuli 
and upstream signalling events in cells.  For example, various cell surface receptors 
become ubiquitylated upon stimulation with extracellular ligands (Hicke and Dunn; 
2003).    In  addition,  many cytoplasmic and nuclear  proteins become  ubiquitylated 
following  their  phosphorylation  (Fiore  et  al.;  2003;  Muratani  and  Tansey;  2003).  
Moreover,  the  functions  of  Ub  ligases  are  tightly  regulated  by  signal-induced 
mechanisms  such  as  compartmentalisation,  degradation,  oligomerisation  and  post-
translational modifications  (Hershko and Ciechanover; 1998;  Thien  and  Langdon; 
2001; Dikic and Giordano; 2003).  Regulation at this level is particularly important, 
since Ub ligases play a central role in substrate recognition and specificity.  A second 
key  feature  of  the  ubiquitylation  system  is  that  Ub  can  be  rapidly  removed  by 
deubiquitylating enzymes (DUBs), which serve to switch off the Ub signal or to shift 
between different modifications of the same Lys residue (Hershko and Ciechanover; 
1998; Amerik et al.; 2006). Notably, ubiquitylation shares the two above-mentioned 
similarities  with  protein  phosphorylation.  In  addition,  both  modifications  are 
recognised by specific protein domains, providing a mechanism for translation of the 
Ub or phospho-specific signal to downstream effectors (Pawson et al.; 2001; Hicke et 
al.;  2005).  Intriguingly,  although  it  might  not  be  universally  required, 
phosphorylation is a signal that often precedes ubiquitylation of proteins either at the 
level of the E3 Ub ligase (e.g. Cbl) or the substrate protein (e.g. Eps15, Hrs and IқB). 
This shows that the two modifications are in tight cooperation in cells.  A major 
difference  between  the  two  systems  is  that  Ub  is  a  chemically  more  complex 
molecule than phosphate, since it has a larger surface to interact with other proteins.  
The fact that Ub can form chains increases the complexity even further.  In fact, the 
Lys63 and Lys48 chains have different conformations, with Lys63 chains being much 
more extended than those linked via Lys48, indicating that they likely have distinct 
targets and functions in the cell (Pickart and Fushman; 2004). All these features allow 
the ubiquitylation system to integrate and synchronise protein networks all the way 
from the cellular membrane to the nucleus.   35 
1.6.2  Proteasomal degradation 
 
Ub-mediated  protein  degradation  provides  a  major  mechanism  for  controlled 
proteolysis of targeted proteins. Ub conjugation to a substrate involves a cascade of at 
least three different enzymatic reactions (Figure1. 6).  First, Ub is activated by E1, the 
Ub-activating enzyme, to form a high-energy thioester linkage between its C-terminal 
glycine  residue  and  an  active  cysteine  on  the  E1.  Next,  the  thiol-linked  Ub  is 
transiently transferred  to the  next  enzyme  in  the  cascade E2, the  Ub  conjugating 
enzyme.  Finally, an E3 ubiquitin ligase either transfers the activated Ub molecule 
from the E2 to a lysine residue on the substrate or facilitates the transfer of Ub from 
the E2 directly to the substrate (Hershko and Ciechanover; 1998; Gao and Karin; 
2005).   
 
 The  substrates  marked  with  a  Lys48-linked  polyubiquitin  chain  are  selectively 
targeted  for  26S  proteasome-mediated  degradation  (Wilkinson  et  al.;  2001).  The 
consequences of Ub attachment depend upon how many Ub moieties are attached and 
the chain-linkage involved. Recognition for degradation by the proteasome involves 
polyubiquitin chains of at least four molecules in length (Thrower et al.; 2000) in 
which each Ub is linked via an isopeptide bound from the carboxy-terminus of one 
Ub to K48 on the adjacent Ub (Petroski and Deshaies; 2005). A proteomics screen of 
Ub conjugates in Saccharomyces cerevisiae found Ub modified at all seven lysine 
residues (Peng et al.; 2003).  The 26S proteasome consists of the 20S core complex, 
composed of four stacked rings of seven subunits that contain the proteolytic sites in 
the central cavity (Groll et al.; 1997). and a multisubunit 19S regulatory particle that 
caps both ends of the 20S particle.  The 19S particle, comprising a lid, a linker and a 
base, mediates the recognition of polyubiquitinated targeted proteins and promotes 
their unfolding in an ATP-dependent reaction. The base contains eight subunits (six 
ATPases of the AAA family and two large subunits, S2/Rpn1 and S1/Rpn2) and is 
connected to the lid by the S5a/Rpn10 protein (Ferrell et al.; 2000).  
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Figure 1. 6 Overview of the Ub Conjugation Pathway 
Ub is first activated by a Ub-activating enzyme E1; activated Ub is then transferred to 
a Ub-conjugating enzyme E2; a Ub ligase E3 facilitates the transfer of Ub from E2 to 
the protein substrate. There are two major classes of E3 Ub ligases: proteins with a 
HECT catalytic domain and proteins with a RING finger adaptor domain. Additional 
E3s, such as those containing a U box, were recently described. Substrates marked 
with a Lys48-linked polyubiquitin chain are selectively targeted to 26S proteasome-
mediated  degradation,  whereas  certain  substrates  conjugated  with  mono-  or 
multiubiquitins or Lys63-linked polyubiquitin chains are targeted for endocytosis or 
are enabled to engage in new protein-protein interactions. The polyubiquitin chain 
can be removed from the substrate by a  DUBs (Gao and Karin; 2005). 
 
1.7  E3 ligase and STAT degradation 
 
Ubiquitination  is  implicated  in  the  regulation  of  STATs.  The  ubiquitination  of 
STAT1 has been reported (Kim and Maniatis; 1996), but the underlying molecular 
mechanisms remained unknown. Proteasome inhibitors were also shown to stabilise 
the  tyrosine-phosphorylated  forms  of  STAT4,  STAT5,  and  STAT6  (Wang  et  al.; 
2000). Recent findings have clarified the role of ubiquitination in the regulation of 
STATs  and  provided  insights  into  the  specificity  of  this  modification.   37 
Paramyxoviruses  efficiently  use  the  Ub  pathway  as  a  mechanism  to  escape  the 
antiviral activities of IFNs (Horvath; 2004b). Paramyxoviruses are RNA viruses and 
include  the  human  pathogens  mumps,  measles,  and  Nipah  viruses  (Nishio  et  al.; 
2002). Their host evasion mechanisms are largely attributed to the V proteins. At 
least three V proteins function as E3 ligases with high specificity for STAT1, STAT2, 
or  STAT3.  The  V  proteins  form  a  multisubunit  E3  enzyme  complex  that  shows 
homology to the SOCS-E3 complex. The current model of the E3 ligase suggests a 
complex that contains the V protein and the cellular V-interaction proteins (VIPs), as 
well as additional proteins, including DDB1 (an ultraviolet- damaged DNA binding 
protein) and members of the Cullin family, especially Cullin 4A (Cul4A). The E3 
complex is termed VDC (for V/DDB1/CUL4A or V-dependent degradation complex) 
(Figure 1.7). VDC mediates STAT degradation using a combination of virus-encoded 
and cell-derived factors, where VIPs are the core degradation complex and the other 
cellular cofactors are responsible for the variations in V-protein target specificities 
(Ulane and Horvath; 2002). 
 
Recently, SLIM,  an  Ub  E3  ligase for  Tyr-phosphorylated  STATs,  was  identified, 
promoting  the  ubiquitination  and  degradation  of  STAT1  and  STAT4.    This  is 
supported by the enhanced protein levels of STAT1 and STAT4 observed in SLIM-
deficient mice (Tanaka et al.; 2005). SLIM also inhibited the Tyr phosphorylation of 
STATs, which is independent of its role in proteasomal degradation. There are two 
plausible  interpretations.  First,  SLIM  could  act  as  an  adaptor  molecule  to  recruit 
phosphatase  to  dephosphorylate  STAT.  Second,  ubiquitination  may  induce 
conformational change that would enable the association with phosphatase (Figure 
1.7). Whether SLIM can also ubiquitinate other STATs remain to be investigated. 
 
A  growing  body  of  evidence  suggests  that  ubiquitin-mediated  proteosomal 
degradation plays an important role in the regulation of cytokine signalling, such as 
JAK-STAT pathway (Figure 1.7). 
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Figure  1.7  Schematic  model  of  JAK/STAT  regulation  through  the  ubiquitin- 
proteasome pathway. 
Ligand binding induces receptor tyrosine phosphorylation by tyrosine kinases of the 
JAK family, producing a docking site for the STAT family of transcription factors. 
Phosphorylated STAT dimers translocate to the nucleus to initiate the transcription of 
target genes. At the receptor complex, activated JAKs interact with SOCS proteins 
and  become  polyubiquitinated  and  degraded  in  a  SOCS  box–dependent  manner 
mediated  by  the  elongin  B/C  (EloB  and  EloC)–Cul2–Rbx1  E3  ligase  complex. 
Rubulaviruses  can  target  STATs  for  ubiquitin-mediated  proteasomal  degradation 
using a VDC E3 ligase complex that requires the participation of V protein, VIPs, 
DDB1, and Cul4A. In the nucleus, STAT interaction with SLIM E3 ligase can result 
in  STAT  ubiquitination  and  degradation  or  dephosphorylation  (Ungureanu  and 
Silvennoinen; 2005). 
 
1.8  Aims and objectives of research 
Immune cell trafficking between tissues compartments is regulated in part by ECs 
surface  ARs.   Endothelial  cells  have  multiple  roles  in  inflammation  and  innate   39 
immunity.  Indeed, the first events recognised as inflammation are mediated solely or 
largely by endothelial cells.  In response to inflammatory mediators, endothelial cells 
express adhesion molecules, which are responsible for the recruitment of leukocytes 
to inflamed sites.  Endothelial cells synthesise and release mediators, such as platelet 
activating factor, IL-8 and IL-6, which have a direct role in the inflammatory process 
by conducting the movement of leukocytes between tissue compartments. Functional  
expression of A2A and A2BARs on various types of vascular ECs is well documented 
(Fredholm et al.; 2001), whereas there is little evidence for the functional expression 
of A1 and A3ARs (Montesinos et al.; 1997). 
 Moreover,  it  is  becoming  increasingly  apparent  that  pro-inflammatory  signalling 
pathways are subject to regulate by non-cytokine stimuli, providing an alternative 
control  mechanism.   For  example,  the  chemokine  IL-8  and  bacterial-derived 
chemoattractant fMetLeuPhe promote the accumulation of SOCS-1 in myeloid cells 
and neutrophils, following activation of their cognate G-protein-coupled receptors, 
resulting  in  an  inhibition  of  STAT3  phosphorylation  in  response  to  granulocyte 
colony-stimulating factor (Stevenson et al.; 2004).  The G-protein-coupled A2AAR 
has emerged as an important suppressor of inflammatory responses in vivo (Ohta and 
Sitkovsky; 2001; Sitkovsky et al.; 2004), but the mechanisms responsible for this 
effect  remain  to  be  fully  defined.   Studies  in  several  labs  and  elsewhere  have 
demonstrated that an important aspect of the A2AAR’s effects is its ability to inhibit 
NF-κB  activation  by  multiple  cell  type-specific  mechanisms  (Majumdar  and 
Aggarwal; 2003; Sands et al.; 2004). However, given its potent anti-inflammatory 
effects in vivo, this is unlikely to be the only cytokine-activated pathway affected. 
Following on from these findings, I am goind to focus during my study on A2AAR as 
a  potent  inhibitor  of  inflammatory  processes.  It  has  emerged  as  an  important 
suppressor of inflammatory responses in vivo (Ohta and Sitkovsky; 2001; Sitkovsky 
et  al.;  2004),  but  the  mechanisms  responsible  for  this  effect  remain  to  be  fully 
defined.  To  study  the  effects  of  potentiating  A2AAR  signalling  on  inhibiting 
inflammatory responses, we have generated a recombinant adenovirus (AV) encoding   40 
the human A2AAR gene for expression in a human umbilical vein endothelial cell 
(HUVEC). This facilitates highly efficient delivery of A2AAR to endothelial cells in 
vitro  to  examine  the  effects  of  an  increase  in  receptor  signalling  upon  cellular 
response to inflammatory stimuli. The consistent anti-inflammatory role for A2AAR 
signalling  in  a  variety  of  different  models  of  inflammation  indicates  a  possible 
common mechanism of action. A considerable number of studies suggest that this 
inhibition may occur at the level of transcription. The aim of this project is to study 
the  effect  of  A2AAR-overexpression  on  activation  of  the  JAK-STAT  pathway  in 
vascular ECs. Specifically, I aimed to test the effect of the A2AAR-overexpression on 
STAT  phosphorylation  and  expression  in  response  to  multiple  cytokines  (i.e  sIL-
6/IL-6, IFNα and leptin). The dissection of the pathways involved may ultimately 
lead to designing more specific and potentially useful drugs for the treatment of pro-
inflammatory diseases. 
 
At the end I would like to summarise the hypothesis of my work in two questions, 
which are; 
Does  A2AAR  gene  transfer  to  HUVECs  suppress  sIL-6/IL-6,  IFNα  and  leptin 
signalling? 
Is SOCS3 induction an important mechanism or are other processes involved? 
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Chapter 2 
Materials and Methods 
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2.1   Chemicals and Suppliers 
All reagents were of the highest grade commercially available and obtained from the 
 
 
Abcam Ltd., Cambridge 
Rabbit polyclonal antibody to STAT4 (cat# ab7967), Mouse mAb to anti-
glyceraldehyde-3-phosphate dehydrogenase GAPDH (cat# ab8245) 
 
Amersham Biosciences AB, Uppsala, Sweden 
Glutathione-Sepharose beads
TM 4B, 
 
Affinity Bioreagents, Golden, Co, USA 
 Anti-A2AAR-specific antibody 
 
BioRad Laboratories Ltd, Hemel Hempstead UK 
 Protein assay dye reagent concentration (Bradford's Reagent) 
 
BDH Laboratories Supplies, Pooles UK 
 Ammonium persulphate (APS), acetic acid, isopropylalcohol, methanol, potassium 
chloride, potassium hydroxide, sodium chloride. 
 
Cambrex BioScience Wokingham Ltd. Wokingham, Berkshire 
Endothelial Basal Media-2
TM (EBM-2) and the following supplements (foetal bovine 
serum  (FBS),  hydrocortisone,  fibroblast  growth  factor-B  (hFGF-B),  vascular 
endothelial growth factor (VEGF), insulin-like growth factor-l (IGF-l), ascorbic acid, 
epidermal  growth  factor  (hEG-F),  gentamicin  sulphate  and  amphotericin-B  (GA-
l000) and heparin). 
 Human umbilical vein endothelial cells (HUVECs), SeaPlaque ® agarose, Dulbeco’s 
modified  Eagle’s  medium  (DMAM),  cell  culture  grade  phosphate-buffered  saline 
(PBS) 
 
    following suppliers:-   43 
Calbiochem-Novabiochem (UK) Ltd., Nottingham 
MG132, JAK inhibitor I 
 
Cell Signalling Technology Inc., Beverly, MA USA 
Anti-phospho STAT3 (Tyr705) (cat# 9138), Anti-phospho STAT1 (Tyr701) (cat# 
9171), Anti-STAT3 (cat# 9132), Anti-STAT1 (cat# 9172), Anti-VEGFR2 (cat# 2479) 
 
Duchefa Biochemie, Haarlem, Netherlands 
Yeast extract, tryptone, microagar 
 
Astra-Zeneca Pharmaceuticals Alderley Park 
ZM241385 
 
 
N-(2-Hydroxyethyl)-piperazine-N’-(2-ethanesulfonic acid) (HEPES), sodium dodecyl 
sulphate  (SDS),  ethylenediaminotetra-acetic  acid  (EDTA),  dimethyl  sulphoxide 
(DMSO),  ethidium  bromide  solution,  glacial  acetic  acid,  absolute  ethanol, 
concentrated hydrochloric acid (HCL), glycine, sodium hydroxide, Tris(hydromethyl-
amino)ethane (TRIS) base, sodium carbonate, sodium hydrogen carbonate, sodium 
dihydrogen  ortho-phosphate,  di-sodium  hydrogen  ortho-phosphate,  boric  acid, 
chloroform, sucrose. 
 
GIBCO BRL Life Technologies, Paisley UK 
Isopropanol, OptiMEM. 
 
Interactiva- Thermo Hybaid, Thermo Biosciences GmbH, UIm, Germany  
HPLC-purified custom synthesised oligonucleotides 
 
Inverclyde Biologicals, Strathclyde Business Park, Bellshill, UK  
Schleicher and Schuell protran nitrocellulose membrane (0.2 m pore size) 
Fisher Scientific, Loughborough, Leicestershire UK   44 
Melford laboratories, Chelsworth, Ipswich, UK 
Dithiothreitol (DTT), isopropyl-β-D-thiogalactopyranoside (IPTG) 
 
New England Biolabs Inc., Beverley, MA USA 
Pre-stained protein molecular weight markers (ranging from 6.5-175kDa). 
 
Perkin-Elmer Life and Analytical Sciencesa, Monza, Italy 
Enhanced chemiluminescence (ECL) reagents 
 
Pierce, Rockford, IL, U.S.A. 
 Western Blot Stripping Solution, Slider-A-Lyzer ® Dialysis Cassette (0.5-3 ml 
capacity) 
 
Promega, Southhampton UK 
T4  DNA  Ligase,  Promega
TM  Wizard  plus  SV  DNA  mini-prep  kit,  restriction 
enzymes,  deoxynucleotides  triphosphates  (dNTPs),  Ableson  Maloney  leukaemia 
virus  (AMV  reverse  transcriptase),  ribonuclease  inhibitor,  Taq  DNA  polymerase, 
DNA molecular size markers (ranging from 100bp-1kbp). 
 
Qiagen, Crawley, West Sussex UK 
 DNA plasmid maxi-prep kit 
 
Reidel-de Haen, Seezle, Germany 
Glycerol, calcium chloride 
 
Research Biochemicals International, Natick, MA, USA 
CGS 21680 
 
Roche Applied Science USA 
FuGENE6 transfection reagent 
 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA 
Anti-ubiquitin Antibody (PD41) (cat# D1206), Anti-STAT3 (cat# H3104)   45 
Sigma-Aldrich Company Ltd., Poole, UK 
Triton  X-100,  soybean  trypsin  inhibitor,  benzamidine,  IgG-free  bovine  serum 
albumin (BSA), protein A-Sepharose, sodium periodate, 30% (w/v) acrylamide/0.8% 
(w/v) bisacrylamide solution, horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse IgG, HRP-conjugated  goat anti-rabbit IgG, HRP-conjugated rabbit anti-goat 
IgG,  thimerosal, bromophenol blue, sodium azide,  agarose, deoxycholic acid sodium 
salt,  polyethylenimine,  ampicillin,    paraformaldehyde,  N,N,N’,N’-
tetramethylethylenediamine  (TEMED),  phenylmethylsulphonyl  fluoride  (PMSF), 
foetal  bovine  serum  (FBS),  cell  culture  grade  trypsin  EDTA,  endothelial  grade 
trypsin  EDTA,  penicillin,  L-glutamine,  bicinchonic  acid  salt  (  BCA),  3,3’5,5’  -
tetramethylbenzidine (TMB), human  recombinant interferon-α (IFN-α), anti-FLAG
® 
M2  monoclonal  antibody  F-3165,  sodium  fluoride,    sodium  potassium  tartrate, 
deoxycholic  acid  (sodium  salt),    Trizol  reagent,  lysosyme,  sodium  orthovanadate, 
phenol:chloroform:isoamyl  alchol  (25:24:1  (v/v/v)),  ethylene  glycol-bis  (2-
aminoethylether)-N,N,N’,N’-tetracetic  acid  (EGTA),  mouse  anti-eNOS  antibody 
(cat# AF400594).   
 
Whatman International Ltd., Maidstone, Kent UK  
 
 Filter paper protran 300 mm x 3m (Conv.No# FM0535-1). 
 
 
Adenoviruses  (AVs)  encoding  Flag  epitope-tagged  wild-type  (WT)  and  Tyr705        
Phe-mutated  murine  STAT3  were  generously  donated  by  Prof.  Brian  Foxwell 
(Kennedy  institute  of  Rheumatology,  U.K.)  and  Prof.  Keilko  Yamauchi-Takihara 
(Osaka  University  Health  Care  Centre,  Japan)  and  described  in  (Kunisada  et  al.; 
1998; Williams et al.; 2004) 
 
A  pGEX-KG  bacterial  expression  construct  encoding  a  glutathione-S-transferase 
(GST)  fusion  protein  containing  the  ubiquitin-associated  (UBA)  domain  from 
Saccharomyces cerevisiae Dsk2p (Funakoshi et al.; 2002)  was generously donated 
by Prof. Hideki Kobayashi ( Kyushu University, Japan).    46 
 
2.2   Cell Culture & Transfection Methods 
 
2.2.1  Cell maintenance 
 
All cell types were grown at 37°C in a humidified atmosphere containing 5% (v/v) 
CO2. HUVECs were maintained in endothelial basal medium supplemented with 2% 
(v/v) foetal bovine serum, 0.04% (v/v) hydrocortisone, 0.4% (v/v) human fibroblast 
growth factor-B (hFGF-B), 0.1 % (v/v) vascular endothelial growth factor (VEGF), 
0.1% (v/v) insulin-like growth factor-l (IGF-l), 0.1% (v/v) ascorbic acid, 0.1% (v/v) 
human  epidermal  growth  factor  (hEGF),  0.1%  (v/v)  gentamicin  sulphate  and 
amphotericin-B (GA-1000) and 0.1% (v/v) heparin. Since HUVECs rapidly adapt in 
culture  conditions,  they  were  not  used  after  passage  5  (Muller  et  al.,  2002).  For 
passaging, confluent cells were washed in 5 ml of PBS and then treated briefly with 3 
ml  endothelial  grade  trypsin  in  order  to  detach  the  cells.  The  trypsin  was  then 
neutralised  with  10  ml  of  spent  medium  and  the  contents  transferred  to  a  50  ml 
centrifuge tube. Cells were centrifuged for 5 min at 1000g and the supernatant was 
discarded.  The  cell  pellet  was  gently  resuspended  in  medium  at  a  dilution  factor 
suitable to establish a cell density that could be reliably counted within a standard 
haemocytometer, typically 1:10 dilution. Wells were then seeded at an appropriate 
level according to the analysis performed as indicated in the figure legends. Typically 
a  6-well  plate  would  be  seeded  with  1  x  10
5  cells/well,  ready  for  infection  the 
following day with adenovirus. A minimum of 1x10
4 cells was used to maintain the 
cell line in a fresh 150 cm
2 tissue culture flask to which 11 ml of fresh medium was 
added. 
 
Human  embryonic  kidney  293  cells  (HEK  293)  were  maintained  in  DMEM 
supplemented with 10% (v/v) FBS, 1 mM L-glutamine, 100 units/ml penicillin and 
100  g/ml streptomycin. Confluent monolayers were washed once in 5 ml of sterile 
PBS  and  then  treated  with  1  ml  trypsin  EDTA.  Cells  were  then  returned  to  the 
incubator for a few minutes before the flask was disrupted to dislodge the cells. Cells   47 
were then typically diluted 1:8, 7 ml of which was used in experimental analysis and 
1 ml was used to maintain the cells to which 9 ml of fresh DMEM was added.  
 
 
2.2.2  Transfection with Fugene 
 
In a sterile microfuge tube 2  g of plasmid DNA was incubated with 200  l of serum 
free medium per well of a 6 well dish and vortexed briefly. 10  l of Fugene was 
added mixed gently and incubated for 15 min at room temperature. The DNA-Fugene 
mix was then added to each well containing 2 ml of fresh medium and left to incubate 
overnight. The next day, the medium was replaced with fresh growth medium. For 
experiments, cells were analysed 48 hr after transfection. 
 
2.2.3   Infection of HUVECs with AVs 
 
1x10
5 HUVECs were seeded in a 6 well plate and grown to 70% confluence.  The 
cells were then infected for 24 hr at a m.o.i. of 25 pfu/cell with recombinant AVs. 
The next day, the medium was replaced with fresh growth medium. The following 
day, confluent HUVECs in six-well plates were treated as described in the figures 
prior to washing in ice cold PBS and solubilised by  50  l/well detergent lysis buffer ( 
Section 2.5.1). 
 
2.3    Molecular Biology 
 
2.3.1   Preparation of antibiotic agar plates 
 
LB  agar  (1  %  (w/v)  bactotryptone,  0.5%  (w/v)  yeast  extract,  1  %  (w/v)  sodium 
chloride,  7%  (w/v)  agar)  was  prepared,  autoclaved  and  allowed  to  cool  before 
addition of ampicillin at the final concentrations 50  g/ml. The liquid LB agar was 
then poured into 90 mm-diameter Petri dishes, allowed to solidify and then allowed to 
sweat overnight at room temperature to get rid of excess moisture. Plates were then 
stored at 4°c until required for a maximum period of 2 weeks. 
   48 
2.3.2  Preparation of competent BL21 E.coli 
 
An overnight culture of BL21 E. coli was grown in 3 ml of LB broth containing 50 
 g/ml tetracycline. The following day, this was used to inoculate 250 ml of LB broth, 
which was then grown with aeration in a 37°C shaking incubator at 200 rpm, until the 
growth  rate  reached  log  phase  as  determined  by  the  culture  reaching  an  optical 
density at 600 nm of 0.35-0.375. Bacteria were transferred to two chilled 250 ml 
sterile centrifuge tubes and left for one hour on ice. Bacteria were then sedimented by 
centrifugation  at  3,500  g  for  20  min  at  4°C  and  the  supernatant  discarded.  The 
bacterial  pellet  was  then  washed  and  resuspended  in  62.5  ml  of  ice-cold  0.1M 
magnesium chloride. Following another 20 min centrifugation at 3,500g, the bacteria 
were  resuspended  in  62.5ml  of  ice-cold  15%  (v/v)  glycerol  with  0.1M  calcium 
chloride.  250   l  of  bacteria  were  aliquoted  into  sterile  microfuge  tubes  in  a  
ice/methanol bath to induce rapid freezing, and stored at -80 
oC until required. 
 
2.3.3   Transformation of competent BL21 E.coli 
 
Approximately 30-50 ng of plasmid DNA was added to a plastic 13 ml Falcon round-
bottom tube on ice. Once thawed 80  l/tube of competent E.coli was immediately 
added and the mix incubated on ice for 30 min. The tubes were incubated for 2 min at 
42°C before tube placed on ice and 1 ml of LB per tube was then added. Tubes were 
then shaken at 37°C for 30 min.  The transformation mix was then plated out onto LB 
agar plates containing the appropriate selection antibiotic and incubated overnight at 
37°C. 
 
2.3.4   Preparation of plasmid DNA 
 
Transformed colonies picked from agar plates using sterile pipette tips, were used to 
inoculate 10 ml of LB ( 1% (w/v) bactrotryptone, 0.5 % (w/v) yeast extract, 1% (w/v) 
sodium  chloride  broth  supplemented  with  the  appropriate  selection  antibiotic 
(50 g/ml ampicillin), and placed in the shaking incubator at 37°C overnight. Plasmid 
DNA was then isolated using the Promega 
TM Wizard plus SV miniprep purification   49 
system as per the manufacturer’s instructions. For larger quantities of plasmid DNA, 
the initial 10 ml culture was then used to inoculate a 500 ml culture containing the 
appropriate antibiotic and grown overnight at 37
oC with shaking. Plasmid DNA was 
isolated  using  the  Qiagen  Maxi  Kit  system  as  directed  by  the  manufacturer’s 
instructions.  The  concentration  of  double  stranded  DNA  obtained  was  calculated 
based on the assumption that 1 absorbance unit (A260) is equivalent to 50  g/ml of 
double stranded DNA. An absorbance ratio (A260/A280) greater than or equal to 1.6 
indicated good quality DNA. 
 
2.3.5  Digestion of plasmid DNA 
 
1-2  g of purified plasmid DNA was digested in a sterile microfuge tube containing 
the appropriate enzyme  buffer and 2-4 units of enzyme as per the manufacturer's 
instructions. In certain cases it was necessary, due to incompatible buffers, to purify 
the linearised plasmid DNA from the first digestion, before digestion with the second 
enzyme and buffer. This was achieved by phenol extraction and ethanol precipitation. 
Briefly  1/10  volume  of  3M  sodium  acetate  and  3  volumes  of  ice-cold  absolute 
ethanol were added to the sample. Following 30 min incubation on ice, samples were 
centrifuged at 4°C for 30 min at 13,000g and the supernatant removed. The DNA 
pellet was washed 3x in 50  l of 70% (v/v) ethanol, centrifuged at 4°C for 5 min at 
13,000g  and  allowed  to  air-dry.  It  was  then  resuspended  in  15   l  of  the  second 
enzyme  buffer  before  the  addition  of  2-4  units  of  the  second  enzyme  as  per  the 
manufacturer instructions. Restriction fragments were typically resolved on a 1 % 
(w/v) agarose gel containing 2.5  g/ml ethidium bromide run at 75 mV for 20-30 min 
in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, and 0.1 % (v/v) glacial acetic 
acid).  
 
2.3.6  Preparation of RNA 
 
A 6-well plate was seeded with HUVECs at density of 1x10
5 and was treated as 
described in the figure legend. Total RNA from HUVECs was isolated using Tri-  50 
Reagent (sigma-Aldrich, Irvine, U.K.). Briefly, cells were washed 3 times in ice cold 
PBS and solubilised by scraping into 0.5 ml of Tri- reagent. 0.2 ml of chloroform was 
added and the samples were thoroughly mixed and incubated at room temperature for 
5 min. Samples were then centrifuged at 13000g in a bench centrifuge for 5 min. The 
upper colourless layer which contains the RNA was transferred to a new RNASe 
tube, to which 1 ml of absolute ethanol was added. After spinning the samples at 4 
oC 
for 30 min at full speed.  The supernatant was discarded and the pellet was washed 
once in 1 ml of 70% (v/v) ethanol, then centrifuged for 5 min and the supernatant was 
discarded.   The pellet was air-dried by putting it on a heater at 37 
oC.  Once dry, the 
pellet was resuspended in 15  l of RNAase free water. The concentration of RNA 
obtained was calculated based on the assumption that 1 absorbance unit (A260) is 
equivalent to 40  g/ml of RNA. 
 
2.3.7   Reverse transcription-PCR (RT-PCR) 
 
For making cDNA from RNA (Section 2.3.6) 1  g RNA was mixed with 90 ng of 
Random hexanucletide primers in total volume of 15  l. Samples were heated at 70 
oC for 3 minutes and then immediately placed on ice to cool.  A mixture of 5x reverse 
transcriptase buffer  ( supplied with kit) and dNTPs was made and added to each 
reaction to give final concentrations of 50 mM Tris-HCl (pH 8.3 at 25 
oC), 40 mM 
KCl,  8.75 mM MgCl2, 10 mM DTT, 0.1 mg/ml acetylated BSA and 1mM of each 
dNTP. 20U of the Ribonuclease inhibitor and 5U AMV reverse transcriptase were 
then added, the samples mixed by pipetting and incubated at 42
  oC for 3 hrs. The 
cDNA generated was stored at -20
 oC until PCR analysis was performed. 
 
2.3.8   PCR of prepared cDNA 
 
 PCR was carried out using GoTaq® Flexi DNA polymerase kit.  Prior to this, PCR 
conditions were optimised to ensure that primers caused amplification of only one 
product of correct size (human SLIM/Mystique amplicon size of 900bp and human   51 
GAPDH amplicon size of 150 bp). The kit provides 5x Green or Colorless GoTaq® 
Flexi Buffer,  25 mM MgCl2 and . GoTaq® Flexi DNA polymerase  
 
PCR was performed in a sterile nuclease-free microcentrifuge tube, by combine, the 
following components on ice, 17.5  l Green Flexi Buffer,7  l MgCl2 solution (1mM 
for SLIM and 10  l of 1.5 mM for GAPDH), PCR nucleotide Mix 2.8 mM each 
dNTP, primers for SLIM are reverse (5´
-CTCAGGCCCGAGAG-3`) and forward (5´-
GTATGGCGTTGACG-3`)    while    GAPDH  are  reverse  GAPDH1  (5´- 
GAAGATGGTGATGGGATTTC-3`)  and  forward  GAPDH2  (5´-
GAAGATGGTGATGGGATTTC-3`) for GAPDH. GoTaq DNA polymerase 1.24 l 
and 1 l of template DNA were mixed in a final reaction volume of 25 l. 
 
The  thermal  cycling  conditions  for  the  SLIM/Mystique  PCR  amplification  were: 
initial denaturation at 95 
oC for 2 min, followed by 30 cycles of denaturation at 95 
oC 
for 1 min , and annealing at  58 
oC for 1min followed by an extension at 72
 oC for 1 
min/kbp. A final extension at 72 
oC has perform for 5 min.   
 
The conditions for GAPDH were: initial denaturation at 94 for 2 min, followed by 26 
cycles of denaturation at 95 
oC for 1 min, and annealing at 52 
oC 1min, followed by 
extension at 72
 oC for 1 min/kbp. A final extension at 72 
oC has performed for 5 min. 
After that products were then separated by agarose gel electrophoresis and visualized 
with ethidium bromide staining. 
 
2.3.9  Purification of adenoviral vectors 
 
 The generation and purification of plaque-purified adenoviruses (AV) encoding myc 
epitope-tagged human A2AAR and GFP made by (Sands et al.; 2004). The presence 
of the gene encoding GFP in a separate open reading frame allowed us to monitor 
viral  expression  by  fluorescence  microscopy.  8  days  post-infection  low  passage 
HEK293, cells were scraped and collected in a sterile centrifuge tube and pelleted by 
a  5  min  centrifugation  step  at  400g  at  room  temperature.  The  supernatant  was   52 
discarded and the pellet was washed in 1 ml sterile PBS. Cells were then disrupted by 
four freeze/thaw cycles in a dry ice/methanol bath and the pellet resuspended in 10 ml 
of sterile PBS. This was then used to infect two T-150 flasks of 50-60% confluent 
HEK 293 cells, grown in medium containing 2% (v/v) FBS. Virus particles from 
these cells were then prepared 3 days later, and used to infect a larger scale culture of 
20 x T-150 flasks of HEK 293 cells. From this large scale preparation, virus was 
isolated as per the method of (Nicklin et al.; 2001). Briefly, dislodged cells were 
pooled and pelleted by a brief centrifugation at 250g for 10 min at room temp. The 
supernatant was then discarded and the pellet resuspended in 10 ml of sterile PBS. 
The pellet was then washed four times with 1 ml of sterile PBS and the supernatant 
discarded. This was then subjected to four freeze/thaw cycles in order to lyse the cells 
and release the virus particles. The preparation was then added to a discontinuous 
caesium  chloride  gradient  set  up  in  a  13ml  sterile  ultracentrifuge  tube,  and  was 
subjected to centrifugation at 100,000g for 90 min at 8°C with zero deceleration. The 
opaque adenovirus band was then isolated by syringe extraction and added into a 
Slide-A-Lyser that allowed efficient overnight dialysis at 4°C in lL of dialysis buffer 
(15 mM sodium chloride, 51.2  M Tris (pH 7.5), 10  M EDTA) which was changed 
3 times. Virus samples were removed from the Slide-A-Lyser and diluted in a 1:1 
(v/v) ratio with sterile virus storage buffer (10 mM Tris-HC1, pH 8, 100 mM sodium 
chloride, 0.1 % (w/v) BSA, 10% (v/v) glycerol) and stored at -80°C in 30  l aliquots. 
 
Once isolated, the virus was subject to titration by the end-point dilution method 
(Nicklin and Baker, 2001) using GFP as a marker for positive colonies. 1 x 10
4 HEK 
293 cells/well was subcultured into 8x10 wells of a 96-well plate in order to reach 
approximately 50-60% confluency after 24 hr growth. 0.1 ml of virus was then used 
to infect the wells over a range of serial dilutions (10
-2-10
-11). This was incubated for 
18  hr  before  the  virus  was  removed  and  the  medium  replaced. The  medium  was 
replaced every 3 days up to 10 days post-infection until the well showed evidence of 
viral infection as assessed by GFP expression. After 10 days the number of virus 
positive wells was counted for each concentration of virus and the virus titre was.    53 
 
2.3.10    Preparation of GST-UBA Sepharose beads 
 
10 ml of LB broth supplemented with 50  g/ml ampicillin was inoculated from a 
glycerol  stock  of  BL21  E.coli  transformed  with  Dsk2pUBA  was  then  grown 
overnight, shaking at 37 
oC.  This starter culture was then used to inoculate  400ml 
LB containing 50 g/ml ampicillin was grown shaking at 200 rpm for 5 hours  (or 
until OD600 = 0.3 or greater) at 37
 oC.  Fusion protein expression was then induced by 
addition of IPTG to a final concentration of 1mM, and then grown for 4 hours at 37
 
oC with shaking at 200 rpm.  The bacteria were then harvested by centrifugation at 
6700g for 15 min, and the supernatant discarded. The cells were resuspended in 20ml 
lysis buffer (50mM sodium HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA and 1% 
(v/v) Triton-X-100) and incubated at room temperature for 30 min.  The samples 
were then probe sonicated on ice 3 times for 30 second to ensure efficient cell lysis 
and then centrifuged at 27000g for 30 mins to pellet insoluble material.  The cleared 
lysate was then added to 0.6 ml 50 % (v/v) glutathione-Sepharose bead suspension 
and placed on a rotating wheel at 4 
oC for 1 hour to allow the fusion protein to bind.  
The beads were then washed three times with 10 ml PBS and, following the final 
wash,  resuspended  in  50%  (v/v)  glycerol  in  PBS  supplemented  with  protease 
inhibitors  (0.1  mM  PMSF,  10   g/ l  soybean  trypsin  inhibitor  and  10   g/ l 
benzamidine)  for  storage  at  -20
  oC.    The  same  procedure  was  utilised  for  the 
preparation  of  GST-immobilised  Sepharose  beads  which  were  used  as  a  negative 
control.  
 
2.3.11    SPAGE assays for quantitation of immobilised GST fusion proteins. 
 
20  l of prepared bead suspension was centrifuged at 5000g for 20 sec at 4
 oC and the 
supernatant was removed with a 1 ml syringe. The protein was eluted from the beads 
by addition of 20  l of 2% (w/v) SDS sample buffer and incubated at 37 
oC for 30 
min.  The  sample  was  briefly  centrifuged  at  room  temperature  and  the  protein 
containing supernatant was removed via a Hamilton syringe into a fresh microfuge   54 
tube. Known amounts of BSA ranging from 0.2-2  g and 5 l and 10 l of eluted 
proteins were analysed by SDS PAGE using a 10% (w/v) resolving gel.  The gel was 
then stained for 1 hr at RT with Coomassie Brilliant Blue (3mM Coomassie Brilliant 
Blue G, 45% (v/v) methanol, 10% (v/v) acetic acid).  Following destaining overnight, 
the gel was then scanned and the density of the BSA bands were used to generate a 
standard curve from which the concentration of protein immobilised on the GST-
Sepharose beads could be determined (Figure 2.1). The same method used for GST 
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Figure 2.1 SDS-PAGE protein assay for immobilised GST fusion proteins on 
beads 
Known amounts of BSA ranging from 0.2-2  g and 5 l and 10 l of eluted proteins 
were analysed by SDS PAGE. The gel was stained for 1 hr at RT with Coomassie 
Brilliant Blue (3mM Coomassie Brilliant Blue G, 45% (v/v) methanol, 10% (v/v) 
acetic acid). The gel was destained overnight, scanned and the density of BSA bands 
was used to generate a standard curve. The BSA standard curve was then used to 
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estimate the concentration of protein immobilised on the beads. The same method 
was used for GST. 
 
2.4   Laboratory techniques 
 
2.4.1  Cell lysis 
 
Confluent HUVECs in six-well plates were treated as described in the figures prior to 
washing in ice cold PBS and solubilised by  50  l/well detergent lysis buffer (50mM 
sodium HEPES, pH 7.5, 150 mM sodium chloride, 5 mM EDTA, 10 mM sodium 
fluoride,  10  mM  sodium  phosphate  ,  1% (v/v)  Triton  X-100, 0.5%  (w/v)  sodium 
deoxycholate, 0.1% (w/v) SDS, 0.1 mM phenylmethylsulphonyl fluoride, 10  g/ml 
soybean trypsin inhibitor, 10  g/ml benzamidine and EDTA-free complete protease 
inhibitor mix). Samples were then scraped pipeting to microfuge tube and followed 
by brief vortexing, insoluble material was removed by microcentrifugation at 5000g 
for 5 min at 4 
oC  and the supernatant assayed for protein concentration using a  
bicinchonnic acid assay described in (Section 2.5.2). 
 
2.4.2   Discontinuous SDS-PAGE and Immunoblotting 
 
Samples  were  equalised  for  protein  amounts  (typically  10-20   g/sample)  and 
following  the  addition  of  an  equal  of  samples  buffers  were  fractionated  by 
discontinuous  SDS-PAGE  using  a  6  cm  10%  (w/v)  polyacrylamide  resolving  gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4 M Tris (pH 8.8), 0.1 % (w/v) 
SDS,  3%  (v/v)  glycerol,  0.01%  (w/v)  ammonium  persulphate  and  0.001%  (v/v) 
TEMED)  and  a  2  cm  3%  (w/v)  stacking  gel  (3%  (v/v)  acrylamide,  0.1%  (v/v) 
bisacrylamide,  0.1M  Tris  (pH  6.8),  0.1%  (w/v)  SDS,  0.01%  (w/v)  ammonium 
persulphate  and  0.001  %  (v/v)  TEMED).  Pre-stained  protein  markers  (Invitrogen 
Rainbow Markers, range 6.5-175kDa) in sample buffer (50 mM Tris (pH 6.8), 10% 
(v/v) glycerol, 12% (w/v) SDS, 0.0001 % (w/v) of bromophenol blue, 1 mM DTT) 
were also used in order to determine protein molecular mass. Electrophoresis was 
carried out using Biorad Mini-Protean II or III gel electrophoresis systems in running 
buffer  (27.4  mM  Tris,  0.19M  glycine,  0.1  %  (w/v)  SDS)  at  150  V  until  the   57 
bromophenol  blue  dye  front  reached  the  bottom  of  the  gel.  Proteins  were  then 
transferred electrophoretically onto a nitrocellulose membrane at 400 mA for 45 min 
in transfer buffer (24.7 mM Tris, 0.19 M glycine in 20% (v/v) methanol). Following 
transfer to nitrocellulose, membranes were blocked for one hour at room temperature 
in  blocking  solution  (5%  (w/v)  skimmed  milk  in  Tris-buffered  saline  (TBS) 
containing 0.1 % (v/v) Tween-20 (TBST) or 5% (w/v) skimmed milk in phosphate-
buffered saline (PBS), 0.2% (v/v) Triton X-100 in PBS. Antibody, diluted in Blotto 
as indicated in the Figure Legends. This was incubated in the cold room overnight on 
a rotating platform. The membranes were rinsed briefly in PBS before being washed 
three times in Blotto for 10 min. Membranes were then washed again briefly in PBS 
before  being  transferred  to  a  bag  containing  2  ml  of  the  appropriate  secondary 
antibody  conjugated  to  HRP  in  High-Detergent  Blotto  (10%  (v/v)  Blotto  in  PBS 
supplemented with 1.02% (v/v) Triton X-100 and 0.1 % (w/v) SDS). This was then 
placed  on  a  rotating  platform  at  room  temperature  and  incubated  for  1  hr.  The 
membrane was then washed three times for 10 min in Blotto and then washed  a 
further twice for 10 minutes in PBS. Membranes were then exposed to an enhanced 
chemiluminescent  procedure  in  which  HRP-specific  oxidative  degeneration  of 
luminal causes emission of light at 428 nm which is detected by Kodak XOMAT 
Blue X-ray film (see Table 2.1). 
 
2.4.3   Protein concentration  determination using the bicinchonic acid (BCA) 
protein assay 
 
Duplicate  10 l  samples  of  known  BSA  standards  in  the  range  0-2  mg/ml  and 
unknown protein samples were added to a 96-well plate. 0.2 ml BCA solution (1 % 
(w/v)  4,4  dicarboxy-2,2  biquinoline  disodium  salt,  2%  (w/v)  sodium  carbonate, 
0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) 
sodium bicarbonate pH 11.25, 0.08% (w/v) copper (II) sulphate) was then added to 
each  well.  Protein  concentration-specific  reduction  of  Cu
2+  to  Cu
1+  allows  the 
bicinchoninic acid sodium salt to bind the Cu
1+ ion forming an intense purple colour 
allowing measurement of the absorbance at 492 nm using a plate reader. Colour was    58 
There fore allowed to develop at room temperature for 30 min and the absorbance of 
the standards  was  used  to determine  a  straight  line  from which  unknown  protein 
concentrations could be calculated (Smith et al, 1985). 
 
 
 
 
Table 2.1 Antibody Incubation Conditions 
 
 
INCUBATION 
CONDITIONS 
 
BLOTTO 
  PROTEIN 
1ºAB  2ºAB  1ºAB 
 
2ºAB 
 
 
P-STAT1 
 
P-STAT1 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V) 
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
STAT1 
 
STAT1 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V) 
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
P-STAT3 
 
 
P-STAT3 
1:1000 
Overnight, 
cold room 
 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
STAT3 
 
STAT3 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
5% (W/V)  
skimmed milk 
PBS TWEEN   59 
 
P-STAT4 
P-STAT4 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
Ub 
 
 
Ub 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
 
GAPDH 
 
GAPDH 
1:20000 
1hr, room temp 
 
Anti-mouse 
HRP 
1:5000 
1hr, room         
temp 
 
5% (W/V) 
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
 
 
VEGFR2 
 
VEGFR2 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
 
eNOS 
 
eNOS 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:2000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
        TBST 
 
5% (W/V)  
BSA 
       TBST 
 
 
SLIM 
 
 
 
SLIM 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V) 
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
Flag 
 
Flag 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000       
1hr, room 
temp 
5%(W/V) 
skimmed 
milkPBS 
TWEEN 
5%(W/V) 
skimmed 
milkPBS 
TWEEN   60 
 
 
 
P-JAK1 
 
P-JAK1 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
 
P-JAK2 
 
P-JAK2 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
 
JAK1 
 
JAK1 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
 
 
JAK2 
 
JAK2 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
 
 
GFP 
 
 
GFP 
1:10000 
Overnight, 
cold room 
 
Anti-Goat or 
Anti-Sheep 
1:30000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
TBS TWEEN 
 
5% (W/V)  
skimmed milk 
TBS TWEEN 
 
 
 
2.4.4   GST-Dsk2pUBA pull-down assays 
 
Recombinant  GST  and  GST-Dsk2pUBA  were  purified  from  transformed  E.  coli 
BL21  (DE3)  cultures  using  glutathione-Sepharose  beads  following  induction  of 
fusion protein expression with IPTG as described in (Section 2.3.10). For pull-down   61 
assay, confluent HUVECs in six-well dishes were treated as described in the results 
prior to termination of the reactions by addition of ice cold PBS.  All subsequent 
procedures were performed at 4
oC unless indicated otherwise. Cells were solubilised 
by scraping into 0.25 ml/well pull-down lysis buffer (50mm sodium HEPES, pH 7.5, 
150 mM sodium chloride, 5mM EDTA, 1mM sodium vanadate, 6  M MG132, 1 mM 
N-ethylmaleimide, 1% (v/v) Triton X-100, 0.1 mM PMSF, 10  g/ml soybean trypsin 
inhibitor, 10  g/ml benzamidine and EDTA-free complete protease inhibitor mix) and 
incubated on ice for 30 min. Following centrifugation at 5000g for 5 min at 4 
oC to 
pellet  insoluble  material,  samples  were  equalised  for  volume  and  protein  content 
(typically 50  g in 0.2 ml) prior to the addition of either  GST or   GST-Dsk2pUBA 
(5 g/sample)  immobilised  to  glutathione-Sepharose  beads  and  incubated  with 
rotation for 1 hr. Beads were recovered by brief centrifugation and washed five times 
with 1 ml lysis buffer prior to the elution of bound protein by the addition of 50 l 
electrophoresis sample buffer containing 12% (w/v) SDS and incubation at 60 
oC for 
15  min.  Sample  were  then  fractionated  by  SDS-PAGE  and  transferred  to 
nitrocellulose for immunoblotting.  
 
To remove polyubiquitin chains from captured proteins prior to SDS-PAGE, beads 
were washed twice with 1ml deconjugation buffer (50 mM sodium HEPES, pH7.5, 
1mM dithiothretol) after the lysis buffer wash steps and then resuspended in 50 l 
deconjugation buffer supplemented with 0.2  M recombinant human isopeptidease 
T/UBP5  and  incubated  at  37 
oC  for  1  hr.  Reactions  were  terminated  by  brief 
centrifugation and the supernatant containing deconjugated proteins was removed for 
analysis by SDS-PAGE and immunoblotting following the addition of electrophoresis 
sample buffer. 
 
2.4.5  Immunoprecipitation  
 
Confluent HUVECs in six well dishes were pre-incubated with 6  M MG132 for 30 
min  prior  to  treatment  with  or  without  sIL-6Ra/IL-6  as  described  in  the  figure   62 
legends prior to termination of the incubation by placing dishes on ice and washing 
cell monolayers three times with ice-cold PBS. Cells were solubilised by scraping 
into 0.1 ml denaturing lysis buffer (50 mM sodium HEPES, pH 7.5, 100 mM sodium 
chloride, 1 mM N-ethylmaleimide, 2% (w/v) SDS, 0.1 mM phenylmethylsulphonyl 
fluoride, 10  g/ml soybean trypsin inhibitor, 10  g /ml benzamidine and EDTA-free 
complete protease inhibitor mix). The samples were then incubated at 95 
oC for 5 min 
followed by probe sonication on ice 3 times for 30 second. After the addition of 0.9 
ml lysis buffer containing sufficient Triton X-100 and sodium deoxycholate to give 
final concentrations of 1% (w/v) and 0.5% (w/v) respectively, insoluble material was 
removed by centrifugation at 5000g for 5 min at 4 
oC and soluble fractions equalised 
for protein content volume prior to incubation for 1 hr at 4 
oC with rotation with 25  l 
packed volume of protein A-Sepharose beads in the presence of 0.2% (w/v) IgG-free 
BSA.  Anti-STAT3  antibody  (2 g/sample)  was  then  added  and  the  incubation 
continued for a further 1 hr.  Immune complexes were isolated by brief centrifugation 
at 5000g for 5 min at 4 
oC and washed three times with 1 ml detergent lysis buffer 
prior  to  elution  of  precipitated  proteins  by  the  addition  of  40   l  electrophoresis 
sample  buffer  containing  12%  (w/v)  SDS  and  incubation  at  60 
oC  for  15  min. 
Samples  were  then  fractionated  by  SDS-PAGE  using  7.5%  (w/v)  polyacrylamide 
resolving gels and transferred to nitrocellulose for immunoblotting. 
 
Confluent HUVECs in six well dishes were pre-incubated with 6  M MG132 for 30 
min  prior  to  treatment  with  or  without  sIL-6Ra/IL-6  as  described  in  the  figure 
legends prior to termination of the incubation by placing dishes on ice and washing 
cell monolayers three times with ice-cold PBS. Cells were solubilised by scraping 
into 0.1 ml denaturing lysis buffer (50 mM sodium HEPES, pH 7.5, 100 mM sodium 
chloride, 1 mM N-ethylmaleimide, 2% (w/v) SDS, 0.1 mM phenylmethylsulphonyl 
fluoride, 10  g/ml soybean trypsin inhibitor, 10  g /ml benzamidine and EDTA-free 
complete protease inhibitor mix). The samples were then incubated at 95 
oC for 5 min 
followed by probe sonication on ice 3 times for 30 second. After the addition of 0.9 
ml lysis buffer containing sufficient Triton X-100 and sodium deoxycholate to give   63 
final concentrations of 1% (w/v) and 0.5% (w/v) respectively, insoluble material was 
removed by centrifugation at 5000g for 5 min at 4 
oC and soluble fractions equalised 
for protein content volume prior to incubation for 1 hr at 4 
oC with rotation with 
Recombinant Flag-tagged STAT3 was immunoprecipitated by the addition of 20  l 
packed volume of anti-Flag M2-Sepharose beads and incubation with rotation for 1 hr 
at 4 
oC. Immune complexes were isolated by brief centrifugation at 5000 xg for 5 min 
at 4 
oC and washed three times with 1 ml detergent lysis buffer prior to elution of 
precipitated proteins by the addition of 40  l electrophoresis sample buffer containing 
12% (w/v) SDS and incubation at 60 
oC for 15 min. Samples were then fractionated 
by SDS-PAGE using 7.5% (w/v) polyacrylamide resolving gels and transferred to 
nitrocellulose for immunoblotting. 
 
 
2.4.6  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 2H-tetrazolium  bromide  (MTT) 
assay of cell viability 
 
HUVECs were seeded in a 24 well plate and grown to 70% confluence.  The cells 
were then infected for 48 hr with recombinant AVs. On the next day, the medium was 
replaced with fresh growth medium. The following day, cells were treated with sIL-
6Ra/IL-6 for 3hr or 0.1 (w/v) sodium azide for 16 hr.  Then 20  l of 12  M MTT (3-
[4,5-dimethylthioazol-2-yl] was added to each well for 2 hrs. After that the medium 
in  use  was  discarded  and  200   l  of  dimethyl  sulfoxide  (DMSO)  was  used  to 
solubilize samples. 150  l from each well was then added to 96 well plates and the 
formazan product was determined by   measuring the absorbance at 550 nm.  
 
2.4.7   Statistical Analysis 
 
Statistical analysis was carried out using the Student t-test using GraphPad Instat 3 as 
indicated in the Figure Legends. Significance was assessed as p<0.05. 
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Chapter3 
Effect of A2AAR Expression on Cytokine Activation of the 
JAK-STAT pathway in vascular ECs 
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3.1    Introduction 
 
Endothelial cells were once viewed as relatively inert cells lining the vasculature. 
They are now recognized as active and responsive regulators of coagulation, platelet 
adhesion,  fluid  homeostasis,  wound  healing,  leukocyte  extravasation  and  vascular 
tone. Endothelial cells play a key role in the host response to infectious agents by 
regulating leukocyte trafficking, producing inflammatory cytokines  and  presenting 
antigen in association with major histocompatibility class II (MHC II) molecules (Cid 
et  al.;  1998)  .  A  number  of  infectious  induce  pathology  by  interacting  with 
endothelial  cells.  Infection  of  endothelial  cells  can  promote  thrombosis,  vascular 
leakage,  and  increased  adherence  and  emigration  of  leukocytes.  Furthermore, 
activation of a systemic inflammatory response, in the absence of direct endothelial 
cell  infection,  can  also  lead  to  endothelial  cell  dysfunction.  The  endothelial 
dysfunction occurs under activation conditions, with the acquisation of many new 
functional, inflammatory and immune properties. A consequence of this is to display 
many different transcription profiles. In addition, endothelial cells selectively control 
vascular  permeability,  which  is  important  in  many  pathophysiological  processes 
(Mader; 1996). 
 
Endogenous adenosine is a potent regulator of inflammation. It has been reported that 
adenosine  accumulation  underlines  the  anti-inflammatory  action  of  anti-rheumatic 
drugs such as methotrexate (Montesinos et al.; 2000). Monocytes and macrophages 
synthesise and release into their environment a variety of cytokines and other proteins 
that play a central role in the development of acute and chronic inflammation. There 
is evidence suggesting a regulatory connection between adenosine and its receptors 
and  inflammatory  cytokines.  In  human  and  murine  monocytes/macrophages,  the 
activation of adenosine receptors, particularly A2AAR, by adenosine or it analogues, 
modulates the production of inflammatory cytokines including TNF-α, IL-10, and IL-
12 (Hasko et al.; 2000). IL-12, a pro-inflammatory cytokine and a central inducer of   66 
Th1  responses  and  cell-mediated  immunity,  is  suppressed  by  adenosine  and  its 
analogues (Hasko et al.; 2000; Link et al.; 2000) . 
 
In human peripheral blood mononuclear cells, treatment with cAMP-elevating agents, 
such as the PDE4 inhibitor rolipram, causes complete inhibition of TNF-α production 
and an increase in IL-10 synthesis (Eisenhut et al.; 1993). In the same way, cAMP 
agonists  inhibit  endotoxin-induced  IL-6  expression  in  monocytes  or  macrophages 
differentiated in cell culture (Eigler et al.; 1998). Identification of A2AAR as natural 
brakes  of  inflammation  has  provided  a  useful  framework  for  understanding  how 
tissues  regulate  inflammation.  Thus,  targeting  the  endogenous  inflammatory 
pathways such as JAK-STAT signalling pathway by the A2AAR might be a useful 
strategy in the clinical management of inflammation. The aim of this chapter was to 
determine what effect adenoviral gene transfer of the myc-His-tagged human A2AAR 
would have on the inflammatory response in HUVECs, and what A2AAR-stimulated 
molecular mechanism were involved. 
 
A2AARs  have  a  non-redundant  role  in  the  attenuation  of  inflammation  and  tissue 
damage in vivo. Sub-threshold doses of an inflammatory stimulus as ((Tiegs; 1997; 
Kaneko et al.; 2000) showed cause minimal tissue damage in wild-type mice were 
found to cause extensive tissue damage, more prolonged and higher levels of pro-
inflammatory cytokines, and death of male animals deficient in the A2AAR. Similar 
observations were made in studies of three different models of inflammation and liver 
damage as well as during bacterial endotoxin-induced septic shock.  Previous studies 
suggest  that  A2AAR  plays  a  critical  role  in  the  physiological  negative  feedback 
mechanism  for  limiting  and  terminating  both  tissue-specific  and  systemic 
inflammatory responses.  Accumulation of extracellular adenosine in inflamed and 
damaged tissues (Rudolphi et al.; 1992) and the immunosuppressive properties of 
cAMP-elevating adenosine receptors (Cronstein; 1994; Huang et al.; 1997; Sullivan 
et al.; 2000) indicate that A2AAR signalling in immune cells is a possible natural 
mechanism of inhibition and/or termination of inflammation.    67 
3.2    Results  
 
HUVECS are a commonly used endothelial cell  in studies of inflammation (Ahn et 
al.; 2003; Carman et al.; 2003), as they grow more easily in cell culture compared to 
other  human  endothelial  cell  type.  It  is  widely  accepted  that  a  heterogeneity  of 
endothelial  function  (Yang  et  al.;  1991)  and  phenotype  exists  depending  on  the 
vascular bed of origin (Page et al.; 1992). One of the major documented differences 
between endothelial cells, as far as inflammatory processes are concerned, relates to 
responses to cytokines. HUVEC respond to cytokines such as sIL-6Rα/IL-6 and IFNα 
by  changinly  their  targe  gene  expression  as  well  as  allowing  mononuclear  cell 
transmigration.  However, a disadvantage of using primary endothelial cells is the 
difficulty  with  which  new  cDNAs  can  be  introduced.  This  was  important  as  any 
inhibitory effect of the A2AAR activation in transfected cells would be undetected if 
transfection  efficiencies  were  poor.  Generally  standard  transfection  methods  yield 
poor  transfection  efficiencies  (2-10%)  in  endothelial  cells  (Teifel  et  al.;  1997). 
Therefore,  in  order  to  bypass  this  problem,  a  replication-deficient  recombinant 
adenovirus  encoding  a  myc-His-tagged human  A2AAR, was  used  to  obtain  higher 
level  of  A2AAR  infection.This  facilitates  highly  efficient  delivery  of  A2AAR  to 
endothelial cells in vitro to examine the effects of an increase in receptor signalling 
upon cellular responses to class I cytokines. Several experiments have been designed 
to investigate the effect of overexpression of A2AAR in HUVECs to the same level as 
endogenous A2AAR level during the inflammation such as in hypoxia and its ligands 
on  the  function  of  IL-6,  IFNα  and  Leptin  in  HUVECs.  Specifically,  experiments 
tested the effects of IL-6 and IFNα on the activity of downstream signal transduction 
proteins (JAK-STAT pathway).  Previous work undertaken in our lab has shown that 
A2AAR-mediated inhibition of nuclear factor кB (NFкB) activation is a critical aspect 
of its anti-inflammatory signalling properities and that the molecular basis of this 
inhibition is cell type-specific (Sands et al.; 2004). Thus, experiments initially tested 
the effect of simply overexpressing the A2AAR (Figure 3.1A) on cytokine stimulation 
of the JAK-STAT pathway in these cells. It was necessary to ensure adequate A2AAR   68 
overexpression levels were achieved via adenoviral gene transfer before utilising this 
binding to examine the effect of the A2AAR on JAK-STAT pathway. Adenoviral gene 
transfer  was  necessary  due  to  the  passage-dependant  loss  of  endogenous  A2AAR 
expression observed in HUVECs. Confluent monolayers of HUVECs were infected 
with 25pfu/cell of either AdA2AAR or control virus AdGFP, which was required to 
achive  consistent  A2AAR-expression.  Infected  cells  were  identified  under 
fluorescence by the presence of green fluorescent protein GFP). (Figure 3.1B) shows 
A2AAR  gene  transfer  in  HUVECs  under  phase  and  fluorescence  light  with  the 
infected efficiency was determined to be ¬75%. GFP gene transfer was found to have 
an infection efficiency of ¬75% (Figure 3.1B). Moreover, immunoblot probe with 
anti-GFP  antibody  shows  there  is  no  different  in  GFP-expression  between  GFP-
overexpressing cells and A2AAR-overexpressing cells (Figure 3.1C). 
 
 In control GFP-overexpressing cells, treatment with a sIL-6Rα/IL-6 trans-signalling 
complex produced a transient increase in the phosphorylation of STAT1 on Tyr701 
and STAT3 on Tyr705. Overexpression of the A2AAR significantly reduced STAT 
phosphorylation at each time point after 15 min (Figure 3.2 and 3.3).   Interestingly, 
while total levels of STAT1 and STAT3 were unaltered by sIL-6Rα/IL-6 treatment of 
GFP-overexpressing cells, a marked decreased in the amount of total STAT1 and 
STAT3 in A2AAR-overexpressing HUVECs was detectable from as early as 30 min 
(Figure 3.2 and 3.3). To determine whether this effect was restricted to sIL-6Rα/IL-6, 
the effect of A2AAR overexpression on IFNα-mediated activation of the JAK-STAT 
pathway was also tested. In GFP-overexpressing cells, IFNα treatment produced a 
more transient increase in the Tyr-phosphorylation of STAT1 and STAT3 as sIL-
6Rα/IL-6.  Nevertheless,  A2AAR  overexpression  inhibited  phosphorylation  at  each 
time point (Figure 3.4 and 3.5). In addition, levels of total STAT1 and STAT3 were 
markedly reduced as early as 15 min following IFNα exposure (Figure 3.4 and 3.5). 
More extensive characterisation of the effect of sIL-6Rα/IL-6 and IFNα on STAT 
levels over time revealed that for sIL-6Rα/IL-6, STAT1 and STAT3 were reduced to 
almost undetectable levels after 3hrs in A2AAR-overexpressing HUVECs (Figure 3.6   69 
and 3.7) whereas, for IFNα,  STAT1 and STAT3 were reduced to almost undetectable 
levels  after  2hrs  (Figure  3.8  and  3.9).  In  contrast,  cytokine  exposure  of  GFP-
overexpressing HUVECs under the same conditions produced no detectable change 
in total levels of STAT1 or STAT3 in response to either cytokine, demonstrating that 
the down-regulation effect is specific for overexpression of the A2AAR (Figure 3.2-
3.9). Finally, the effect of the (A2AAR-selective agonist) CGS21680 and the (A2AAR 
antagonist) ZM241385 on cytokine stimulation of the JAK-STAT pathway in these 
cells  was  investigated.  Thus,  to  assess  the  functional  consequences  of  cAMP 
elevation  on  sIL-6Rα/IL-6.  The  effect  of  A2AAR  overexpression  on  STAT1  and 
STAT3 phosphorylation and down regulation could be rescued by co-incubation of 
sIL-6Rα/IL-6  with  the  A2AAR-selective  antagonist  ZM241385  (3.10,  3.11). 
Conversely,  co-incubation  with  the  selective  agonist  CGS21680  did  not  further 
potentiate  the  effect  of  receptor  expression  to  down  regulate  STAT  in  A2AAR-
overexpressing cells (Figure 3.10, 3.11).  
 
Importantly,  the  cytokine-stimulated  decrease  in  STAT  phosphorylation  did  not 
simply reflect reduced HUVECs viability following A2AAR overexpression. For that 
the  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 2H-tetrazolium bromide (MTT assay) 
used  to  demonstrate  that  GFP-  and  A2AAR-overexpressing  HUVECs  had  similar 
viabilities that were not affected by sIL-6Rα/IL-6 exposure at a 3 hr time point at 
which STAT degradation was detectable only in A2AAR-overexpressing cells (Figure 
3.12). 
 
The ubiquitin-proteasome pathway plays a central role in the targeted destruction of 
cellular proteins, including cell cycle regulatory proteins. Because these pathways are 
critical  for  the  inflammation,  proliferation  and  survival  of  all  cells,  proteasome 
inhibition is a potentially attractive therapeutic target in eukaryotic cells (Section 1.6). 
Regulated degradation is a commonly utilised mechanism by which cellular levels of 
transcription  factors,  such  as  p53  (Watson  and  Irwin;  2006),  are  controlled.  To 
determine  whether  STATs  are  targeted  for  degradation  by  the  proteasome,   70 
experiments were performed to investigate the effect of proteasome inhibition on the 
ability of the A2AAR overexpression to prime STATs for cytokine-mediated down-
regulation. Pre-incubation with the proteasome inhibitor MG132 was sufficient to 
abolish the effect of the A2AAR overexpression on priming both STAT1 and STAT3 
for down-regulation in response to sIL-6Rα/IL-6 (Figure 3.13 and 3.14). In addition, 
Mg132 was sufficient to abolish the effect of the A2AAR overexpression on priming 
both STAT1 and STAT3 for down-regulation in respone to IFNα (Figure 3.15 and 
3.16). Blocking of proteasomal degradation with MG132 abolished A2AAR inhibition 
of both sIL-6Rα/IL-6 and IFNα-mediated phosphorylation of STAT1 and STAT3, 
suggesting that STAT degradation is the only mechanism responsible for this effect 
(Figure 3.17-3.20). 
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Figure 3.1  A2AAR gene transfer to HUVECs 
 
Panel A: HUVECs were infected with the indicated AVs at an MOI of 25 pfu /cell as 
indicated in the Materials and Methods prior to preparation of soluble cell extracts for 
SDS-PAGE  and  immunoblotting  with  anti-myc  Ab  9E10  to  identify  recombinant 
A2AARs.  
 
Panel  B:  48hrs  post-infection,  HUVECS  were  examined  for  GFP  via  fluorescent 
microscopy. 
 
Panel C: HUVECs were infected with the indicated AVs at an MOI of 25 pfu /cell as 
indicated in the Materials and Methods prior to preparation of soluble cell extracts for 
SDS-PAGE and immunoblotting with anti-GFP Ab to identify the GFP-expression 
between GFP-overexpressing cells and A2AAR-overexpressing cells. 
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Figure  3.2  Effect  of  A2AAR  gene  transfer  on  STAT1  phosphorylation  and 
expression in response to sIL6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of phospho-STAT1 and total STAT1 levels from 
three  experiments  is  presented  (***p<0.001  and  *P<0.05  versus  the  response 
observed in AV.GFP-infected cells). Basal set at 100. 
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Figure  3.3  Effect  of  A2AAR  gene  transfer  on  STAT3  phosphorylation  and 
expression in response to sIL6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of phospho-STAT3 and total STAT3 levels from 
three  experiments  is  presented  (***p<0.001  and  *P<0.05  versus  the  response 
observed in AV.GFP-infected cells). Basal set at 100. 
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Figure 3.4 Effect of A2AAR gene transfer on STAT1 phosphorylation and 
expression in response to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative  analysis  of  phospho-STAT1  and  total  STAT1  levels  from  three 
experiments is presented (***p<0.001 and *p<0.05 versus the response observed in 
AV.GFP-infected cells). Basal set at 100. 
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Figure 3.5 Effect of A2AAR gene transfer on STAT3 phosphorylation and 
expression in response to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative  analysis  of  phospho-STAT3  and  total  STAT3  levels  from  three 
experiments is presented (***p<0.001 and *p<0.05 versus the response observed in 
AV.GFP-infected cells). Basal set at 100. 
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Figure 3.6 Effect of A2AAR gene transfer on STAT1 expression in response to 
prolonged exposures to IL-6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of total STAT1 levels from three experiments with 
each cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at 
the given time point). Basal set at 100. 
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Figure 3.7 Effect of A2AAR gene transfer on STAT3 expression in response to 
prolonged exposure to sIL-6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of total STAT3 levels from three experiments with 
each cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at 
the given time point). Basal set at 100. 
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Figure 3.8   Effect of A2AAR gene transfer on STAT1 expression in response to 
prolonged exposure to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative  analysis  of  total  STAT1  levels  from  three  experiments  with  each 
cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at the 
given time point). Basal set at 100. 
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Figure 3.9  Effect of A2AAR gene transfer on STAT3 expression in response to 
prolonged exposure to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative  analysis  of  total  STAT3  levels  from  three  experiments  with  each 
cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at the 
given time point). Basal set at 100. 
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Figure  3.10  Effect  of  A2AAR  on  STAT1  phosphorylation  and  expression  in 
response to sIL-6 Rα/ IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding cells were 
infected  with  the  indicated  AVs  prior  to  pre-treatment  with  or  without  6 M 
CGS21680 or 1 M ZM241485 for 1hr and treatment with 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for 1hr as indicated. The final concentration of vehicle (DMSO) in all wells was 
0.1% (V/V). Soluble cell extracts equalised for protein content were then fractionated 
by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies.  Quantitative 
analysis  of  phospho-STAT1  and  total  STAT1  levels  from  four  experiments  is 
presented (***p<0.001 and **p<0.01 versus the levels in untreated AV.mycA2AAR-
infected cells). Basal set at 100. 
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Figure  3.11  Effect  of  A2AAR  on  STAT3  phosphorylation  and  expression  in 
response to sIL-6 Rα/ IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding cells were 
infected  with  the  indicated  AVs  prior  to  pre-treatment  with  or  without  6 M 
CGS21680 or 1 M ZM241485 for 1hr and treatment with 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for 1hr as indicated. The final concentration of vehicle (DMSO) in all wells was 
0.1% (V/V). Soluble cell extracts equalised for protein content were then fractionated 
by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies.  Quantitative 
analysis  of  phospho-STAT3  and  total  STAT3  levels  from  four  experiments  is 
presented (**p<0.01  versus  the  levels  in  untreated  AV.mycA2AAR-infected cells). 
Basal set at 100. 
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Figure 3.12 Effect of A2AAR expression and sIL-6Rα/IL-6 expression on 
HUVECs viability 
HUVECs were infected with the indicated AVs prior to treatment with or without 
25ng/ml sIL-6 Rα/5ng/ml IL-6 for 3 hrs or 0.1% (w/v) sodium azide for 16 hrs. Cell 
viability was then determined by measurement of MTT reduction. This is one of three 
experiments that produced similar data. 
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Figure 3.13  Effect of MG132 on sIL-6Rα/IL-6-induced STAT1 downregulation 
in A2AAR-expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V). Soluble cell 
extracts  equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.14  Effect of MG132 on sIL-6Rα/IL-6-induced STAT3 downregulation 
in A2AAR-expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts  equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.15  Effect of MG132 on IFNα-induced STAT1 downregulation in 
A2AAR-expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.16  Effect of MG132 on IFNα-induced STAT3 downregulation in 
A2AAR-expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.17 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT1 phosphorylation in response to sIL-6 Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts  equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  Quantitative  analysis  of  phospho-
STAT1 levels from three experiments is presented. Basal set at 100. 
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Figure 3.18 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT3 phosphorylation in response to sIL-6 Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts  equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  Quantitative  analysis  of  phospho-
STAT3 levels from three experiments is presented. Basal set at 100. 
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Figure 3.19 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT1 phosphorylation in response to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  Quantitative  analysis  of  phospho-
STAT1 levels from three experiments is presented. Basal set at 100. 
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Figure 3.20 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT3 phosphorylation in response to IFNα 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  Quantitative  analysis  of  phospho-
STAT3 levels from three experiments is presented. Basal set at 100. 
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3.3     Discussion  
 
Numerous pharmacological studies have identified the A2AAR as a protective anti-
inflammatory G-protein-coupled receptor (Lappas et al.; 2005). Gene dosage studies 
have provided evidence to show that, at least in T-lymphocytes, there is no A2AAR 
reserve (Armstrong et al.; 2001).  Consequently, pathophysiological conditions that 
alter  A2AAR  expression,  such  as  the  onset  of  hypoxia  (Kobayashi  and  Millhorn; 
1999) and EC exposure to Th1 cytokines (Nguyen et al.; 2003), are likely to alter 
cellular  responsiveness  to  inflammatory  stimuli.  However,  despite  unequivocal 
evidence of its potent anti-inflammatory properties across different cell types, only 
the  ability  of  the  receptor  to  suppress  NF-қB  activation  has  been  offered  as  an 
explanation  for  its  effects  to  date  (Majumdar  and  Aggarwal;  2003;  Sands  et  al.; 
2004).   
 
This  study  has  extended  these  observations  by  demonstrating  that  the  A2AAR 
overexperession  can  prime  cytokine-activated  STATs  for  degradation  by  the 
proteasome.  Similar to the effect observed on suppression of  NF-қB in two separate 
cell systems (Sands et al.; 2004), overexpression of the A2AAR in the absence of any 
added agonist was sufficient to prime STATs for degradation (Figure 3.2-3.9). Thus, 
the  receptor  may  be  sufficiently  active  in  the  absence  of  agonist  to  trigger  its 
associated  signalling  pathways.  This  phenomenon  has  been  observed  for  both 
endogenous  receptors  and  overexpression  studies  of  GPCRs  (Bond  and  Ijzerman; 
2006; Vischer et al.; 2006). Reversal of the effect of receptor over-expression on 
STAT down-regulation by the A2AAR-selective antagonist ZM241385 (Figure 3.10 
and 3.11) is consistent with this hypothesis. Therefore, “constitutive” activation of the 
A2AAR,  whether  due  to  high  agonist-independent  activity  or  elevation  in  locally 
generated  adenosine  levels,  may  represent  an  especially  important  aspect  of  its 
function.  Moreover,  the  effect  is  not  restricted  to  overexpressed  A2AARs,  since 
exposure  of  low  levels  of  endogenous  A2AAR  in  HUVECs  with  ZM241385  also 
potentiates  sIL-6Rα/IL-6-stimulated  phosphorylation  of  STAT3  (W.Sands   99 
unpublished data).  Endothelial cells are an abundant source of adenosine in vitro, 
partly due to expression of CD39 which converts adenosine triphosphate/adenosine 
diphosphate  (ATP/ADP)  to  adenosine  monophosphate  (AMP)  and  CD73  which 
converts  AMP  to  adenosine  (Eltzschig  et  al.;  2004;  Zernecke  et  al.;  2006).  Both 
CD39 and CD73 are each strongly induced upon the onset of hypoxia, and CD73 
expression  can  also  be  potentiated  by  IFN-α  and  adenosine  itself  via  receptor-
mediated elevation of cAMP (Narravula et al.; 2000; Niemela et al.; 2004). Thus, 
control  of  adenosine  accumulation  and  initiation  of  protective  signalling  clearly 
represents an important adaptive mechanism by which hypoxia-mediated damage to 
the endothelium is minimised. The resulting accumulation of adenosine in large blood 
vessels is thought to play an important protective role in vivo by limiting endothelial 
cell activation and subsequent monocyte attachment (Zernecke et al.; 2006).  
 
To begin identifying potential mechanisms by which A2AAR overexpression could 
impact on cytokine signalling, we have been examining the effects of A2AAR on sIL-
6Rα/IL-6  and  IFNα  signalling  in  vascular  ECs  and  assessing  its  functional 
significance. A2AAR overexpression led to the more rapid degradation of STAT1 and 
STAT3 upon sIL-6Rα/IL-6 and IFNα stimulation. To determine whether STATs are 
targeted  for  degradation  by  the  proteasome,  experiments  were  performed  to 
investigate  the  effect  of  proteasome  inhibitor  MG132  on  the  ability  of  A2AAR 
overexpression to prime STATs for cytokine-mediated down-regulation. Figure 3.13-
3.16 show that MG132 was sufficient to abolish the effect of A2AAR overexpression 
on priming STATs for down-regulation in response to cytokines. Moreover, results in 
this Chapter show that blocking of proteasomal degradation with MG132 abolished 
A2AAR  inhibition  of  both  sIL-6Rα/IL-6  and  IFNα-stimulated  phosphorylation  of 
STATs.  Cross-talk  between  cAMP-mediated  signalling  pathways  and  STAT 
activation has been previously reported by Sengupta et al. (1996), and suggests that 
A2AAR-mediated  inhibition  of  STAT  is  cAMP-dependent.  In  addition,  studies  by 
Ivashkiv  et  al.  (1996)  have  shown  that  in  T  cell  activation,  cAMP  can  inhibit 
accumulation of  STAT1 protein. The A2AAR is highly expressed within most cells of   100 
the immune system, platelets, heart, lung and endothelium (Fredholm et al.; 2001) . 
Classically, the A2AAR signals via the Gs family of G proteins leading to an activation 
of adenylyl cyclase and the generation of cAMP. It is thought to mediate the vast 
majority  of  its  intracellular  effects  by  binding  and  activating  cAMP-dependent 
protein  kinase  (PKA),  which  controls  the  phosphorylation  status  and  activity  of 
multiple  intracellular  substrates  (Tasken  and  Aandahl;  2004).  However,  another 
family  of  intracellular  cAMP  sensors  termed Epacs  have  also  been  identified (de 
Rooij et al.; 1998). Epac1 and -2 function as cAMP-activated  guanine  nucleotide 
exchange factors specific for the Rap family of small G proteins and, thus promote 
the accumulation of active GTP-bound Rap1 and -2 (Rooij et al.; 1998; Bos; 2003). 
Interestingly, a role for Epac in EC function was recently revealed by the finding that 
the  Epac-mediated  activation  of  Rap1  and  the  subsequent  formation  of  adherens 
junctions  contribute  toward  the  ability  of  cAMP  to  enhance  endothelial  barrier 
function, an important aspect of its anti-inflammatory effects in vascular ECs (Cullere 
et al.; 2005; Fukuhara et al.; 2005). Previous work undertaken in our lab has shown 
that inhibition of STAT phosphorylation and induction of SOCS3 can occur via a 
cAMP/Epac/Rap1 pathway to limit IL-6 receptor signalling (Sands et al.; 2006). In 
addition, new evidence indicates that increased cAMP levels inhibit angiotensin II-
mediated JAK/STAT3 activation by a variety of mechanisms. Interestingly, cAMP-
elevating agents were  shown to inhibit IL-6-induced STAT activation in monocytes 
(Sengupta et al.; 1996). Together, these data establish a link for crosstalk between 
cAMP and JAK/STAT3, although at present, it is not known how cAMP inhibits 
STAT activation. In addition, in this study we showed that inhibition of proteasome 
function  was  sufficient  to  block  the  effect  of  A2AAR  overexpression  on  STAT 
degradation. This demonstrates that priming of STAT1 and STAT3 for degradation is 
the only mechanism responsible for the down regulation of STATs upon cytokine 
stimulation in our model. 
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In summary, many different mechanisms have  been implicated in downregulating 
STAT1  and  STAT3  signalling.  However,  for  many  of  these  the  molecular 
mechanisms  have  not  been  well  characterised.  Several  cytoplasmic  tyrosine 
phosphatases,  including  tyrosine  phosphatases  containing  a  SH2  domain  (SHP-1), 
CD45, and protein tyrosine phosphatase 1B, are implicated in the dephosphorylation 
of STAT1 and STAT3. In addition, SOCS are potentially key negative regulatory 
modulators  of  STAT1  and  STAT3  signalling  as  they  bind  to  Tyr  phosphorylated 
cytokine receptors and JAK catalytic sites. Moreover, the protein PIAS3 was found to 
be specific for the inhibition of activated STAT3 (Chung et al.; 1997a). Scaffolding 
proteins such as the STAT3-interacting protein (StIP1), a novel protein consisting of 
12 WD40 repeats, can also inhibit STAT3 signalling by modulating the formation of 
multiprotein  complexes  that  are  central  in  the  regulation  of  signal  transduction, 
transcription, and targeted proteolysis. (Collum et al.; 2000) demonstrated that StIP1 
had a high affinity for unphosphorylated JAK and STAT3, and when overexpressed 
blocks STAT3 activation and dimerisation/DNA binding, nuclear translocation, and 
reporter gene transcription following stimulation with IL-6.  
 
Data in this Chapter reveals several important aspects of A2AAR overexpression on 
cytokine and JAK-STAT signalling pathway. These include: 
 
(1) Potentiation of A2AAR function by increasing its overexpression reduces cytokine 
receptor  activation  of  the  JAK-STAT  pathway  by  priming  Tyr-phosphorylated 
STATs for proteasomal degradation. 
 
 (2) Over-expression of the A2AAR in HUVECs suppresses the ability of IFNα and a 
sIL-6Rα/IL-6 trans-signalling complex to promote Tyr-phosphorylation of STATs 1 
and 3 by targeting cytokine-activated STATs for proteasomal degradation.  
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(3) Pre-incubation with the proteasome inhibitor MG132 was sufficient to abolish the 
effect  of  A2AAR  overexpression  on  priming  both  STAT1  and  STAT3  for  down-
regulation in response to sIL-6Rα/IL-6 and IFNα. 
 
(4) The results show that inhibition of proteasome function was sufficient to block the 
inhibitory  effect  of  the  A2AAR  overexpression  on  STAT3  phosphorylation, 
demonstrating  that  priming  of  STATs  for  degradation  is  the  only  mechanism 
responsible for the reduced cytokine-stimulated STAT phosphorylation observed in 
A2AAR-overexpressing cells. 
 
(5) The effect of A2AAR overexpression on STAT1 and STAT3 phosphorylation and 
down regulation could be rescued by co-incubation of sIL-6Rα/IL-6 with the A2AAR-
selective antagonist ZM241385. Conversely, co-incubation with the selective agonist 
CGS21680  did  not  further  potentiate  the  effect  of  receptor  expression  to  down 
regulate STAT in A2AAR-overexpressing cells.  
 
(6) GFP- and A2AAR-overexpressing HUVECs had similar viabilities that were not 
affected by sIL-6Rα/IL-6 exposure at a 3 hr time point at which STAT degradation 
was detectable only in A2AAR-overexpressing cells. 
 
The  results  in  this  chapter  have  demonstrated  that  adenovirus-mediated  human 
A2AAR  gene  transfer  to  vascular  ECs  in  vitro  was  sufficient  to  prime  Tyr-
phosphorylated STATs for proteasomal degradation upon stimulation of sIL-6Rα/IL-
6  and  IFNα.  Both this study  and  others  describing  agonist-independent signalling 
from  the  A2AAR  have  been  cell  systems  in  which  the  recombinant  receptor  is 
overexpressed (Chen et al.; 2004). Therefore, the physiological significance in vivo of 
any  basal  activity  of  endogenous  A2AAR  expressed  at  low  level  is  unclear.  Gene 
dosage studies have provided evidence to show that, at least in T-lymphocytes, there 
is no A2AAR reserve (Armstrong et al.; 2001).  Consequently, pathophysiological 
conditions that alter A2AAR expression, such as the onset of hypoxia (Kobayashi and   103 
Millhorn; 1999) and EC exposure to Th1 cytokines (Nguyen et al.; 2003), are likely 
to alter cellular responsiveness to inflammatory stimuli. The availability of A2AAR- 
deficient mice can now allow assessment of the presence and importance of A2AAR 
expression and function as a potent anti-inflammatory mechanism in vivo. The effect 
of  A2AAR  overexpression  on  STAT1  and  STAT3  in  this  study  was  limited  to 
HUVECs in vitro. Differences between endothelial types are well documented such 
as  different  vascular  beds  displaying  distinct  biochemical  and  immunological 
properties (Sands and Palmer; 2005). Arterial ECs for example are more sensitive to 
eicosanoids and less competent than venous and post capilliary ECs in their ability to 
upregulate adhesion molecule expression such as E-selectin and VCAM-1 (Amberger 
et al.; 1997). 
 
The  effect  of  mechanotrasduction  has  also  not  been  investgated  in  this  study. 
Normally ECs are exposed to various degrees of pulsatile and shear stresses that vary 
in magnitude in a manner determined by position along the vascular tree and local 
vascular tone. Such forces are well known to affect EC gene expression (Li et al.; 
2005). So, the response in vivo may be different to those of culture system. Viral 
proteins could also change the endothelial function. Although experiments do use 
control virus it cannot rule out the possibility that viral protein somehow contribute to 
the observed effect of A2AAR overexpression. However uninfected cells of very low 
passage (which still contain endogenous low levels of A2AAR) still show inhibition of 
IL-6-mediated STAT phosphorylation when treated with an A2AAR-selective agonist 
CGS21680 (W.Sands unpublished data). 
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Chapter 4 
 
Mechanisms Controlling the Effects of A2AAR Expression on 
Cytokine-Stimulated Degradation of STATs 
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4.1     Introduction 
 
Physiological responses to cytokine stimulation must be regulated appropriately in 
order to prevent over active and damaging inflammatory processes. Several different 
mechanisms by  which  cytokine  signalling  is  attenuated  have been  identified.  The 
details,  however,  in  determining  the  functions  of  specific  inhibitors  of  cytokine 
signalling within particular cytokine signal transduction pathways have often been 
difficult to elucidate. SOCS knockout mice have pointed to the crucial functions of 
specific SOCS proteins in attenuating signalling by specific cytokines (Section 1.6). 
However, for the vast number of cytokines, the picture is complicated and in many 
cases  multiple  functionally  redundant  inhibitors  are  probably  responsible  for 
attenuating  signal  transduction.  Identifying  the  roles  of  negative  regulators  of 
cytokine  signalling  in  the  plethora  of  signalling  networks  that  are  activated  in 
response to cytokine is an interesting challenge.  
 
The  potent  anti-inflammatory  effect  of  the  A2AARs  have  been  demonstrated  in  a 
variety of different cell types (Section 1.5.1.1). One possible reason for this is that 
A2AAR activation can activate common mechanisms that lead to the suppression of 
inflammation. The results in Chapters 3 and 4 suggest that the A2AAR overexpression 
primes cytokine-activated STATs for degradation by the proteasome. The cytokine 
dependence  of  STAT  degradation  in  A2AAR-overexpressing  cells  raised  the 
possibility  that  JAK-mediated  STAT  phosphorylation  may  responsible  for  this 
phenomenon.  In  addition,  STATs  may  be  ubiquitylated  in  A2AAR-overexpressing 
HUVECs following cytokine exposure. Among the key proteins degraded by the Ub-
proteasome  system  are  those  involved  in  the  control  of  inflammation,  cell  cycle 
regulation and gene expression (Popat et al.; 2006). E3 Ub ligases play a key role in 
governing  the  cascade  of Ub  transfer  reactions  by  recognising  and  catalysing  Ub 
conjugation  to  specific  protein  substrates  (Section  1.7).  The  E3s,  which  can  be 
generally  classified  into  HECT-type  and  RING-type  families,  are  involved  in  the 
regulation  of  many  aspects  of  the  immune  system,  including  the  development,   106 
activation, and differentiation of lymphocytes, induction of T cell-tolerance antigen 
presentation,  immune  evasion,  and  virus  budding  (Mueller;  2004).  In  addition  to 
proteasome-mediated degradation, E3-promoted ubiquitination affects a wide array of 
biological processes, such as receptor down-regulation, signal transduction, protein 
processing  or  translocation,  protein-protein  interaction  and  gene  transcription 
(Passmore and Barford; 2004). Deficiency or mutation of some of  E3s, such as Cbl, 
Cbl-b or Itch, cause abnormal immune responses which can result in autoimmunity, 
malignancy, and inflammation (Bachmaier et al.; 2000; Wohlfert et al.; 2006). 
 
Interestingly, IFN-γ is a key pleiotropic regulatory cytokine (Goldberg et al.; 2002). It 
controls an inducible proteolytic cascade, which consists of PA28 and other inducible 
proteasome  subunits,  and  the  activity  of  aminopeptidases,  which  lead  to  increase 
peptide production for MHC I presentation. In addition, IFN-γ also decreases peptide 
destruction  by  down-regulating  the  expression  of  a  metalloproteinase,  thimet 
oligopeptidase, that  actively  destroys  many antigenic peptides (York  et  al.;  1999; 
Saveanu et al.; 2005). The UPS plays a significant role in the regulation of both T cell 
receptor (TCR) and co-stimulatory CD28 signalling through the action of ubiquitin 
ligases of the Cbl family (Zhang et al.; 2002a). CD28 co-stimulation results in the 
ubiquitination and degradation of Cbl-β, which eliminates the negative regulators and 
allows the expression of pro-inflammatory cytokines and their receptors. However, 
the most important link between the UPS and inflammation is related to NF-κB. NF-
κB is a master regulator of many inflammatory cytokine genes, and its activation is 
mediated through the UPS. NF-κB is actively inhibited when bound to IκBα. NF-κB 
activation  follows  the degradation  of  IκBα,  which is dependent  on  Lys 48-linked 
polyubiquination  of  IκBα  followed  by  proteasomal  degradation.  In  addition,  the 
proteasome has been shown to regulate inflammatory responses by controlling the 
function of macrophages (Qureshi et al.; 2005). It has also been reported that the de-
ubiquitinating enzyme CYLD posatively regulates proximal T cell receptor signalling 
in thymocytes by selectively binding to and deubiquitinating the active form of the 
kinase  Lck.  Due  to  defects  in  T  cell  development,  CYLD-deficient  mice  had   107 
substantially  fewer  mature  CD4+  and  CD8+  single-posative  thymocytes  and 
peripheral T cells (Reiley et al.; 2006). Hence, alterations in the UPS have profound 
effects on immune responses including the regulation of an array of inflammatory 
cytokines. 
 
 Results in Chapter 3 show that the A2AAR overexpression primes cytokine-activated 
STATs  for  degradation  by  the  proteasome.  In  addition,  pre-incubation  with 
proteasome  inhibitor  MG132  was  sufficient  to  abolish  the  effect  of  the  A2AAR 
overexpression on priming STAT3 and STAT1 for down-regulation in response to 
cytokines. Because of that, we have investigated the responsibility of JAK for the 
tyrosine phosphorylation of STAT upon cytokine stimulation. In addition, we have 
tested  the  hypothesis  that  STAT  is  ubiquitylated  in  A2AAR-overexpressing  cells 
following cytokine stimulation before degradation by the proteasomal system.  
 
4.2    Results 
 
Phosphorylation is a commonly utilised signal that regulate substrate recognition by 
E3 ubiquitin ligases. For example, IκB kinase (IKK)-stimulated phosphorylation of 
IκBα on Ser32 and 33 is required for its recognition by the F-box component of the 
βTrCP/SCF1 E3 ligase complex (Liu et al.; 2005; Nalepa et al.; 2006). The cytokine 
dependence  of  STAT  degradation  in  A2AAR-overexpressing  cells  raised  the 
possibility  that  JAK-mediated  STAT  phosphorylation  was  a  trigger  of  this  event. 
Thus,  several  experimental  approaches  were  used  to  test  this  hypothesis  in  more 
detail.  Firstly, the effect of inhibiting JAK activity on STAT degradation in A2AAR-
overexpressing cells was examined. This demonstrated that 0.1  M of JAK inhibitor 
1 (A potent cell-permeabile and ATP-competitive inhibitor of JAKs. Display spotent 
inhibitory activity against JAK1, JAK2, JAK3 and Tyk2) (Pedranzini et al.; 2006) 
was  sufficient  to  inhibit  JAK1  and  JAK2  tyr-phosphorylation  (Figure  4.1A)  and 
STAT1 Tyr-phosphorylation (Figure 4.1B) upon sIL-6Rα/IL-6 stimulation. The same 
concentration  of  JAK  inhibitor  was  sufficient  to  abolish  the  down-regulation  of   108 
STAT1  and  STAT3  upon  sIL-6Rα/IL-6  and  IFNα  stimulation  in  A2AAR-
overexpressing cells (Figure 4.2-4.5). Secondly, experiments utilised the presence in 
HUVECs  of  endogenous  Ob-Rb  leptin  receptors.  Leptin-bound  Ob-Rb  selectively 
stimulates JAK-mediated phosphorylation of STAT3 but not STAT1 (Zabeau et al.; 
2003).  Consistent with this observation, exposure of HUVECs to leptin specifically 
promoted  the  Tyr  phosphorylation  of  STAT3  but  not  the  Tyr  phosphorylation  of 
STAT1 whereas sIL-6Rα/IL-6, which was used as a positive control, promoted the 
Tyr  phosphorylation  of  both  STAT1  and  STAT3    (Figure  4.6).  In  GFP-
overexpressing cells, treatment with leptin produced phosphorylation of STAT3 on 
Tyr705. Overexpression of the A2AAR significantly reduced STAT3 phosphorylation 
at each time point after 15 min (Figure 4.7). Leptin treatment also induced a time-
dependent down-regulation of STAT3 but not STAT1 in A2AAR-overexpressing cells 
after  1hr  (Figure  4.8).  Cytokine  binding  to  its  receptor  leads  to  activation  of  the 
receptor-associated tyrosine kinase JAKs. JAKs trans-phosphorylate the intracellular 
domain of the receptor, and these phospho-Tyr residues provide docking sites for 
latent cytoplasmic STATs. STATs are recruited to the receptor via their SH2 domain, 
and JAKs phosphorylate STATs on a specific Tyr residue on their cytoplasmic tail. 
Homo- or heterodimerisation of STATs are achieved via reciprocal binding of this 
critical phospho-Tyr of one monomer and SH2 domain of the binding partner (Haan 
et  al.;  1999).  Following  on  from  our  results  which  show  that  the  A2AAR-
overexpression  can  prime  Tyr-phosphorylated  STATs  for  degradation  by  the 
proteasome  required  JAK  activity.  There  are  two  possible  explanations  for  this 
requirement based on how JAK function. The first one is JAK Tyr-phosphorylated 
STAT.    The  second  possibility  is  JAK  Tyr-phosphrylation  of  the  receptor.  To 
discriminate  between  the  two  possibilities  HUVECs  were  co-infected  with  AVs 
encoding the  A2AAR and either Flag epitope-tagged WT or Tyr705→Phe mutated 
STAT3, since mutation of Tyr705 renders STAT3 resistant to phosphorylation by 
JAKs  (Kaptein  et  al.;  1996).  Under  conditions  in  which  WT  STAT3  underwent 
down-regulation  in  response  to  IFNα  exposure  similar  to  the  effect  observed  for 
endogenous  STATs,  the  levels  of  Tyr705→Phe  mutated  STAT3  were  not  altered   109 
(Figure 4.9). Thus, JAK-mediated phosphorylation of STATs appears to be essential 
for  promoting  their  cytokine-mediated  degradation  in  A2AAR-overexpressing 
HUVECs. Recently, SLIM/Mystique, a ubiquitin E3 ligase for Tyr-phosphorylated 
STATs  was  identified  that  promoted  the  polyubiquitination  and  degradation  of 
phosphorylated STAT1 and STAT4 (Tanaka et al.; 2005). RT-PCR techniques were 
used to test for the presence of SLIM/Mystique mRNA in A2AAR-overexpressing 
HUVECs (Figure 4.10). GAPDH was used as a control for the reverse transcription 
reaction and pcDNAA3/HA-SLIM/Mystique was included as a positive control for 
the  SLIM/Mystique  PCR  reaction.  The  results  showed  that  SLIM/Mystique  was 
undetectable  in  our  system,  despite  being  able  to  detect  the  positive  control.  To 
confirm this lack of SLIM/Mystique mRNA in HUVEC was manifest at the protein 
level, I looked for the presence of SLIM/Mystique protein in HUVECs by western 
blot analysis. HUVECs treated as indicated in the figure legend were solubilised and 
analysed  for  expression  of  SLIM/Mystique  protein  by  immunoblotting  with  anti-
SLIM/Mystique antibody (Figure 4.11). Lysates from HEK293 cells transfected with 
either empty vector or a SLIM/Mystique expression construct were used as negative 
and positive controls respectively for the antibody reactivity (Figure 4.11). Together, 
these  results  suggest  SLIM/Mystique  is  not  expressed  at  detectable  level  under 
conditions in which STAT degradation occurs (Figure 4.11). 
 
Cytokine activation of STATs is also negatively regulated by SOCS proteins, which 
can function as E3 ligases. In addition cAMP can induce SOCS3 via activation of 
Epac/Rap1  (Sands  et  al.;  2006).  Thus,  A2AAR-overexpression  may  potentialy  up-
regulate  SOCS3  expression  upon  cAMP  activation  leading  to  accelerated  STAT 
degradation.  To  further  identify  the  role  of  A2AAR-overexpression  in  priming 
cytokine-activated STATs for degradation by the proteasome, the levels of SOCS3 
protein  was  determined  by  immunoblotting  and  probing  with  an  anti-SOCS3 
antibody.  The  results  showed  that  there  is  a  siginficant  difference  in  SOCS3 
expression between GFP and A2AAR-overexpressing cells upon cytokine stimulation 
at  2  and  3  hrs  (Figure  4.12).  However,  this  does  not  rule  out  the  physiological   110 
function of SOCS3 or other SOCS family members in the down-regulation of STAT1 
and STAT3. Proteins targeted for proteasomal degradation are typically tagged on 
one or more Lys residues with Lys48-conjugated polyubiquitin chains (Liu et al.; 
2005; Nalepa et al.; 2006).  These chains are recognised as a degradation signal by 
the 26S proteasome, which then breaks down the target protein into its constituent 
amino acids for use in new protein synthesis and recycles polyubiquitin chains into 
monomers for further rounds of conjugation (Liu et al.; 2005; Nalepa et al.; 2006).  
To  assess  directly  whether  STATs  were  ubiquitylated  in  A2AAR-overexpressing 
HUVECs following cytokine exposure, STAT3 was immunoprecipitated following 
denaturing  cell  lysis  to  remove  any  STAT-associated  proteins  and  inactivate 
deubiquitylating  enzymes  (DUBs).  Immunoblotting  of STAT3  immunoprecipitates 
with anti-ubiquitin antibody revealed that HUVECs treatment with sIL-6Rα/IL-6 only 
resulted  in  the  accumulation  of  a  smear  of  ubiquitylated  STAT3  in  A2AAR-
overexpressing cells (Figure 4.13). Thus, the accumulation of ubiquitin-conjugated 
STATs in HUVECs occurred under conditions that also promoted their degradation. 
 
A  similar  immunoprecipitation  approach  was  attempted  for  STAT1  but  was 
unsuccessful due to its inefficient immunoprecipitation with commercially available 
antibodies.    Instead,    a  strategy  employing  the  ability  of  the  UBA  domain  from 
Saccharomyces cerevisiae protein Dsk2p to specifically isolate ubiquitylated proteins 
from  whole  cell  extracts  in  vitro  was  used  (Funakoshi  et  al.;  2002).  Using 
recombinant  GST-Dsk2pUBA  immobilised  to  glutathione-Sepharose,  Tyr701-
phosphorylated  STAT1  could  only  be  captured  from  A2AAR-overexpressing 
HUVECs  after  treatment  with  sIL-6Rα/IL-6,  i.e.  conditions  that  promoted  STAT 
degradation (Figure 4.14). Probing of immunoblots with an anti-ubiquitin antibody 
also  confirmed  the  ability  of  GST-Dsk2pUBA  but  not  GST  alone  to  specifically 
capture ubiquitylated proteins from soluble HUVECs extract (Figure 4.14). 
 
Ubiquitin is a relatively stable protein in yeast despite its covalent linkage to many 
proteins  destined  for  proteasomal  or  vacuolar  degradation  (Swaminathan  et  al.;   111 
1999).  This  is  possible  because  ubiquitin-protein  modification  is  transient. 
Deubiquitylating  enzymes  release  ubiquitin  from  polyubiquitin  conjugates  by 
cleaving the isopeptide bond between the ubiquitins in a chain or at the ubiquitin C 
terminus linked to substrate. The yeast DUB family consists of at least 20 members, 
including 16 in the ubiquitin-specific processing protease (UBP) subfamily (Amerik 
et al.; 2000; Amerik and Hochstrasser; 2004). To further confirm the specificity of 
STAT  binding  to  GST-Dsk2pUBA  in  vitro,  immobilised  proteins  were  incubated 
with or without recombinant human isopeptidase T/UBP5, which selectively removes 
ubiquitin monomers from modified proteins  (Lacombe  and Gabriel; 2002). Under 
these  conditions,  incubation  of  GST-DsK2pUBA-immobilised  beads  with  UBP5 
promoted the release of Tyr701-phosphorylated STAT1 (Figure 4.15). No significant 
release  was  detectable  if  the  reaction  was performed  at 4 
oC,  suggesting that  the 
release  of  STAT1  from  GST-Dsk2pUBA  required  its  deubiquitylation  by 
enzymatically active UBP5 (Figure 4.15). 
 
To determine the relationship between STAT ubiquitylation and Tyr phosphorylation 
in A2AAR-overexpressing cells, Flag-tagged WT and Tyr705→Phe-mutated STAT3 
were co-expressed in HUVECs with the A2AAR and immunoprecipitated with anti-
Flag  antibody-conjugated  Sepharose  beads  following  denaturing  cell  lysis  after 
cytokine treatment (Figure 4.16). This demonstrated that under conditions in which 
recombinant WT STAT3 is polyubiquitylated similarly to the endogenous STAT3 in 
response  to  sIL-6Rα/IL-6,  no  ubiquitylation  of  the  Tyr705→Phe-mutated  STAT3 
could  be  detected  (Figure  4.16).  Taken  together,  these  data  are  consistent  with  a 
model  where  by  A2AAR-overexpression  specifically  primes  JAK-phosphorylated 
STATs for polyubiquitylation and subsequent degradation by the proteasome.  
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Figure 4.1  Effect of JAK inhibition 1 on sIL-6Rα/IL-6-induced  JAK1, JAK2 
and STAT1 phosphorylation  
 
Panel A: 1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, 
cells were pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to 
treatment  with  or  without  sIL-6Rα/IL-6  for  30  min  as  indicated.  The  final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).   Soluble cell extracts 
equlised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with anti-phospho-JAK1, anti-phospho-JAK2, anti-JAK1 and anti-
JAK2. 
 
Panel B: 1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, 
cells were pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to 
treatment  with  or  without  sIL-6Rα/IL-6  for  30  min  as  indicated.  The  final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equlised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with anti-phospho-STAT1 antibody. 
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Figure 4.2  Effect of JAK inhibition on sIL-6Rα/IL-6-induced STAT1 
phosphorylation and downregulation of STAT1 in A2AAR expressing HUVECs 
 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to treatment 
with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 4. 3 Effect of JAK inhibition on sIL-6Rα/IL-6-induced STAT3 
downregulation in A2AAR expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to treatment 
with  or  without  25ng/ml  sIL-6  Rα/5ng/ml  IL-6  up  to  3hr  as  indicated.  The  final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 4.4 Effect of JAK inhibition on IFNα-induced STAT1 downregulation in 
A2AAR expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to treatment 
with or without 500 unit/ml IFNα up to 3hr as indicated.  The final concentration of 
vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated  antibodies.  Quantitative  analysis  of  total  STAT1  levels  in  A2AAR-
expressing  cells  from  three  experiments  is  presented  (***p<0.001  versus  STAT1 
levels in vehicle-pretreated cells at the given time point). Basal set at 100. 
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Figure 4.5 Effect of JAK inhibition on IFNα-induced STAT3  downregulation in 
A2AAR expressing HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1  M JAK inhibitor I for 30 min prior to treatment 
with or without 500 unit/ml IFNα up to 3hr as indicated. The final concentration of 
vehicle (DMSO) in all wells was 0.1% (V/V).   Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated  antibodies.  Quantitative  analysis  of  total  STAT3  levels  in  A2AAR-
expressing  cells  from  three  experiments  is  presented  (***p<0.001  versus  STAT3 
levels in vehicle-pretreated cells at the given time point). Basal set at 100. 
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Figure 4.6  Leptin stimulates the specific phosphorylation of  STAT3 but not  
STAT1 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml  IL-6  or  100  ng/ml  leptin  for  the  indicated  times.  Soluble  cell  extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting with the indicated antibodies.  
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Figure 4.7 Effect of A2AAR gene transfer on STAT3 phosphorylation and 
expression in response to leptin 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 100 ng/ml leptin 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative analysis of phospho-STAT3 and STAT3 levels from three experiments 
is presented (**p<0.005 and *p<0.05 versus corresponding STAT levels in AV.GFP-
infected cells at the given time point). Basal set at 100. 
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Figure 4.8 Effect of A2AAR gene transfer on STAT1 and STAT3 expression in 
response to prolonged exposure to leptin 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 100 ng/ml leptin 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies. 
Quantitative analysis of total STAT3 levels in A2AAR-expressing cells from three 
experiments is presented (*p<0.05 versus corresponding STAT levels in AV.GFP-
infected cells at the given time point). Basal set at 100. 
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Figure 4.9 Effect A2AAR gene transfer on WT and Tyr705→Phe mutated 
STAT3 expression levels. 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected  with  AV  myc-A2AAR  and  either  AV.  Flag-WT  STAT3  or  AV.Flag- 
Tyr705→Phe mutated STAT3 prior to treatment with or without 500 unit/ml IFNα 
for 1 hr as indicated. Soluble cell exracts equalised for protein content were then 
fractionated  by  SDS-PAGE  for  immunoblotting  with  the  indicated  antibodies.  
Quantitative analysis of WT and Tyr705→Phe mutated STAT3 down-regulation in 
A2AAR-expressing  cells from  three  experiments is presented  (***P <0.001  versus 
WT). Basal set at 100. 
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Figure  4.10  Effect  of  A2AAR  gene  transfer  on  mRNA  levels  of  the  phospho 
STAT-specific E3 Ub ligase SLIM/Mystique in vascular endothelial cells under 
conditions that promote STAT degradation 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 2hr. Cells were harvested into 0.5 ml of Tri-reagent and RNA 
extracted as described in section 2.3.6. 1 g RNA of each sample was then used to 
generate cDNA as described in 2.3.7. To assess SLIM/Mystique expression 1  l of 
cDNA  was  used  per  reaction.  As  positive  control  50  ng  of  pcDNAA3/HA- 
SLIM/Mystique  plasmid  was  used.    PCR  conditions  were  given  in  section  2.3.8. 
DNA was then fractionated by agarose gel. Results are typical of three experiments is 
presented.  
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Figure 4.11  Effect of A2AAR gene transfer on protein expression of the phospho 
STAT-specific E3 Ub ligase SLIM/Mystique in vascular endothelial cells under 
conditions that promote STAT degradation 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 2hr. Soluble cell extract of HEK293 cells express pcDNAA3/HA-
SLIM/Mystique plasmid used as positive control. Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies.  
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Figure 4.12 Effect of A2AAR gene expression on SOCS3 induction in response to 
sIL-6 Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with MG132 for 30 min and 
treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 for up to 3 hrs as indicated. Soluble 
cell extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 levels 
from three experiments is presented. Control 100 set at 0 hr of GFP cells. 
 
 
 
 
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
20
40
60
80
100
120
140
160
GFP SOCS3
A2AAR SOCS3
sIL-6Ra a a a/IL-6 Exposure Time (hr)
T
o
t
a
l
 
S
O
C
S
3
(
%
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
 
AV.GFP  AV.mycA2AAR 
45 
45 
30 
GAPDH 
   0         1        2        3         0      1       2      3 
Incubation time (hr)                           
+sIL 6Rα/IL 6   
30  SOCS3   127 
Figure 4.13 A2AAR expression primes STAT3 for cytokine-triggered 
ubiquitylation 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6 M MG132 
for 30 min and incubation with 25ng/ml sIL-6 Rα/5ng/ml IL-6 for 1 hr. Samples were 
then denatured by heating in SDS-containing buffer prior to dilution into excess non-
ionic  detergent  for  preparation  of  clarified  extracts  and  immunoprecipitation  of 
STAT3.  Immunoprecipitates were fractionated  by SDS-PAGE for immunoblotting 
with anti-ubiquitin and STAT3 antibodies.  
 
 
 
 
 
 
 
 
Mr   128 
Figure 4.14 A2AAR expression primes STAT1 for cytokine-triggered 
ubiquitylation 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected  with  AV.mycA2AAR  were  pre-treated  with    6 M  MG132  followed  by 
exposure to 25ng/ml sIL-6 Rα/5ng/ml IL-6.Cells were then harvested for preparation 
of protein-equalised soluble fractions and pull-down experiment using 5ug/sample of 
GST (negative control) or GST-Dsk2pUBA. Captured proteins were fractionated by 
SDS-PAGE  for  immunoblotting  with  anti-ubiquitin,  phospho-STAT1  and  total 
STAT1 antibodies. This is one of three experiments that produced similar results.  
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Figure 4.15 Effect of UBP5 on release of STAT1 from GST-Dsk2p 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected  with  AV.mycA2AAR  were  pre-treated  with  6 M  MG132  followed  by 
exposure to 25ng/ml sIL-6Rα/5ng/ml IL-6. Cells were then harvested for preparation 
of protein-equalised soluble fractions and capture of ubiquitylated proteins with GST-
Dsk2pUBA. Following the final wash, beads were resuspended in reaction buffer and 
incubationed  with  or  without  UBP5  for  1hr  at  the  indicated  temperatures.  The 
reaction buffer was then analysed  for the presence of Tyr701-phosphorylated and 
total STAT1 by SDS-PAGE and immunoblotting. This is one of three experiments 
that produced similar results.  
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Figure 4.16 A2AAR expression primes Flag-WT but not Tyr705→Phe mutated 
STAT3 for cytokine-triggered ubiquitylation 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected  with  AV.myc-A2AAR  and  either  AV.Flag-WT  STAT3  or  AV.Flag-
Tyr705→Phe mutated STAT3 pritotreatment with 6 M MG132 and 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 1 hr as indicated. Cells were then denatured by heating in SDS-
containing buffer prior to dilution into excess non-ionic detergent for preparation of 
clarified  extracts  and  immunoprecipitation  of  Flag-STAT3  proteins  using  M2 
antibody-coupled Sepharose beads. Samples were then fractionated by SDS-PAGE 
prior to immunoblotting with anti-ubiquitin and STAT3 antibodies.  
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4.3    Discussion 
 
JAKs are no longer implicated only in classic cytokine receptor-mediated signalling 
pathways, but are now also known to integrate indirectly into other receptor-mediated 
signal  transduction  processes.  Therefore,  an  increasing  number  of  therapeutic 
applications  exist for  biological response  modifiers that  can modulate  JAK/STAT 
activity. Exciting breakthroughs in both physiological and pharmacological methods 
of selective inhibition of cytokine JAK-STAT pathways have recently emerged in the 
form of suppressors of cytokine signalling. The basis of these and other mechanisms 
of negative regulation of JAK activity, including the suppression of JAK expression 
levels caused by tumour- or pathogen-derived  agents, the complex interactions of 
JAKs  with  phosphatases.  The  possibility  of  modulating  selected  JAK/STAT-
mediated  cellular  signals  by  inhibiting  JAK  kinase  activity  to  obtain  a  posative 
therapeutic  outcome  is  a  tantalising  prospect,  as  yet  incompletely  realised.  While 
current  data  suggest  no  therapeutic  use  for  JAK1  and  TyK2  inhibition,  JAK2 
inhibition  seems  a  promising  but  untested  strategy  for  therapeutic  intervention 
(Reiterer  and  Yen;  2006).  More  promising,  however,  are  the  data  indicating  a 
possible  therapeutic  use  of  JAK  inhibition.  Results  in  this  Chapter  showed  that 
degradation  of  STATs  required  JAK  activity  since  1)  it  was  blocked  by  pre-
incubation with JAK inhibitor 1. 2) STAT1 but not STAT3 was resistant to both 
tyrosine  phosphorylation  and  down-regulation  in  response  to  leptin  and  3)  a 
Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered degradation, 
suggesting that JAK-mediated phosphorylation of this residue is required to produce 
the effect. The importance of JAK in mediating cytokines signalling has been shown 
in many studies including in vivo studies, where Tyk2 has been shown to be  partially 
necessary for IFN-α/β-induced tyrosine phosphorylation of STAT3 (Karaghiosoff et 
al.; 2000; Shimoda et al.; 2000). The SOCS protein family comprises a group of 
cytokine-inducible genes that were discovered initially to suppress STAT signalling 
by binding to and inhibiting JAKs (Starr and Hilton; 1999; Yasukawa et al.; 1999). 
Some  of  these  proteins  are  transcriptionally  regulated  by  STATs  themselves,   132 
suggesting that STATs can negatively regulate their own phosphorylation state. The 
kinase activity of the Tel-JAK2 fusion protein is associated with leukemia and known 
to  activate  STAT5  (Levy  and  Gilliland;  2000).  SOCS1  has  been  demonstrated  to 
block  Tel-JAK2-mediated  transformation  of  hematopoietic  cells  (Frantsve  et  al.; 
2001). Recently, a deletion on chromosome 16p that contains SOCS1 has been found 
in 48% of primary hepatocellular carcinomas, raising the possibility that inactivation 
of this gene may participate in hepatocarcinogenesis (Koyama et al.; 1999). It can 
therefore  be  speculated  that  negative  regulators  of  STAT  signalling  might  play 
important roles in the control of tumour incidence and/or progression. 
 
Many studies have demonstrated that GPCRs have been shown to be connected to the 
JAK/STAT pathway (Lukashova et al.; 2001). However, the mechanisms involved in 
regulating  the activation  of  this  signalling  pathway  by  GPCRs  remain  limited.  In 
addition, little is known about the role of the JAK pathway in the physiological or 
pathophysiological  functions  of  GPCRs.  Despite  the  obvious  importance  of  the 
A2AAR  in  controlling  the  expression  and  function of  various  transcription  factors 
such as p53 (Watson and Irwin; 2006), NF-қB (Chen; 2005) and Smads (Izzi and 
Attisano;  2006),  relatively  few  reports  have  examined  Ub  capacity  to  regulate 
STATs. Our results show that over-expression of the A2AAR in HUVECs led to the 
more  rapid  degradation  of  STAT1  and  STAT3  in  A2AAR  overexpressing  cells.  
Interestingly, cAMP-elevating agents have been shown to inhibit IL-6-induced STAT 
activation  in  monocytes  (Sengupta  et  al.;  1996).  These  data  establish  a  link  for 
crosstalk between cAMP-mediated signalling pathway and STAT, and suggest that 
A2AAR mediated inhibition of STAT may possibly be cAMP-dependent. 
 
The  ability  of  V  proteins  encoded  by  paramyxoviruses  to  function  as  STAT  E3 
ubiquitin  ligases  is  a  well-established  mechanism  by  which  they  subvert  the 
interferon response (Horvath; 2004a), native cellular mechanisms controlling STAT 
degradation are rather less well defined. The first description of STAT degradation 
centred around the observation that proteasome inhibition produced a more robust   133 
accumulation of tyrosine-phosphorylated STAT1 in HeLa cells following exposure to 
IFNγ.  This  suggests  that  proteasomal  degradation  is  an  important  mechanism  by 
which STAT1 function is turned off in these cells (Kim and Maniatis; 1996). It was 
been shown that removal of IL-3 from 32D myeloid cells results in a time-dependent 
proteasomal  degradation  of  STAT5  but  not  STAT1,  2  or  3  (Wang  et  al.;  2000), 
although  nuclear  translocation  rather  than  tyrosine  phosphorylation  seems  to  be 
required for degradation to occur (Chen et al.; 2006).  Another study has shown that 
the  degradation  of  STAT3  in  H4IIE  hepatoma  cells  could  be  triggered  by 
hyperosmotic  stress  and  occurred  independently  of  phosphorylation  on  Tyr705 
(Schafer et al.; 2005). Taken together, none of these observations are consistent with 
a  single  unifying  mechanism.  Thus,  while  the  recent  identification  of  the  protein 
“SLIM” as an E3 ubiquitin ligase able to trigger the polyubiquitylation of STAT1 and 
STAT4 is important (Tanaka et al.; 2005), it is unlikely to account for all STAT 
degradation  phenomena  reported  in  the  literature.    In  relation  to  this  issue  it  is 
important to note that inhibition of proteasome function was sufficient to block the 
inhibitory effect of the A2AAR-overexpression on STAT3 phosphorylation (Figures 
3.17-3.20).  This  demonstrates  that  priming  of  STATs  for  degradation  is  the  only 
mechanism responsible for the reduced cytokine-stimulated STAT phosphorylation 
observed  in  A2AAR  overexpressing  cells  (see  Chapter  3).  Identification  of  Ub-
conjugation states and nature of chain linkage on STAT3-recognising the states of Ub 
attachment and identification of the E3 ligase(s) responsible for STAT ubiquitylation 
would define new targets on STATs amenable to therapeutic manipulation. However, 
this identification is hampered by the lack of any consensus ubiquitylation sequences 
displayed by E3s (Nalepa et al.; 2006) and assuming the ubiquitylation states are 
conserved,  the  presence  of  more  than  20  Lys  residues  common  between  human 
STATs 1 and 3. However, the results presented in my thesis suggest that there is no 
detectable SLIM message or protein under conditions in which STAT degradation 
occurs  (Figure  4.10  and  4.11),  suggesting  that  another  E3  is  responsible. 
Identification of this new E3 would constitute a major advance towards designing 
strategies for manipulating STAT function. It is becaming increasingly appreciated   134 
that  SOCS  proteins  also  act  by  promoting  the  degradation  of  specific  signalling 
proteins.  Recent work suggests that SOCS box-containing proteins act as adapter 
molecules  that  recruit activated  signalling  proteins  to  the proteasome.  The  results 
showed that there is a siginficant difference in SOCS3 expression between GFP and 
A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 hrs (Figure 4.12). 
However, this does not rule out the physiological function of SOCS3 or other SOCS 
family members in the down-regulation of STAT1 and STAT3. In addition, we used 
WT  and  SOCS3  knockout  mouse  embryonic  fibroblasts  (MEFs)  to  test  the 
inolvement of SOCS3 in STAT down-regulation. However, these experiments proved 
to be technically difficult as we could not transduce them with the adenovirues at our 
disposal. One study has reported that expression of SOCS1 but not SOCS3 promotes 
the degradation of ubiquitylated JAK2 (Shuai and Liu; 2003) leading to a reduction in 
STAT activation. In addition, STAT1 is known to be regulated by phosphorylation-
dependent polyubiquitination in response to IFN-γ (Kim and Maniatis; 1996). Given 
that SOCS1 can promote the degradation of JAK2, it is also possible that SOCS1 may 
target the degradation of associated STAT1.  
 
In  addition,  to  examine  the  polyubiquitination  of  STATs,  extracts  from  A2AAR 
overexpressing cells treated or not treated with proteasome inhibitor MG132 were 
subjected to immunoprecipitation analysis with anti-STAT3 antibody or pull down 
experiments.  It  is  obvious  that  the  amounts  of  phosphorylated  STAT  in  A2AAR 
expressing  cells  upon  sIL-6Rα/IL-6  stimulation  are  controlled  by  the  ubiquitin-
dependent proteolysis of STAT1 and STAT3, consistent with the finding that STAT1 
proteins activated by IFN-γ may be negatively regulated by the ubiquitin-proteasome 
pathway (Kim and Maniatis; 1996). These results strongly suggest that STAT1 and 
STAT3  are  polyubiquitinated  before  their  degradation  by  the  26S  proteasome.  In 
addition,  Tyr  phosphorylation  is  required  for  cytokine-triggered  degradation  of 
STATs following A2AAR overexpression. However, it is unclear where within the 
cells  ubiquitylation  and  degradation  occur,  which  residues  on  STATs  confer   135 
sensitivity  to  polyubiquitylation,  and  the  nature  of  the  polyubiquitylation  chain 
linkage.  
 
Finally, in this study we have demonstrated that the A2AAR overexpression can prime 
cytokine-activated STATs for polyubiquitylation and subsequent degradation by the 
proteasome. It was found that overexpression of the A2AAR in the absence of any 
agonist was sufficient to prime STATs for degradation. It is possible that over the 
course  of  the  experiments,  endogenous  adenosine  released  by  HUVECs  in  vitro 
reaches extracellular levels sufficient to cause A2AAR activation. However signalling 
from  cytokine  receptors  is  subject  to  strict  negative  regulation  via  several 
mechanisms designed to prevent inappropriately sustained activation of downstream 
responses  (Wormald  and  Hilton;  2004).  In  most  systems  activation  of  STAT  is 
transient. This suggests that efficient mechanisms for STAT inactivation must exist. 
At  least  two  possible  mechanisms  can  be  envisioned.  The  first  one  is 
dephosphorylation  of  Tyr-phosphorylated  STAT.  The  second  mechanism  is 
degradation  of  Tyr-phosphorylated  STAT.  To  determine  whether  the  Tyr-
phosphorylation of STAT1 and STAT3 is involved in ubiquitination and proteasome-
mediated degradation, Flag-tagged WT STAT3 and Tyr705→Phe mutated STAT3 
were  used.  This  demonstrated  that  under  conditions  in  which  recombinant  WT 
STAT3 is polyubiquitylated similarly to the endogenous STAT3 in response to sIL-
6Rα/IL-6, no ubiquitylation of the Tyr705→Phe-mutated STAT3 could be detected. 
This  result  suggested  that  Tyr-phosphorylation  of  STAT  was  crucial  for  STAT 
ubiquitination and degradation in A2AAR overexpressing cells, since we could not 
observed the same effect in Tyr705→Phe-mutated STAT3 as well in untreated cells 
with cytokines. 
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Phosphorylation  is  a  commonly  utilised  signal  involved  in  controlling  substrate 
recognition  by  multiple  ubiquitin  E3  ligases.  The  cytokine  dependence  of  STAT 
degradation in A2AAR overexpressing cells raised the possibility that JAK-mediated 
STAT  phosphorylation  was  a  trigger  for  this  event.  Thus,  several  experimental 
approaches in Chapter 4 were used to test this hypothesis in more detail. 
 
 (1) JAK inhibitor 1 inhibits  Tyr-phosphorylation of JAK1, JAK2 and STAT1. 
  
(2) Degradation required JAK activity since; 
 a) It was blocked by pre-incubation with JAK inhibitor 1. 
 b) STAT1 but not STAT3 was resistant to both tyrosine phosphorylation and 
down-regulation in response to leptin.  
c) A Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered 
degradation,  suggesting  that  JAK-mediated  phosphorylation  of  this  residue  is 
required to produce the effect. 
 
(3) To assess directly whether STATs were ubiquitylated in A2AAR overexpressing 
HUVECs following cytokine exposure, STAT3 and Flag-tagged WT STAT3 were 
immunoprecipitated following denaturing cell lysis to remove any STAT-associated 
proteins  and  inactivate  deubiquitylating  enzymes.  Immunoblotting  of  STAT3 
immunoprecipitates  with  anti-ubiquitin  antibody  revealed  that  HUVEC  treatment 
with  sIL-6Rα/IL-6  only  resulted  in  the  accumulation  of  a  smear  of  ubiquitylated 
STAT3  in  A2AAR-overexpressing  cells.  Thus,  the  accumulation  of  ubiquitin-
conjugated STATs in HUVECs occurred under conditions that also promoted their 
degradation. 
 
(4)  To  determine  the  relationship  between  STAT  ubiquitylation  and  Tyr 
phosphorylation in A2AAR-overexpressing cells, Flag-tagged WT and Tyr705→Phe 
mutated  STAT3  were  co-expressed  in  HUVECs  with  the  A2AAR  and 
immunoprecipitated with anti-Flag antibody-conjugated Sepharose beads following   137 
denaturing cell lysis after cytokine treatment. These experiments demonstrated that 
under conditions in which recombinant WT STAT3 is polyubiquitylated similarly to 
the  endogenous  protein  in  response  to  sIL-6Rα/IL-6,  no  ubiquitylation  of  the 
Tyr705→Phe mutant could be detected. 
 
(5)  To  date  there  is  only  one  mammalian  E3  ligase  known  for  mediating  STAT 
degradation which is SLIM protein. However, our results suggest the involvement of 
another E3 ubiquitin ligase in HUVECs, since we have been unable to detect SLIM 
message or protein in HUVECs under conditions in which STAT degradation occurs. 
The PCR technique has determined by serial dilution of SLIM/Mystique plasmid to 
approximately a few thousand (assuming that 1 g of SLIM plasmid pcDNAA3/HA-
SLIM/Mystique contains 1.5x10
11 copies of target DNA).  For the immunoblotting 
experiment the Ab was able to detect the positive control (which was lysates from 
HEK293  cells  transfected  with  SLIM/Mystique  cDNA),  but  the  endogenous 
SLIM/Mystique which may be induced in A2AAR overexpressing cells was below the 
detection limit of the Ab. 
 
(6) The results showed that there is a siginficant difference in SOCS3 expression 
between GFP and A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 
hrs  (Figure  4.12).  However,  this  does  not  rule  out  the  physiological  function  of 
SOCS3 or other SOCS family members in potentially mediating the down-regulation 
of STAT1 and STAT3. 
 
The limitations of approaches in Chapter 4 are the same as in Chapter 3 for the use of 
HUVECs and overexpression of A2AAR (pages 102-103).  
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Chapter 5 
 
Effect of A2AAR Expression on STAT3 Regulated Genes 
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5.1     Introduction 
 
VEGFR-2/Flk-1/KDR  is  exclusively expressed  in endothelial cells and appears  to 
play a pivotal role in endothelial cell differentiation and vasculogenesis (Millauer et 
al.; 1993; Quinn et al.; 1993). Many studies have provided evidence for the role of 
VEGFR-2/Flk-1/KDR  in  tumour  vascularisation,  growth,  and  metastasis.  For 
example, the manipulation of the cloned receptor to create a “dominant negative” 
mutation is one experimental technique that has helped establish the relevance of Flk-
1  to  tumour  angiogenesis.  The  biological  relevance  of  the  VEGFR-2/Flk-1/KDR 
receptor/ligand  system  for  tumour-associated  angiogenesis  in  vivo  has  been 
demonstrated using a retrovirus encoding a dominant-negative Tyr705→Phe mutant 
of the VEGFR-2 ( inhibit kinases), which  prevented the growth of a transplanted 
glioblastoma (Millauer et al.; 1994). Recently, using an anti-sense oligonucleotids 
directed against Flk-1 and Flt-1, it has been shown that VEGF stimulates, endothelial 
cell proliferation, migration, and platelet-activating factor synthesis via VEGFR-2. 
Inhibition  of  Flt-1  expression  failed  to  affect  VEGFs  ability  to  modulate  these 
activities  (Bernatchez  et  al.;  1999).  These  studies  have  validated  targeting  of  the 
VEGFR-2 signalling pathway for the development of antiangiogenic agents.  
 
The JAK/STAT and PI-3َ -K/Akt are two parallel pathways responsible for mediating 
many  downstream  functions  of  many  receptor  and  nonreceptor  tyrosine  kinases, 
including EGFR, Her-2 and c-Src (Liu et al.; 1998; Laughner et al.; 2001; Yu and 
Jove;  2004).  gp130,  which  is  frequently  activated  in  a  wide  range  of  cancers 
(Hideshima  et  al.;  2004),  also  signals  through  both  JAK/STAT  and  PI-3َ -K/Akt 
pathways  (Falcone  et  al.;  1999;  Hideshima  et  al.;  2001).  Over-expression  and/or 
persistent activation of EGFR/Her-2, Src and IL-6R are known to promote tumour 
growth/survival and to induce VEGF expression and angiogenesis (Laughner et al.; 
2001; Semenza; 2003; Yu and Jove; 2004). As IL-6 activates PI-3َ -K/Akt via SHP2 
activation  by  gp130  this  leads  to  activation  of  downstream  kinases  such  as  Akt 
(Hideshima et al., 2001). Interestingly, it has been shown that blocking STAT3, but   140 
not PI-3َ -K activity, inhibits VEGF expression in tumour cells with constitutive IL-6 
signalling (Wei et al.; 2003), suggesting that STAT3 continues to activate VEGF 
expression in the absence of PI3K/Akt signalling. 
 
EC dysfunction is characterised by decreased bioavailability of NO, caused in part by 
increased oxidant stress and by decreasing NO synthesis (Cai and Harrison; 2000; 
Fulton et al.; 2001). In the vasculature, NO is normally synthesised by the endothelial 
isoform of eNOS, where it plays a protective role by inhibiting leukocyte trafficking 
and  by  decreasing  platelet  adhesion  and  aggregation  (Fleming  and  Busse;  1999; 
Stuehr; 1999; Dudzinski et al.; 2006). NO production by endothelial cells is regulated 
by changes in eNOS enzyme activity and gene expression. The expression of eNOS 
can be regulated by biophysical stimuli (such as shear stress or hypoxia), growth 
factors  (such  as  TGF-β1,  FGF,  VEGF,  or  PDGF),  hormones  (such  as  estrogens, 
insulin, angiotensin II, or endothelin 1) (Li et al.; 2002), or NO itself (Dudzinski et 
al.; 2006) and IL-6 (Saura et al.; 2006). 
 
The results in Chapters 3 and 4 suggest that A2AAR overexpression primes JAK-
phosphorylated  STATs  for  polyubiquitylation  and  subsequent  degradation  by  the 
proteasome.  For  the  down-regulation  of  STAT  proteins  observed  in  A2AAR-
overexpressing cells to be considered functionally significant, the ability of cytokines 
to  promote  the  accumulation  of  STAT-regulated  target  gene  products  should  be 
compromised.  In  the  course of  our studies,  we  identified the  vascular  endothelial 
growth factor (VEGF) receptor VEGFR-2 and eNOS as proteins in HUVECs whose 
levels are  controlled  by  STAT3.  Since  multiple  studies have  shown  that  elevated 
levels  of  STAT3  phosphorylation  are  associated  with  increased  expression  of 
potential downstream targets of STAT3, such as VEGF  (Turkson; 2004) and down 
regulation of eNOS in ECs (Saura et al.; 2006). Inhibition of constitutively active 
STAT3  signalling  pathways  may  inhibit  inflammation  and  tumour  cell  growth  in 
vitro and in vivo as well as provide a novel means for therapeutic intervention in   141 
human diseases. In this Chapter we investigate the effect of A2AAR overexpression 
on the physiologically relevant genes regulated by STAT3 in HUVECs. 
 
5.2    Results 
 
The STATs function as downstream effectors of cytokine and growth factor receptor 
signalling. Compared with normal cells and tissues, constitutively activated STATs 
have been detected in a wide variety of human cancer cell lines and inflamed tissue. 
STATs are activated by tyrosine phosphorylation, which is normally a transient and 
tightly  regulated  process  (Heinrich  et  al.;  2003).  The  down-regulation  of  STAT 
proteins observed in A2AAR-overexpressing cells would be predicted to modify the 
ability of cytokines to promote STAT-induced target gene expression. VEGFR-2 is a 
protein  in  ECs  whose  levels  are  positively  controlled  by  STAT3.  Incubation  of 
HUVECs with sIL-6Rα/IL-6 for 4 hr increased VEGFR-2 (Figure 5.1). The cytokine 
dependence  of  STAT  degradation  in  A2AAR-overexpressing  cells  (see  Chapter  3) 
raised the possibility that JAK-mediated STAT phosphorylation was a trigger for this 
event. JAK inhibition experiments demonstrated that 0.1  M of JAK inhibitor 1 was 
sufficient  to  inhibit  Tyr-phosphorylation  of  JAKs  and  STATs  upon  sIL-6Rα/IL-6 
stimulation. In this Chapter I wanted to test the effect of JAK inhibition on VEGFR-2 
expression when HUVECs were stimulated with sIL-6Rα/IL-6. My results show that, 
expression  of  VEGFR-2  upon  sIL-6Rα/IL-6  stimulation  was  blocked  by  JAK 
inhibitor 1 pre-treatment (Figure 5.2). Furthermore, in Chapter 4 we demonstrated 
that JAK-mediated phosphorylation of STATs was the critical step triggering down-
regulation when HUVECs were co-infected with AVs encoding the A2AAR and either 
Flag epitope-tagged WT or Tyr705→Phe mutated STAT3, since mutation of Tyr705 
renders STAT3 resistant to phosphorylation by JAK (Kaptein et al.; 1996). In this 
Chapter expression of VEGFR-2 was abolished by overexpression of a dominant-
negative  Tyr705→Phe  STAT3  mutant  and  produced  by  overexpression  of  WT 
STAT3 (Figure 5.3). The results show that A2AAR overexpression has two effects on 
VEGFR-2 expression. The first effect was incubation of A2AAR-overexpressing cells   142 
with  sIL-6Rα/IL-6  for  4  hr  triggered  a  91±6%  down  regulation  of  VEGFR-2 
compared to levels in untreated controls (Figure 5.4). The second effect was that 
over-expression  of  the  A2AAR  alone  increased  VEGFR-2  expression  (Figur  5.4), 
although this phenomenon appears to be STAT-independent since receptor expression 
alone produces no detectable changes in STAT phosphorylation (see Chapter 3). The 
data  are  consistent  with  the  hypothesis  that  A2AAR  overexpression  can  prime 
cytokine-activated  STATs  for  degradation  by  the  proteasome.  Also,  A2AAR-
overexpression was able to down regulate VEGFR-2 expression. This may occur via 
inhibition of STAT3 regulation of VEGF expression.  
  
NO  produced  by  endothelial  cells  plays  a  crucial  role  for  regulation  of  many 
biological  functions  such  as  vasodilatation,  host  defense,  tissue  respiration,  and 
substrate utilisation (Moncada et al.; 1991; Trochu et al.; 2000). Many studies have 
show that IL-6 can decrease eNOS expression in ECs. It has been shown that IL-6 
treatment of human aortic endothelial cells (HAEC) decreases steady-State levels of 
human eNOS mRNA and protein and this decrease in eNOS expression is caused in 
part by IL-6 inhibition of transactivation of the human eNOS promoter (Saura et al.; 
2006).  cAMP  signal  transduction  is  a  novel  pivotal  mechanism  for  regulation  of 
endothelial  NO  production  and  may  play  a  crucial  role  in  the  control  of 
cardiovascular function. For example, many studies have shown that heart failure is 
associated  with a depressed systemic  and cardiac  endothelial NO production, and 
defective endothelial NO formation has been recognised as an important mechanism 
contributing to the progressive deterioration of this disease (Katz et al.; 1993; Mohri 
et al.; 1997; Zhang et al.; 1999b). To investigate if over-expression of the A2AAR 
could regulate eNOS expression, several experimental approaches were used. The 
data  shown  in  Figure  5.5  shows  that  levels  of  eNOS  were  reduced  by  transient 
overexpression of WT STAT3. In contrast, eNOS levels were up-regulated by over-
expression of a dominant-negative Tyr705→Phe mutated STAT3. From Figure 5.6 it 
can be seen that there is no significant change in eNOS expression when the cells are 
incubated  with  sIL-6Rα/IL-6.  However  incubation  of  A2AAR-overexpressing  cells   143 
with  sIL-6Rα/IL-6  for 2hr  marginally up-regulates  eNOS expression  compared  to 
controls (Figure 5.7). These results suggest that STAT3 negatively regulates eNOS 
expression upon sIL-6Rα/IL-6 in A2AAR-overexpressing cells.  
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Figure 5.1 Effect of sIL-6Rα/IL-6 on VEGFR2 expression 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
serum starving for 4 hrs prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for the indicated times. Soluble cell extracts equalised for protein content were 
then fractionated by SDS-PAGE for immunoblotting with the indicated antibodie. 
Quantitative analysis of VEGFR2 levels from three experiments is presented (***P 
<0.001 versus the response observed in control cells). Basal set at 100. 
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Figure 5.2 Effect of JAK inhibition 1 on sIL-6Rα/IL-6-induced VEGFR2 
expression in HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
then serum starving for 4 hrs prior to pre-incubation with or without 0.1 uM JAK 
inhibitor I for 30 min then treatment with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 
for 30 min as indicated.  Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with anti-VEGFR2 antibody. (**P 
<0.005 and ***P <0.001 versus the response observed in control cells). Basal set at 
100. 
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Figure 5.3 Effect of WT and Tyr705→Phe mutated STAT3 expression on 
VEGFR2 expression in HUVECs 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV.  Flag-WT STAT3 or AV.Flag-Tyr705→Phe mutated STAT3 
prior  to  treatment  with  or  without  25ng/ml  sIL-6  Rα/5ng/ml  IL-6  for  1  hr  as 
indicated. Soluble cell exracts equalised for protein content were then fractionated by 
SDS-PAGE for immunoblotting with the indicated antibodies (***P <0.001 versus 
the response observed in mutant STAT3). Basal set at 100. 
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Figure 5.4 Effect of A2AAR gene transfer on VEGFR2 expression in response to 
sIL-6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to  serum starving for 4hr and treatment with or 
without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  Quantitative  analysis  of  VEGFR2 
down-regulation  in  A2AAR-expressing  cells  from  three  experiments  is  presented 
(***P <0.001 versus the response observed in AV.GFP infected cells) Basal set at 2 
hrs.  
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Figure 5.5 Effect of WT and Tyr705→Phe mutated STAT3 expression on eNOS 
expression 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV.  Flag-WT STAT3 or AV.Flag-Tyr705→Phe mutated STAT3 
prior  to  treatment  with  or  without  25ng/ml  sIL-6  Rα/5ng/ml  IL-6  for  1  hr  as 
indicated. Soluble cell exracts equalised for protein content were then fractionated by 
SDS-PAGE for immunoblotting with the indicated antibodies (***P <0.001 and *P 
<0.05 versus the response observed in WT STAT3). Basal set at 100.  
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Figure 5.6 Effect of sIL-6Rα/IL-6 on eNOS expression 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
serum starving for 4 hrs prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for the indicated times. Soluble cell extracts equalised for protein content were 
then fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Basal set at 100. 
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Figure 5.7 Effect of A2AAR gene transfer on eNOS expression in response to sIL-
6Rα/IL-6 
1x10
5 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to  serum starving for 4hr and treatment with or 
without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts 
equalised  for  protein  content  were  then  fractionated  by  SDS-PAGE  for 
immunoblotting  with  the  indicated  antibodies.  (**P  <0.005  versus  the  response 
observed in AV.GFP infected cells).  Basal set at 100.  
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5.3    Discussion 
 
VEGF is up-regulated by multiple stimuli, including hypoxia (Levy et al.; 1995b; 
Levy et al.; 1995a), growth factors (Nauck et al.; 1997), and cytokines (Li et al.; 
1995; Ryuto et al.; 1996). Conversely, few agents have been shown to reduce VEGF 
expression as described presently for A2AAR agonists. Glucocorticoids inhibit the up-
regulation of VEGF induced by stimuli such as serum, platelet-derived growth factor, 
phorbol esters, and platelet-activating factor in different cell types (Finkenzeller et 
al.; 1995; Heiss et al.; 1996; Nauck et al.; 1997).  
 
 VEGFR2 is one of the major regulators of vasculogenesis and angiogenesis. The 
detailed analysis of the role of VEGFR2-mediated signal transduction suggested that 
the inhibition of VEGFR pathway would provide a powerful antiangiogenic signal 
that could be highly useful in inhibiting pathogenic angiogenesis To date, several 
small molecule VEGFR2 kinase (KDR) inhibitors have been tested in animal cancer 
models and resultant changes in tumor vasculature have been described. Strong anti-
angiogenic responses are induced by SU5416 (a potent  inhibitor of VEGFR protein 
kinases) (Vajkoczy et al.; 1999; Laird et al.; 2000). While the mechanism by which 
A2AAR activation results in VEGFR2 down-regulation has begun to be explored, our 
results show that A2AAR overexpression down-regulated VEGFR-2 under the same 
conditions that promoted STAT degradation after cytokine stimulation (see Chapter 
3).  In  A2AAR-overexpressing  cells,  the  ability  of  the  A2AAR  to  stimulate  down 
regulation  of  VEGFR-2  after  4hr  of  sIL-6Rα/IL-6  stimulation  was  significant 
compared with control cells. The expression of VEGFR-2 upon sIL-6Rα/IL-6 was 
inhibited by JAK inhibitor 1, abolished by over-expression of Tyr705→Phe mutated 
STAT3 and induced by overexpression of WT STAT3. Several studies have reported 
that  VEGF-induced  proliferation  is  mediated  by  the  interaction  of  VEGF  with 
VEGFR2 in both breast cancer cells and in endothelial cells (Mercurio et al.; 2004; 
Liang and Hyder; 2005). However, the role of A2AAR in VEGFR2 regulation may be 
complex.  In  addition  VEGFR2  is  exclusively  expressed  in  endothelial  cells  and   153 
appears to play a pivotal role in endothelial cell differentiation and vasculogenesis 
(Millauer  et  al.;  1993;  Quinn  et  al.;  1993).  It  has  also  been  demonstrated  that 
VEGFR-2  signals  through  STAT3  (Bartoli  et  al.;  2003).  Blocking  STAT3  in 
endothelial cells inhibit their migration and vessel formation (Yahata et al.; 2003). 
Interestingly, a relationship between tumour STAT3 activity and STAT3 signalling 
has  been  recently  described  (Wang  et  al.;  2004).  Our  results  in  Chapter  3 
demonstrated that the human A2AAR overexpression was able to confer an ability of 
sIL-6Rα/IL-6 to trigger a time-dependent reduction in the levels of STAT proteins 
that  was  due  entirely  to  proteasomal  degradation.  In  terms  of  functional 
consequences, the results of this Chapter show that the degradation was associated 
with an attenuation of sIL-6Rα/IL-6-stimulated STAT3-dependent up-regulation of 
VEGFR2. Blocking STAT3 signalling in either tumour or dendritic cells abrogates 
tumour-induced inhibition of dendritic cell maturation (Wang  et al.; 2004). Thus, 
STAT3 plays a central role in propagating oncogenic signals from tumour cells to 
effector  cells  involved  in  tumour  angiogenesis  and  immune  evasion.  It  is  a  well 
established fact that blocking STAT3 signalling in tumour cells inhibits  tumour cell 
proliferation and induces apoptosis (Darnell; 2002; Yu and Jove; 2004). In diverse 
human  cancers  displaying  dependence  on  persistently  activated  STAT3  for 
survival/proliferation  (Darnell;  2002;  Yu  and  Jove;  2004),  targeting  STAT3  is 
expected to evoke potent anti-tumour effects through direct tumour cell death, anti-
tumour immune responses and anti-angiogenesis.  PC12 cells, which express A2A and 
A2BARs (Arslan et al.; 1999), have been employed to study AR signal transduction 
and physiological activity. It has been shown previously that activation of the A2AAR 
in PC12 cells results in a substantial reduction of VEGF, which is observed at both 
the mRNA and protein levels. Furthermore, this down-regulation of VEGF mRNA 
occurs because of an inhibition of VEGF gene transcription (Olah and Roudabush; 
2000).  The  nonselective  AR  agonist,  5-(N-ethylcarboxamido)  adenosine,  was  also 
reported to down-regulate VEGF expression in PC12 cells (Kobayashi and Millhorn; 
1999).  Other  cell  types  have  been  shown  to  respond  to  AR  agonists  with  either 
increases or decreases in VEGF expression (Grant et al.; 1999; Wakai et al.; 2001;   154 
Feoktistov et al.; 2002). This differential regulation may exist because of the subtype 
specificity of various AR ligands, and because of cell-specific variations in the signal 
transduction cascade to which a distinct AR subtype may be linked. Stimulation of 
the A2AAR in PC12 cells substantially reduces VEGF mRNA expression and VEGF 
protein secretion. Regulation of VEGF secretion by the A2AAR, or perhaps other G 
protein-coupled receptors, on selected targets may represent a means to positively or 
negatively regulate angiogenesis for therapeutic benefit. In this study  A2AAR was 
able  to  down-regulate  the  VEGFR-2  under  the  same  conditions  promoted  STAT 
degradation after cytokines stimulation.  
 
It  has  been  demonstrated  that  adenosine  enhances  IL-1-induced  NO  production 
through activation of  A2AAR (Ikeda et al.; 1997a; Ikeda et al.; 1997b; Dubey et al.; 
1998). In addition, activation of the A2AAR can increase NO production in porcine 
coronary endothelial cells (Olanrewaju and Mustafa; 2000) and in HUVECs (Wyatt et 
al.; 2002). In this study, we have demonstrated that A2AAR overexpression increases 
eNOS induction in A2AAR overexpressing cells. This increase in eNOS induction is 
consistent  with  our  results  in  Chapter  3  which  show  that  overexpression  of  the 
A2AAR triggers the down-regulation of STAT after treatment with sIL-6Rα/IL-6 for 
3hr. In addition our results show that Tyr705→Phe-mutated STAT3 enhances eNOS 
expression, while overexpression of WT STAT3 reduces eNOS expression. Different 
studies have found that inflammatory mediators decrease eNOS expression (Marsden 
et al.; 1992; Weiss et al.; 1994; Tai et al.; 2004). Furthermore, TNF-α can decrease 
eNOS  expression  by  inhibiting  eNOS  promoter  transactivation  and  also  by 
destabilising eNOS mRNA (Yoshizumi et al.; 1993; Alonso et al.; 1997; Searles; 
2006). CRP, an effector of the acute phase response, decreases eNOS expression by 
destabilising its mRNA (Venugopal et al.; 2002; Verma et al.; 2002). IL-6, a major 
trigger of the APR, has been shown to decrease eNOS expression.  Recent studies 
point to IL-6 as a marker of cardiovascular disease as well as systemic inflammation 
(Tracy et al.; 1997; Libby; 2001; Ridker et al.; 2001). IL-6 plasma levels are elevated 
in myocardial infarction, unstable angina, and atherosclerosis. Chronic inflammation   155 
may  trigger  synthesis  of  IL-6,  which  activates  STAT3.  STAT3  in  turn  drives 
transcription of acute phase response reactants, such as CRP that contribute to the 
development  and  progression  of  atherosclerosis  (Verma  et  al.;  2005;  Paffen  and 
DeMaat; 2006). Accumulating evidence demonstrates that the A2AAR increases the 
production of NO by human and porcine arterial endothelial cells, which in turn leads 
to vasodilation (Lin et al.; 2007). 
 
Our results show that incubation of A2AAR-overexpressing cells with sIL-6Rα/IL-6 
for 2 hr up-regulates eNOS expression compared with control cells. This result is 
consistent  with  finding  that  adenosine-induced  NO  production  is  blocked  by  the 
potent eNOS inhibitor l-NIO (Jiang et al.; 2002; Benamar et al.; 2003) but not by the 
selective iNOS inhibitor l-NIL (Connor et al.; 1995), suggesting eNOS but not iNOS 
is responsible for the effect of adenosine on NO production. The importance of eNOS 
in NO production by adenosine is further supported by the observation that adenosine 
enhances phosphorylation of eNOS at its activation sate (Ser 1177) (Albrecht et al.; 
2003; Zhang and Hintze; 2006). Moreover, adenosine significantly increased eNOS, 
but not iNOS, activity (Albrecht  et al.; 2003).  It has been suggested that a large 
amount of NO produced by iNOS is toxic, whereas eNOS is a protective enzyme 
(Albrecht  et  al.;  2003).  Therefore,  it  is  highly  likely  that  adenosine-induced  NO 
generation  through  eNOS  can  result  in  cardioprotection,  which  may  explain  the 
cardioprotective effect of adenosine. Multiple lines of evidence have suggested that 
the  A2AAR  is  critical  for  adenosine-mediated  protection  against  ischaemia-
reperfusion injury. A2AAR-mediated inhibition of tissue ischaemia-reperfusion injury 
has been documented in various organ systems, including liver, lung, kidney, and 
heart (Okusa et al.; 1999; Harada et al.; 2000). However, the precise mechanisms 
responsible for A2AAR-mediated tissue protection remain unknown. The A2AAR is 
widely distributed and mediates a variety of physiological responses in mammals. 
A2AARs couple to Gs proteins and activate adenylyl cyclase, leading to an increase in 
cellular  cAMP  levels  (Dobson  and  Fenton;  1997;  Sullivan  et  al.;  2001).  The 
mechanisms of protection mediated by A2AAR activation may include inhibition of   156 
leukocyte-mediated inflammatory response, chemokine production and vasodilation 
(Shryock  et  al.;  1998;  Lew  and  Kao; 1999).  A  recent study has  also  shown  that 
cAMP  induces  eNOS  activation  and  increases  endothelial  NO  production  from 
isolated canine and porcine coronary microvessels (Kudej et al.; 2000; Zhang et al.; 
2002b). In cultured endothelial cells, both PKA and PKB have been reported to have 
effects on eNOS phosphorylation and activation (Dimmeler et al.; 1999; Fulton et al.; 
1999; Michell et al.; 2001; Boo et al.; 2002). These observations may suggest that 
expression of A2AARs elevate cAMP which induce eNOS expression as our results 
would suggest A2AAR-expressing cells up-regulates eNOS expression (Figure 5.4). 
Thus the data suggest there are two possible mechanisms; the first one is cAMP via 
ERK directly up-regulate eNOS. The second mechanism is cAMP up-regulates eNOS 
expression  via  down-regulation  of  STAT3.  In  summary  the  results  suggest  that 
STAT3 regulates eNOS expression upon sIL-6Rα/IL-6, since A2AAR overexpression 
which  primes  cytokine-activated  STATs  for  degradation  by  the  proteasome,  was 
sufficient to up-regulate eNOS expression. 
 
Data in Chapter 5 reveals several important aspects. These include: 
 
(1) Incubation of HUVECs with sIL-6Rα/IL-6 for 4 hr increased VEGFR-2 protein 
levels. 
 
(2) Expression of VEGFR-2 upon sIL-6Rα/IL-6 stimulation was blocked by JAK 
inhibitor 1 pre-treatment. 
 
 (3)  Expression  of  VEGFR-2  was  abolished  by  over-expression  of  a  dominant-
negative Tyr705→Phe STAT3 mutant and induced by overexpression of WT STAT3.  
 
(4)  The  results  show  that  A2AAR  overexpression  has  two  effects  on  VEGFR-2 
expression. The first effect was incubation of A2AAR overexpressing cells with sIL-
6Rα/IL-6  for 4  hr triggered  a  91±6% down  regulation  of  VEGFR-2  compared  to   157 
levels in untreated controls. The second effect was that over-expression of the A2AAR 
alone increased VEGFR-2 expression.  
 
 (5) The result shows that levels of eNOS were reduced by transient overexpression 
of WT STAT3. In contrast, eNOS levels were up-regulated by overexpression of a 
dominant-negative Tyr705→Phe mutated STAT3. 
 
(6)  There is no significant change in eNOS expression when the cells are incubated 
with sIL-6Rα/IL-6. 
 
 (7) Incubation of A2AAR-overexpressing cells with sIL-6Rα/IL-6 for 2 hr marginally 
up-regulates eNOS expression compared to controls. 
 
In the course of my studies, I have identified the vascular endothelial growth factor 
(VEGF) receptor VEGFR2 and eNOS as proteins in ECs whose levels are controlled 
by  STAT3.    The  interaction  between  the  eNOS  promoter  and  STAT3  has  been 
studied by Marta Saura et al. (2006). They first studied the effects of IL-6 upon the 
human eNOS 5′-flanking region extending 1600 bp upstream from the transcriptional 
start site. Then, they transfected HAEC with an eNOS promoter luciferase construct 
(eNOS-Luc). While Control cells were also co-transfected with plasmid constitutively 
expressing  Renilla  luciferase.  Then,  human  eNOS  promoter  transactivation  was 
measured as firefly luciferase activity normalised to Renilla luciferase activity. Their 
data  show  that  STAT3  upon  IL-6  activation  inhibits  eNOS  promoter  activity  in 
endothelial cells in a dose-dependent manner. While any interaction between STAT3 
and the VEGFR2 promoter has yet to be identified, several experiments could be used 
to address this issue. One approach is chromatin immunoprecipitation (ChIP) analysis 
which  could  be  applied  to  assess  cytokine-inducible  STAT3  recruitment  to  the 
VEGFR2 promoter. To perform this experiment, cells have to be stimulated with and 
without  IL-6  and  then  fixed.  Then  DNA  has  to  be  sheared  to  fragment  sizes  of 
roughly 500 bp. STAT3 is then immunoprecipitated and DNA fragments analysed by   158 
PCR.  Primers would be designed to amplify a target sequence of no greater then 200 
bp that incorporates any putative STAT3  binding sites in the VEGFR2 promoter. 
Secondly, reporter gene assays could be employed to confirm IL-6-inducible STAT3 
activation  of  VEGFR2  promoter.  This  could  be  done  by  cloning  the  VEGFR2 
promoter upstream of a luciferase ORF in a mammalian expression vector such as 
pLuc (Chiou et al.; 2000). If cytokine activation of luciferase expression is observed, 
the STAT sites in the promoter could be mutated and used to compare their ability to 
induce luciferase following IL-6 stimulation. Additionally, the effect of the dominant-
negative  Tyr705→Phe  STAT3  mutant  following  IL-6  stimulation  could  also  be 
assessed as further evidence for a role of STAT3.  
 
The limitations of approaches in this Chapter are the same as in Chapter 3 and 4 for 
the use of HUVECs and overexpression of A2AAR (pages 102-103).  
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Chapter 6 
Final Discussion 
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The  pro  and  anti-inflammatory  mediators  are  both  meant  to  be  beneficial  to  the 
organism. During the initial appearance of
 pro- and anti-inflammatory mediators in 
the circulation, the
 beneficial effects usually outweigh their harmful
 effects. However, 
when the balance between these two opposing forces is lost,
 the mediators become 
harmful.  Sequelae  of  inappropriate  or  prolonged  inflammation  contribute  to  the 
pathogenesis of many diseases including atherosclerosis (D'Cruz; 1998; Sands and 
Palmer; 2005), rheumatoid arthritis (Karouzakis et al.; 2006) sepsis, (D'Cruz; 1998; 
Kinlay et al.; 2001; Greaves and Channon; 2002; Gueler et al.; 2004), heart disease 
(Kinlay et al.; 2001), and cancer (Howe; 2007). Fundamental to the inflammatory 
response  is  the  interaction  between  ECs  and  leukocytes.  This  interaction  triggers 
further  downstream  signalling  events  leading  to  cytokine,  chemokine  and  growth 
factor release, surface expression of adhesion molecules and expression of other pro-
inflammatory proteins.  
 
In this investigation, I have demonstrated that the A2AAR overexpression can prime 
cytokine-activated STATs for polyubiquitylation and subsequent degradation by the 
proteasome (Figure 3.2-3.9).  Similar to the effect observed on suppression of  NF-қB 
in two separate cell systems (Sands et al.; 2004), expression of the A2AAR in the 
absence of any agonist was sufficient to prime STATs for degradation. Pre-incubation 
with  the  proteasome  inhibitor  MG132  was  sufficient  to  abolish  the  effect  of  the 
A2AAR overexpression on priming both STAT1 and STAT3 for down-regulation in 
response  to  both  cytokines  sIL-6Rα/IL-6  and  IFNα.  Our  data  reveals  several 
important  aspects  of  A2AAR  overexpression  on  JAK-STAT  upon  cytokine 
stimulation.  These  include:  (1)  Potentiation  of  A2AAR  function  by  increasing  its 
expression  reduces  cytokine  receptor  activation  of  the  JAK-STAT  pathway  by 
priming Tyr-phosphorylated STAT for proteasomal degradation. (2) Over-expression 
of the A2AAR in HUVECs suppressed the ability of IFNα and a sIL-6Rα/IL-6 trans-
signalling complex to promote Tyr-phosphorylation of STATs 1 and 3 by targeting 
cytokine-activated STATs for proteasomal degradation. (3) Immunoprecipitation and 
pull-down experiments revealed that endogenous and recombinant WT STAT3 were   161 
ubiquitylated following cytokine treatment of A2AAR overexpressing cells while no 
detectable  ubiquitylation  of  Tyr705→Phe-mutated  STAT3  was  observed. 
Degradation  required  JAK-mediated  phosphorylation  of  STATs  as  deduced  from 
three lines of evidence. First, the effect was abolished by a concentration of JAK 
inhibitor  1  that  abolished  Tyr-phosphorylation  of  STAT1  and  STAT3.  Second, 
STAT3 but not STAT1 was targeted for degradation following exposure of A2AAR- 
overexpressing cells to leptin, reflecting the ability of leptin to specifically promote 
the  Tyr-phosphorylation  of  STAT3.  Third,  a  Tyr705→Phe  mutated  STAT3  was 
resistant to both JAK-mediated phosphorylation and cytokine-triggered degradation 
in A2AAR overexpressing cells.  
 
The multiple signalling employed by the A2AAR to inhibit STAT activity raise an 
important  question.  How  does  the  A2AAR  affect  STAT  activity  by  different 
mechanism? One possibility is that A2AAR overexpression leads to the activation of 
multiple  distinct  signalling  molecules,  which  then  affect  the  STAT  pathway  by 
independent mechanism. One key feature of the A2AAR is the long C-terminal tail, 
which plays a role in regulating the high level of constitutive activity of the receptor 
(Klinger et al.; 2002). In addition it is shown to be involved in the formation of 
heterodimers with the dopamine D2 receptors within the rat striatum (Canals et al.; 
2003), although it is not required for the formation of A2AAR homodimers (Canals et 
al.; 2004). Therefore its precise role in the formation of oligomers is still unclear. In 
order  to  understand  the  molecular  events  by  which  STAT  degradation  occurs,  it 
would an important step to identify which A2AAR-activated signalling pathways are 
responsible.  A2AAR  activation  has  been  reported  to  activate  at  least  two  primary 
signalling  cascades  in  vascular  ECs.  The  first  one  is  the  cAMP-adenylyl  cyclase 
(Linden; 2001), causing an elevated levels of intracellular cAMP. cAMP causes the 
activation of cAMP-dependent protein kinase (PKA) and “exchange protein activated 
by cAMP” (Epac). Epac functions as a guanine nucleotide exchange factor for the 
Rap family of small G-proteins (Bos; 2003; Tasken and Aandahl; 2004). The second 
pathway  is  extracellular  signal-regulated  kinase  (ERK).  cAMP-independent   162 
activation of ERK through the activation of A2AAR (Sexl et al.; 1997) is thought to 
be  required  for  receptor-mediated  generation  of  nitric  oxide,  which  subsequently 
activates soluble guanylyl cyclase (Wyatt et al.; 2002). The resulting accumulation of 
cyclic GMP (cGMP) activates cGMP-dependent protein kinase. A range of selective 
inhibitors  and  activators  of  relevant  intracellular  signalling  pathways  would  be 
needed to be tested for their ability to either block or mimic A2AAR-mediated priming 
of  STAT  degradation.  For  example,  a  contribution  of  Epac  could  be  tested  by 
determining  the  extent  to  which  Epac-selective  activator  8-pCPT-2′-O-me-cAMP 
(Kooistra  et  al.;  2005)  can  prime  STATs  for  cytokine-triggered  degradation,  and 
whether its depletion by siRNA abolished the A2AAR’s effect. 
 
To date, only one mammalian E3 Ub ligase (termed “SLIM” or “Mystique”) has been 
demonstrated to target Tyr-phosphorylated STATs for polyubiquitylation (Tanaka et 
al.; 2005). However, the results presented here suggest that there is no involvement of 
SLIM under conditions in which STAT degradation occurs, suggesting that another 
E3 is responsible. Identification of this new E3 would constitute a major advance 
towards designing strategies for manipulating STAT function, and is therefore a key 
objective.  There  are  several  technically  distinct  strategies  that  could  be  used  to 
identify the E3 ligase. First strategy is the STAT3 proteomics.  The most straight 
forward method for identifying the protein responsible would be to purify STAT-
associated proteins in cytokine-stimulated A2AAR-overexpressing cells via a two-step 
tandem  affinity  purification  (TAP)  procedure  (see  Chapter  7).  Similar  approaches 
have  already  been  used  to  demonstrate  that  KLHL12  function  as  the  substrate 
recognition  component  of  the  E3  complex  responsible  for  degradation  of  Dsh 
proteins (Angers et al.; 2006).  The second strategy is using E3 Ub ligase siRNA 
library screening (see Chapter 7). This approach is particulary suited to HUVECs 
since our lab and others  have been able to  achieve almost complete target  gene 
knockdown  following  siRNA  transfection  into  these  cells  (Huang  et  al.;  2005; 
Kooistra et al.; 2005). 
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The A2AAR displays two desirable features that would make it suitable to act as a 
brake of the inflammatory response. One important feature is the level of constitutive 
activity displayed by the receptor, an activity which is associated with the C-terminal 
of the receptor, since its removal can inhibit the level of constitutive activity (Klinger 
et al.; 2002). The constitutive activity of the receptor would allow the receptor to 
mediate its anti-inflammatory effects even in the absence of agonist as described in 
this thesis. The constitutive activity of the receptor suggests that regulation of A2AAR 
expression would be critical in the inhibition of inflammatory responses. Studies in 
A2AAR
-/- cells showed that there  was no significant compensatory increase in the 
expression  of  any  of the  other  ARs,  suggesting  that  the anti-inflammatory  events 
triggered by A2AAR expression are specific for this receptor (Lukashev et al.; 2003). 
In  addition,  demonstration  of  the  absence  of  receptor  reserve  in  murine  T-cells 
suggests  that  A2AAR  expression  needs  to  be  tightly  regulated  (Armstrong  et  al.; 
2001). The regulation of A2AAR expression is supported by the reported alterations in  
expression  in  response  to  Th1  cytokines  in  Ecs  is  likely  to  alter  cellular 
responsiveness to inflammatory stimuli (Nguyen et al.; 2003). Moreover, in mature 
plasmacytoid dendritic cells, the A2AAR becomes up-regulated in response to CpG 
oligodeoxynucleotide activation of TLR-9, leading to a decrease in IL-6, IL-12 and 
IFNα  production  (Schnurr  et  al.;  2005).  Therefore,  there  are  precedents  for  the 
regulation of A2AAR expression by different inflammatory stimuli resulting in the 
inhibition of inflammatory responses. 
 
 A2AAR overexpression leads to the accelerated degradation of Tyr-phpsphorylated 
STATs. The JAK-STAT signalling cascade plays an important role in the activation 
of several different inflammatory genes including eNOS and VEGF. Targeting STAT 
proteins  for  therapeutic  intervention  in  cancer  remains  to  be  fully  explored.  In 
addition  to  the  development  of  tyrosine  kinase  inhibitors,  antisense  STAT 
oligonucleotides, it will be important to consider alternative strategies for targeting of 
constitutive STAT signalling (Seidel et al.; 2000; Turkson and Jove; 2000). Such 
strategies could potentially include: (1) development of receptor-ligand interaction   164 
antagonists,  such  as  cytokine  antagonists  and  receptor-neutralising  antibodies;  (2) 
inhibition  of  STAT  activating  tyrosine  kinases;  (3)  activation  of  STAT-specific 
phosphatases;  (4)  targeting  of  STAT-regulated  genes  involved  in  malignant 
progression;  and  (5)  development  of  small  molecule  inhibitors  that  interfere  with 
STAT dimerisation and/or DNA binding. With regard to the latter, recent progress 
has been made in design of short peptides that effectively block STAT3 dimerisation 
and  DNA-binding  activity  both  in  vitro  and  in  vivo  (Turkson  et  al.;  2001). 
Importantly, these peptides inhibit cell transformation mediated by activated STAT3 
and provide the basis for development of peptidomimetics with drug-like features. 
For drug development, molecular assays that are designed to specifically measure 
activated STAT3 DNA-binding or gene-regulatory activities can be applied for drug 
refinement  through  structure-activity  relationship  studies.  In  the  clinical  setting, 
immunohistochemical  assays  for  detection  of  activated  phosphotyrosine-forms  of 
STAT3 and STAT5 can provide convenient molecular markers for monitoring the 
efficacy  of  inhibitors  of  STAT  signalling  in  biopsies  from  cancer  patients.  Gene 
expression  profiling  by  microarray  technology  is  expected  to  reveal  a  molecular 
signature of STAT-regulated genes that may have diagnostic as well as prognostic 
applications (Turkson and Jove; 2000; Nikitakis et al.; 2004).  
 
 STAT activation is negatively regulated by SOCS proteins. Our results do not rule 
out the physiological involvement of SOCS3 in down-regulation of STAT in A2AAR-
overexpressing  cells.  Thus,  A2AAR  overexpression  may  up-regulate  other  SOCS 
expression such as SOCS1 leading to accelerated STAT1 and STAT3 degradation. 
SOCS  proteins  were  originally  identified  as  cytokine-inducible  SH2-domains-
containing proteins (CIS). They are known to inhibit STAT activation by at least two 
distinct mechanisms that differ between family members:  SOCS1 inhibits activation 
of JAK by directly binding to JAK, while SOCS3 inhibits the action of JAK only 
when bind to receptors such as gp130 (Section 1.3). Expression of SOCS1 but not 
SOCS3 promotes the degradation of ubiquitinylated JAK2 leading to the reduction of 
STAT activation (Shuai and Liu; 2003). Moreover, STAT1 is known to be regulated   165 
by phosphorylation-dependent ubiquitination in response to IFNγ (Kim and Maniatis; 
1996). SOCS proteins typically consist of a phosphotyrosine-binding SH2 domain, a 
C-terminal SOCS-box involved in proteasome recruitment and a pre-SH2 domain that 
only  in  the  case  of  SOCS1  and  SOCS3  contains  a  JAK-blocking  KIR  domain. 
Association of SOCS proteins with their target substrates is believed to occur solely 
via their SH2 domain. Given that SOCS can promote the degradation of JAK, it is 
also  possible  that  SOCS  can  target  the  degradation  of  associated  STAT  proteins. 
Therefore  A2AAR  overexpression  may  negatively  regulate  STAT1  and  STAT3 
protein  levels  by  increasing  the  levels  of  SOCS  expression.    However,  results  in 
Chapter 4 suggest there is a significant difference in SOCS3 expression between GFP 
and A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 hrs (Figure 
4.12). However, this does not rule out the physiological function of SOCS3 or other 
SOCS  family  members  in  the  down-regulation  of  STATs.  To  further  identify  the 
precise  role  for  A2AAR-mediated  anti-inflammatory  effects,  immuoblotting  using 
anti-SOCS  antibodies  or  employing  SOCS
-/- cells  could  be used to  determine  the 
effect  of  the  A2AAR  on  SOCS  expression.  In  addition,  it  would  be interesting  to 
determine if this represents a common mechanism of action.  For example, STAT 
activation is also stimulated by other cytokines like IL-11, which utilises a common 
gp130 receptor component. Similar analysis of STAT1 and STAT3 activation and 
SOCS expression could be used to determine if A2AAR is important in this way. 
Another important topic for future studies is to define the mechanisms of crosstalk 
between  JAKs  and  other  pathways.  For  instance,  the  receptor  Notch  has  been 
reported to promote STAT3 activation, and the Notch effectors Hes1 and Hes5 have 
been found to associate directly with JAK2 and STAT3 (Kamakura et al.; 2004). 
Evidence for cooperation between the JAK/STAT and Notch pathways has also been 
provided  by  work  in  Drosophila  (Josten  et  al.;  2004)  and  genetic  screens  in 
Drosophila have identified additional potential modifiers of the JAK/STAT pathway 
(Bach et al.; 2003). JAKs have also been reported to be activated by a variety of 
structurally  diverse  receptors  beyond  the  cytokine  receptors.  Examples  include 
receptor  tyrosine  kinases,  and  G-protein-coupled  receptors  (such  as  chemokine   166 
receptors). Hyperactivation of STAT1 and STAT3 due to either inactivation of SOCS 
promoters by methylation (Niwa et al.; 2005) or mutationally activated JAK/other 
STAT-phosphorylating tyrosine kinases has been observed in breast cancer cell lines 
as well as prostate, ovarian, pancreatic and hepatocellular carcinomas (Verma et al.; 
2003).  Importantly, in many of these cases, blockade of STAT activation triggers 
apoptosis  of  the  affected  cells  (Verma  et  al.;  2003;  Yu  and  Jove;  2004).  Thus, 
manipulation of the A2AAR signalling system might provide one strategy with which 
to  arrest  tumour  growth  resulting  from  inappropriate  activation  of  STATs.  In 
addition, VEGF is up-regulated by multiple stimuli, including hypoxia (Levy et al.; 
1995b), growth factors (Nauck et al.; 1997), and cytokines (Li et al.; 1995; Ryuto et 
al.; 1996).  
 
 Since  Tyr-phosphorylation  is  clearly  the  critical  step  in  targeting  STATs  for 
degradation  in  A2AAR  overexpressing  cells,  it  is  extremely  important  to  clarify 
whether  it functions  simply  as a  classical  phosphodegron, or  whether  the  nuclear 
translocation that occurs as a result of phosphorylation is also important for localising 
the phosphorylated STAT dimer with the relevant E3 ubiquitin ligase. This may be 
tested by comparing the extent to which the A2AAR overexpression primes STATs 
for  cytokine-triggered  polyubiquitylation  and  degradation  in  cytosolic  and  nuclear 
fraction (see Chapter 7).  
 
In  conclusion,  the  identification  in  this  study  of  a  previously  unappreciated 
mechanism by which a GPCR can negatively control STAT function by targeting 
tyrosine-phosphorylated  STATs  for  degradation  has  significant  implications  for 
diseases associated with altered regulation of the JAK-STAT pathway in vascular 
endothelium.  It  also  suggests  that  potentiation  of  A2AAR  overexpression  function 
might  prove  a  particularly  useful  strategy  with  which  to  down-regulate  pro-
inflammatory responses in vascular endothelium by virtue of its capacity to inhibit 
both  the  JAK-STAT  and  NF-қB  signalling  pathways  utilised  by  distinct  pro-
inflammatory stimuli.   167 
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The centeral hypothesis of the future work is that the over-expression of the A2AAR 
primes STATs for cytokine-triggered polyubiquitylation and protesomal degradation, 
and that this is achieved by increasing the activity and/or expression of an E3 Ub 
ligase that specifically targets Tyr-phosphorylated STATs. I also hypothesise that this 
previously  unappreciated  process  is  an  important  mechanism  by  which  the 
inflammatory  response  could be  suppressed  by  this  receptor. Processes  regulating 
protein turnover by the UPS are attractive targets for therapeutic intervention but are 
currently underexploited (Nalepa et al.; 2006). Thus, while the machinery controlling 
STAT degradation in ECs has tremendous potential for the generation of novel anti-
inflammatory therapeutics for treatment of CVDs, fully exploiting this opportunity 
would require a detailed understanding of the molecular mechanisms responsible. To 
achieve this, future work would be aimed at : 
 
1)  Characterising in detail and defining the subcellular localisation of the STATs 
ubiquitylation and degradation events. 
2)  Identification the A2AAR-regulated E3 Ub ligase responsible. 
3)  Identification of Ub-conjugation sites and the nature of any chain linkage on 
STAT3. 
4)  Identification of the A2AAR-activated signalling pathway(s) responsible for 
priming STATs for degradation. 
 
Proposal experimental procedures: 
 
1)  Characterisation  and  localisation  of  STAT  polyubiquitylation  and 
degradation 
 
 Having  demonstrating  that  Tyr-phosphorylation  is  required  for  cytokine-triggered 
degradation  of  STATs  following  A2AAR  overexpression,  it  is  unclear  where 
ubiquitylation and degradation occur. These questions could be answered as follows:- 
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1.1)  Are STATs degraded in the nucleus?  
 
Tyr-phosphorylation is followed by the α-importin-mediated translocation of STAT 
dimer into the nucleus (Norman and Shiekhattar; 2006). This would be tested by 
comparing  the  extent  to  which  the  A2AAR  overexpression  primes  STATs  for 
cytokine-triggered  polyubiquitylation  and  degradation  in  cytosolic  and  nuclear 
fractions. Based on these findings, several experimental approaches such as siRNA-
mediated knockdown of importin-α (Which play important role in translocation of 
STATs from cytosol to the nucleus) could be use to test the important of nucleus 
loclisation  in  STAT  degradation.  Moreover,  nuclear  import  of  STAT1  has  been 
shown to be mediated by importin-α 5/NPI-1, one of the importin- α family members. 
Here, we attempt to determine whether the stimulation-induced nuclear import of 
STAT3  is  mediated  by  importin-α  similar  to  the  import  of  STAT1.  The  domain 
structure of importin-α could be divided into an N-terminal region (the importin-β 
binding domain), a central region (classical NLS binding domain), and a short C-
terminal region. It is well known that the N-terminal domain of importin-α is essential 
for importin-β binding, and that the deletion of this domain causes a loss of import 
activity. In the case of STAT1, N-terminal deletion mutants of importin-α 5/NPI-1 
lack  the  importin-β  binding  domain  and  cannot  bind  to  importin-β,  inhibiting  the 
nuclear import of STAT1 (Sekimoto et al.; 1997; McBride et al.; 2002). Therefore, 
we could examine the issue of whether the N-terminal deletion mutant of importin-α 
5/NPI-1  inhibits  the  nuclear  import  of  STAT3  and  its  degradation  in  A2AAR-
overexpressing cells. 
 
During the process of  IL-6-mediated transcriptional activation of STAT3, STAT3 
proteins translocate into the nucleus and are subsequently exported from the nucleus 
in a chromosomal region maintenance 1 (CRM1)-dependent manner (Bhattacharya 
and Schindler; 2003). Use of nuclear export inhibitor leptomycin B (to inhibit STAT 
nuclear export) and expression of STAT3 mutants in which nuclear localisation or 
export  sequences  are  disrupted)  could  be  used  to  determine  whether  Tyr-  170 
phosphorylation alone is sufficient for STAT ubiquitylation and degradation, or if 
nuclear localisation is also critical. If degradation occurs in the nucleus, it would be 
expected that blocking export will cause nuclear accumulation of Ub STAT. 
 
2)  Identification of the E3 ligase for STAT ubiquitylation 
 
To date only one E3 ligase termed “SLIM or Mystique” has been demonstrated to 
target  Tyr-phosphorylated  STATs  for  polyubiquitylation  (Tanaka  et  al.;  2005). 
However I have been unable to detect SLIM message or protein under conditions 
resulting  in  STAT  degradation  suggesting  that  another  E3  is  responsible. 
Identification of this new E3 would constitue a major advance towards designing 
strategies for manipulating STAT function. Two different strategies are proposed:- 
 
A) Tandem affinity purification (TAP) of STAT-associated E3 ligase 
The most straightforward strategy for identifying the protein responsible would be to 
purify STAT-associated protein in cytokine-stimulated A2AAR-overexpressing cells 
via two-step tandem affinity purification (TAP) procedure. Similar approaches have 
already been used to demonstrate that KLHL12 function as the substrate recognition 
component of the E3 complex responsible for degredation of Dsh proteins (Angers et 
al.; 2006). To identify the A2AAR-regulated STAT E3, a TAP construct would be 
generated comprising streptavidin-(Streptag) and Ni
2+  chelate-(His6) binding affinity 
tags placed in tandem at the C-terminus of STAT3 (Tagwerker et al.; 2006). The C-
terminus is being chosen as others have demonstrated that even the addition of large 
fluorescent  protein  tags  at  this  terminus  does  not  compromise  STAT3  function 
(Pranada et al.; 2004). The rationale for using these tags is that they allow two-step 
purification  under  denaturing  conditions,  which  is  essential  to  inactivate 
deubiquitylating  enzymes  that  would  otherwise  remove  polyUb  chains  and  the 
associated E3 during purification  (Tagwerker et al.; 2006). A recombinant AV would 
be generated to ensure efficient expression of the TAP-tagged STAT3 in HUVECs to 
the  same  level  as  endogenous  STAT3.  After  confirming  functional  expression,  it   171 
would be co-expressed with the A2AAR and purified by sequential Ni
2+ chelate- and 
streptavidin-affinity  chromatography  steps  following  treatment  with  cytokine  and 
MG132 to promote accumulation of ubiquitylated STATs. To prevent dissociation 
recruited E3s following denaturing cell lysis, cellular protein would be cross-linked 
by treatment with formaldehyde prior to lysis. STAT-associated proteins from the 
final streptavidin-affinity step would be eluted and digested with trypsin for analysis 
of the resulting peptides by tryptic peptide mass fingerprinting using matrix-assisted 
laser desorption/ionisation-time of flight (MALDI/TOF) (Bito et al.; 2003) and/or 
peptide  separation  by  nano-liquid  chromatography  and  analysis  by  tandem  mass 
spectrometry (LC-MS/MS) (Xu and Peng; 2006). Result would be used to interrogate 
EBI  and  NCBI  human  databases  using  publicly  available  MASCOT  search 
algorithms. GFP-expressing HUVECs would be used as a negative control. 
 
B) E3 Ub ligase siRNA library screening  
Libraries of validated siRNAs specific for more than 200 human E3 Ub ligases are 
now available commercially from Dharmacon and Ambion. These provide a rapid 
means with which to screen a range of structurally diverse E3s based on whether 
knockdown  blocks  sIL-6Rα/IL-6-mediated  degradation  of  STATs  in  A2AAR 
overexpressing HUVECs compared with non-targeting siRNA-treated control cells. 
This approach is particularly suited to HUVECs since our lab (Sands et al.; 2006) and 
others (Huang et al.; 2005; Kooistra et al.; 2005) have been able to achieve almost 
complete target gene knockdown following siRNA transfection into these cells. We 
would initially start by screening large numbers of group by dividing the library into 
manageable groups of 50 then screen them to identify the effective group. After that 
we could further subdivided any putative group over several rounds of screening to 
isolate the E3 ligase activity which responsible for STATs ubiquitination. To confirm 
that  it  functions  as  a  bona  fide  Ub  E3  ligase  on  phospho-STAT3,  those  that  are 
identified from our screen will be expressed, purified and used in vitro Ub E3 ligase 
assays using phospho-STAT3 as a substrate. 
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3)  Identification of Ub-conjugation sites  and nature of chain linkage on STAT3 
 
Identifying the sites of Ub attachment would define new targets on STAT amenable 
to therapeutic manipulation. However identification is hampered by the lack of any 
consensus  ubiquitylation  sequences  displayed  by  E3s  (Nalepa  et  al.;  2006)  and 
(assuming  the  ubiquitylation  sites  are  conserved)  the  presence  of  more  than  20 
common Lys between STATs 1 and 3. Thus, Ub attachment sites should ideally be 
determined directly. To achieve this, adenoviruses (AV) would be used to co-express 
Flag-Tagged-WT  STAT3  with  the  A2AAR  prior  to  treatment  with  cytokine  and 
proteasome inhibitor MG132 to promote accumulation of ubiquitylated STAT3 (as 
described in Chapter 2). Flag-STAT3 could then be affinity purified using anti-flag 
antibody  M2-Sepharose  columns  and  eluted  with  Flag  peptide.  Following  SDS-
PAGE  and  Colloidal  Blue  staining,  bands  corresponding  to  ubiquitylated  Flag-
STAT3 would be excised and destained prior to in gel digestion with trypsin and 
peptide extraction. Conjugated ubiquitins are digested by trypsin to either a Gly-Gly 
remnant that adds a mass of 114.043 Da to the affected Lys residue on the tagged 
protein  or  a  longer  Leu-Arg-Gly-Gly  remnant  due  to  miscleavage (Xu  and  Peng; 
2006). Moreover, the ubiquitinated Lys residue on STAT3 will be resistant to trypsin 
cleavage. Following peptide separation by nano-liquid chromatography and analysis 
by tandem mass spectrometry (LC-MS/MS), these modifications are detectable as 
distinctive mass spectrometry (MS/MS) spectra that can be matched to specific Lys 
residues on STAT3 using search algorithms (Xu and Peng; 2006). A similar approach 
has  been  successfully  employed  to  isolate  and  identify  proteins  conjugated  to 
NEDD8,  a  molecule  related  to  Ub  (Norman  and  Shiekhattar;  2006).  Its  success 
depends largely on the ability to sufficient purify enough of ubiquitylated STAT3 for 
mass spectrometry.  
 
To determine the nature of Ub chain linkage, HA-tagged Ub molecules in which all 
Lys residues (Ub contains seven Lys residues Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48  and  Lys63)  could  be  individually  mutated  to  Arg,  co-expressed  with  the   173 
A2AAR  and  tested  for  their  ability  to  form  Ub  chains  by  probing  anti-STAT3 
immunoprecipitates with anti-HA antibody. Attenuated incorporation of mutated Ub 
where different Lys residues are mutated to Arg versus WT would identify the Lys 
residues involved in chain formation. A similar approach, using a mutated Ub in 
which  all  seven  Lys  residues  are  mutated  to  Arg,  would  help  determine  whether 
STAT3 is polyubiquitylated or multimonoubiquitylated. This is because the mutated 
Ub cannot support chain elongation. 
 
4)  Identification of the A2AAR-activated signalling pathway(s) responsible for 
priming STAT degradation 
 
Having identified the molecular events by which STAT degradation occurs, it would 
be important to identify which A2AAR-activated signalling pathways are responsible.   
A2AAR  activation  has  been  reported  to  activate  at  least  two  primary  signalling 
cascades in vascular endothelial cells. One leads to Adenylyl cyclase activation which 
results in the elevation of intracellular cyclic AMP (cAMP) levels, leading to the 
activation of cAMP-dependent protein kinase (PKA) and exchange protein activated 
by cAMP (Epac), which functions as a guanine nucleotide exchange factor for the 
Rap family of small G-proteins (Tasken and Aandahl; 2004).  Another pathway is the  
Extracellular signal-regulated kinase (ERK). cAMP-independent activation of ERK 
by the A2AAR (Sexl et al.; 1997) is thought to be required for receptor-mediated 
generation  of  nitric  oxide,  which  subsequently  activates  soluble  guanylyl  cyclase 
(Wyatt  et  al.; 2002).The  resulting  accumulation  of  cyclic  GMP  (cGMP)  activates 
cGMP-dependent protein kinase. 
 
A  range  of  selective  inhibitors  and  activitors  of  relevant  interacellular  signalling 
pathways will need to be tested for their ability to either block or mimic A2AAR-
overexpression-mediated priming of STAT degradation. Fore example, a contribution 
of Epac can be tested by determining the extent to which Epac-selective activitior 8-
pCPT-2′-O-Me-cAMP  (Kooistra  et  al.;  2005)  can  prime  STATs  for  cytokine-  174 
triggered degradation, and whether its depletion by siRNA abolishes the A2AAR’s 
effect.  Our  Lab  has  successful  applied  such  approaches  to  identify  a  previously 
unkown  Epac1-regulated  anti-inflammatory  signalling  pathway  in  vascular  Ecs 
(Sands et al.; 2006). To determine whether cAMP or ERK pathways may stimulate 
by  the  A2AAR  involve  in  STATs  degradation  in  A2AAR-overexpression  cells,  a 
broader  range  of  inhibitors  and  activators  for  cAMP  and  ERK  will  initially  be 
screened  for  their  ability  to  block  STAT  degradation  prior  to  performing  more 
discriminating siRNA-mediated knockdown experiments to assess any potential role 
of candidate intermediate proteins downstream of the A2AAR. Such as the effect of 
PKA could be inhibited by PKA inhibitors Rp-8-CPT-cAMPS (Park et al.; 2007) or  
H-89 (Kaneto et al.; 2007).  In addition, we could activate PKA by PKA-specific 
activator N(6)-benzoyladenosine 3',5-cyclic monophosphate (N(6)Bz-cAMP) (Kwan 
et al.; 2007) or by the adenylyl cyclase activator forskolin (FSK) (Keller et al.; 2007). 
On  the  other  hand,  the  involvement  of  ERK  in  STAT  degradation  in  A2AAR-
overexpressing HUVECs could be test by using MEK  inhibitor (U0126) (Ciccarelli 
et al.; 2005).  The effect of Raf /MEK/ERK pathway activation could be investigated 
by expressing a Raf-ER fusion protein in A2AAR-overexpressing cells and activating 
the ER by selective ER activator 4-hydroxytamoxifen. This will specifically activate 
the  ERK  pathway  and  will  provide  some  insight  its  role  as  a  possible  STAT 
degradation signal in A2AAR overexpressing cells. 
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